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Abstract: Kidney disease is increasingly being recognized as a public health problem, not only because
large numbers of patients are affected, but also because of the diagnostic and therapeutic challenges asso-
ciated with its management, especially in low resource settings, where conflicts between financing, equity
and social values frequently arise. When kidneys fail, either acutely or chronically, dialysis represents an
immediate life-saving therapy. Dialysis is technically available in most countries, but is time, labor and
resource intensive, which limits access largely to those who can afford to pay when not covered through
universal health coverage or health insurance. Access to dialysis is therefore highly inequitable across
country income groups globally and within countries. Dialysis poses ethical challenges at many levels in
low-resource settings. Policy makers must consider whether to provide dialysis at all or leave it to market
forces. If dialysis is to be provided, who, where and how to dialyze safely and equitably are necessary
questions to consider. When these questions are not addressed transparently at a policy level, clinicians
and families must face complex decisions about whether to start dialysis or not at the bedside. Policy-
making requires evidence. Based on broad inequities in access to dialysis and the potential consequences
for individuals and families, health care workers, the health system and society, this PhD begins with an
epidemiologic description of outcomes in patients requiring dialysis in sub-Saharan Africa and consequent
moral distress experienced by nephrologists at the bedside, investigates overarching strategies to reduce
the global burden of kidney disease, and focuses on the ethical implications of priority setting and policy
making regarding provision of dialysis in sub-Saharan Africa.
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treating	 patients	 with	 kidney	 disease	 in	 sub-Saharan	 Africa	 highlight	 the	 need	 for	





Kidney	 disease	 is	 increasingly	 being	 recognized	 as	 a	 public	 health	 problem,	 not	 only	 because	













Policy-making	 requires	 evidence.	 Based	 on	 broad	 inequities	 in	 access	 to	 dialysis	 and	 the	
potential	consequences	for	individuals	and	families,	health	care	workers,	the	health	system	and	
society,	 this	 PhD	 begins	 with	 an	 epidemiologic	 description	 of	 outcomes	 in	 patients	 requiring	





In	 Chapter	 1,	 the	 results	 of	 two	 systematic	 reviews	 on	 access	 to	 dialysis	 and	 outcomes	 in	
patients	with	both	acute	and	end-stage	kidney	failure	in	sub-Saharan	Africa	are	presented.	Both	
studies	 confirm	 poor	 access	 to	 care	 and	 high	mortality	 even	when	 access	 to	 care	 is	 possible,	
largely	because	of	 reliance	on	out-of-pocket	payments	 in	the	region.	 In	Chapter	2,	 results	of	a	
survey	of	nephrologists	regarding	management	of	patients	who	require	dialysis	 in	sub-Saharan	
Africa	 show	 a	 high	 level	 of	 moral	 distress,	 largely	 driven	 by	 unaffordability	 of	 necessary	
diagnostics	 and	 therapeutics.	 Given	 that	 kidney	 disease	 would	 be	 preventable	 through	
improvements	 in	 living	 standards	 and	 some	 basic	 public	 health	measures,	 and	 treatable	with	
early	 diagnosis	 and	 access	 to	 appropriate	 medicines,	 broad	 strategies	 to	 achieve	 these	 at	 a	
	 4	
public	 health	 and	 a	 policy	 level	 are	 discussed	 in	 Chapter	 3.	 The	 importance	 of	 policy	
development	governing	provision	of,	and	access	to,	dialysis	 is	discussed	in	Chapter	4,	together	
with	an	ethical	analysis	of	potential	policy	approaches.	Policy	development	should	be	inclusive,	





for	 kidney	 disease.	 The	 need	 for	 transparent	 and	 fair	 priority	 setting	 in	 low	 resource	 settings	





















































































































































the	 rich.	 This	 inescapable	 paradox	 has	 been	 the	 driving	 force	 underlying	 this	 PhD.	 The	
overarching	 goals	 have	 been	 to	 understand	more	 about	 the	 global	 burden	 of	 kidney	 disease,	
with	an	emphasis	on	sub-Saharan	Africa	(SSA),	and	to	consider	the	ethical	challenges	associated	
with	 the	 management	 of	 kidney	 disease	 in	 lower	 resource	 settings.	 Much	 has	 been	 learned	
about	the	global	burden	of	kidney	diseases	 in	the	past	4	years	since	the	 initiation	of	 this	PhD,	
which	highlights	the	relevance	of	the	topic.	Some	of	this	knowledge	has	been	contributed	by	the	
work	 done	 during	 this	 PhD.	 For	 completeness,	 rather	 than	 adhering	 to	 the	 chronology	 of	
knowledge	development	in	the	field,	the	latest	data	regarding	the	global	distribution	of	kidney	













in	 such	cases	 is	usually	 required	 for	days	or	weeks.	Depending	on	 the	 severity	of	 the	AKI,	 the	
kidney	 function	may	 return	back	 to	baseline	or	 there	may	be	 some	permanent	 loss	of	 kidney	
function,	 which	 then	 becomes	 chronic	 kidney	 disease	 (CKD).	 CKD	 reflects	 permanent	 loss	 of	













progress	 over	 time	 as	 the	 remaining	 functional	 kidney	 tissue	 overworks	 and	 essentially	
consumes	itself	to	maintain	a	steady	state.		
	
Once	 kidney	 function	 deteriorates	 beyond	 a	 certain	 point	 (around	 30%	 of	 normal	 kidney	
function,	 13	million	 people
3




symptomatic	 enough	 to	 require	 renal	 replacement	 therapy	 (RRT)	 in	 the	 form	 of	 dialysis	 	 or	















placement	 of	 the	 vascular	 or	 peritoneal	 access	 for	 dialysis	 requires	 trained	 operators,	 sterile	
conditions	 and	 technical	 supplies.	 HD	 requires	 functioning	 machines,	 stable	 electricity	 and	 a	
reliable	 water	 supply,	 as	 well	 as	 tubing,	 filters	 and	 other	 supplies,	 mostly	 new	 for	 each	
treatment.	 PD	 requires	 new	 dialysate	 fluid	 bags	 and	 tubing	 for	 each	 exchange.	 Training	 of	
dialysis	 staff	 and	 patients	 is	 required	 for	 both	 HD	 and	 PD.	 The	 costs	 of	 dialysis	 and	







countries	despite	PD	 in	 theory	being	cheaper	as	 it	 requires	much	 less	 infrastructure.
6
	Costs	 in	
SSA	 are	 known	 to	 be	 inflated	 by	 customs,	 “fees”	 and	 middle-men.
7-9
	 Both	 forms	 of	 dialysis	
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replace	around	20%	of	kidney	function	and	therefore	patients	remain	chronically	 ill,	have	high	








affluence,	 from	 under-	 to	 over-nutrition,	 from	 fetal	 life	 to	 old	 age,	 from	 agricultural	 to	
industrialized	 societies,	 from	 traditional	 to	 modern	 medicine,	 from	 infections	 to	 non-




choices	 and	 cheap	 generic	 medications	 to	 highly	 expensive	 therapies	 such	 as	 dialysis	 and	
transplantation.	 Kidney	 disease	 prevalence	 and	 access	 to	 care	 are	 also	 impacted	 by	 ethnicity,	
gender,	 religion,	 occupation,	 geography	 and	 the	 legacy	 of	 colonialism.
11
	 In	 the	 current	 global	
context,	 where	 leaders	 are	 failing	 to	 tackle	 many	 of	 the	 social	 determinants	 of	 health,	
discrimination	 and	 disparities	 remain	 high,	 working	 conditions	 remain	 unsafe,	 pollution	 is	
increasing,	 and	 due	 to	 climate	 change,	 natural	 disasters	 and	 environmental	 threats	 are	









The	World	Health	Organization	 (WHO)’s	Global	 Action	 Plan	 for	NCDs	 has	 focused	 the	world’s	
attention	 on	 4	 NCDs	 (heart	 disease,	 cancer,	 respiratory	 disease	 and	 diabetes),	 with	 a	 recent	




other	 NCDs	 are	 being	 “left	 behind”	 as	 countries	 focus	 on	meeting	 these	 high	 profile	 disease	
targets.	 It	 is	 therefore	not	 surprising	 that	 the	global	burden	of	kidney	disease	 is	 continuing	 to	
rise	 while	 many	 other	 disease	 burdens	 are	 beginning	 to	 stabilize	 or	 improve.
14,15
	 Based	 on	







One	 reason	 for	 the	 under-recognition	 of	 the	 kidney	 disease	 burden	 thus	 far	 may	 be	 the	






track	 the	 incidence	 and	 prevalence	 of	 ESKD.	 Around	 2.4	 million	 people	 are	 known	 to	 die	
annually	directly	 from	CKD	or	 from	 it’s	 contribution	 to	 cardiovascular	deaths.
17
	 The	burden	of	






the	 focus	has	been	on	“premature”	NCD	deaths,	 i.e.	 those	occurring	between	ages	30	and	70	
years.
19


















lower	 income	 settings,	 in	 contrast,	 CKD	 ranking	 remains	 low,	 likely	 because	 of	 persistent	
predominance	 of	 infectious	 causes	 of	 death,	 as	well	 as	missing	 data	 due	 to	 lack	 of	 access	 to	








	 1990	 2006	 2016	 Change	in	rank	
1990-2016	
High	income	countries		 17	 14	 13	 4	
High-middle	income	countries		 22	 18	 17	 5	
Middle-income	countries		 19	 15	 10	 9	
Low-middle	income	countries	 25	 21	 18	 7	





































It	 has	 been	 estimated	 that	 between	 2.3	 and	 7.1	 million	 people	 with	 ESKD	 may	 have	 died	






that	 only	 1.5	 %	 of	 people	 with	 ESKD	 resulting	 from	 of	 hypertension	 or	 diabetes	 (the	 most	
common	 global	 risk	 factors	 for	 ESKD)	 likely	 gain	 access	 to	 treatment	 in	 SSA,	 as	 opposed	 to	
almost	100%	in	high	income	settings.	These	projections,	although	only	estimates,	highlight	the	
glaring	 regional	 inequities	 in	 access	 to	 RRT	 across	 the	 globe.	 Similar	 numbers	 for	 AKI	 are	 not	












The	only	data	from	SSA	 included	 in	this	database	 is	 from	South	Africa	as	 it	 is	 the	only	country	
with	an	ESKD	registry.	South	Africa	was	consistently	ranked	among	the	lowest	countries	globally	














































































































































































































	 In	 most	 countries	 where	 dialysis	 is	 universally	 available	 this	 is	 funded	
through	 governments	 utilizing	 varying	 financing	 schemes,	 as	 the	 annual	 cost	 of	 dialysis	 is	
unaffordable	 for	 individuals.
37
	 In	 these	 countries,	 on	 average	 2-4%	 of	 national	 healthcare	
budgets	 is	 directed	 to	 ESKD	 care,	 which	 affects	 around	 0.15%	 of	 the	 population.
38
	 This	
disproportionate	health	expenditure	has	evolved	as	 consistent	with	prevailing	 social	 values	of	
not	abandoning	patients	 to	almost	certain	death	without	RRT.
39-41
























	 The	 predominant	 ethical	 challenges	 under	 these	
circumstances	 therefore	 concern	 whether	 and	 how	 patients	 who	 should	 be	 dialyzed	 can	 be	
dialyzed;	if	dialysis	is	provided,	who	should	pay	and	how	much,	and	whether	this	involves	quality	
compromises;	 if	 patients	 cannot	 be	 dialyzed,	 what	 alternative	 support	 is	 in	 place?	 Far	 less	
commonly,	 the	 question	 of	 whether	 a	 patient	 who	 technically	 can	 be	 dialyzed	 should	 be	
dialyzed	(e.g.	in	the	case	of	severe	brain	injury)	also	arises.	
	
Over	 the	 past	 few	 decades,	 several	 single-center	 descriptive	 studies	 have	 highlighted	 the	














or	 non-functioning	 dialysis	 equipment	 (22	 children),	 staff	 shortages	 (3	 children),	 or	 staff	
hesitance	 to	 dialyze	 for	 fear	 the	 family	 could	 not	 afford	 it	 (3	 children).
47
	 Surveys	 and	 review	


















the	 Lancet	 Series	 on	 CKD	 in	 2013,	 raised	 vehement	 debate	 from	 senior	 nephrologists	 both	
within	and	outside	of	Africa,	about	whether	countries	in	SSA	should	consider	providing	dialysis,	
given	 the	 high	 costs,	 poor	 infrastructure,	 and	 the	 “few”	 patients	 involved	 (personal	
communication).	 Regardless	 of	 personal	 opinions,	 rigorous	 data	 has	 been	 lacking,	 dialysis	 is	
available	 in	 SSA,	 and	 its	 consequences	 in	 terms	 of	 CHE	 and	 life	 or	 death	 for	 individuals,	 and	




Many	 papers	 and	 book	 chapters	 on	 resource	 allocation	 for	 high-cost	medical	 therapies	 begin	
with	a	description	of	 the	dilemmas	surrounding	 rationing	of	dialysis	 in	 the	United	States	 (US),	











decisions	 on	 who	 should	 receive	 dialysis.
54
	 The	 fact	 that	 these	 decisions	 were	 based	 on	 a	
patient’s	 perceived	 “social	 worth”	 led	 to	 a	 public	 outcry.	 Subsequently,	 based	 on	 the	 rule	 of	
rescue	 and	 a	 significant	 underestimation	 of	 the	 projected	 need,	 all	 ESKD	 patients	 became	
eligible	 for	 dialysis	 under	 the	 Social	 Security	 Act	 Amendment.
39,55
	 This	 decision	 also	 set	 a	










Following	 this	 utilitarian	 approach,	 an	 individual’s	 resources	 no	 longer	 determined	 access	 to	
care	 in	 the	 US	 and	 individual	 patient	 autonomy	 became	 the	 deciding	 factor	 (Figure	 5).	 The	
understanding	 initially	had	been	that	 the	small	number	of	patients	 requiring	dialysis	would	be	
“rehabilitated”	by	this	treatment	and	flourish.	Even	early	on	however	it	was	realized	that	many	
severely	 ill	 patients	were	 surviving,	 but	 not	 thriving	 on	 dialysis,	 raising	 the	 question	 of	which	
patients	were	 “appropriate”	 for	 dialysis.
58
	 Indeed,	 the	 original	 pioneer	 of	 chronic	 dialysis,	 Dr.	
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Belding	 Scribner,	 stated	 there	 should	 instead	 be	 a	 “de-selection	 committee”.
58
	 The	 ethical	
challenges	 associated	with	 dialysis	 therefore	 had	 shifted	 from	 the	macro-	 and	meso-scales	 to	




certain	 patient	 groups,	 especially	 the	 frail	 and	 elderly	may	 actually	 do	 better	without	 dialysis	
and	with	 supportive	 care.
59,60





Throughout	 the	 evolution	 of	 dialysis,	 as	 technical	 and	 access	 barriers	 were	 progressively	
overcome,	the	demand	and	costs	have	grown	far	more	than	initially	anticipated.	Before	dialysis	
became	 routinely	 available	 an	 element	 of	 therapeutic	 nihilism	 prevailed	 regarding	 kidney	
disease.	The	disease	burden	was	therefore	markedly	underestimated.	Given	that	now	over	500	
000	 patients	 in	 the	 US	 receive	 dialysis,	 representing	 <	 1%	 of	 the	 Medicare	 population	 but	
consuming	 7%	 of	 the	 Medicare	 budget
62






lower	 income	countries	 regarding	access	 to	dialysis	are	 therefore	not	new,	and	 it	 is	 likely	 that	




may	 leave	 their	 families	worse	 off.	 How	policy	makers	 should	 approach	 these	 conundrums	 is	
unclear	 given	 their	 roles	 as	 chaperones	 of	 the	 health	 system	 as	 a	 whole,	 but	 also	 their	
obligations	to	help	individuals	to	achieve	their	highest	attainable	state	of	well-being.	
	
The	 work	 presented	 in	 this	 PhD	 represents	 my	 own	 journey	 from	 attempting	 to	 deliver	









The	 public	 health	 importance	 of	 kidney	 disease	 does	 not	 only	 lie	 in	 the	 large	 numbers	 of	
patients	affected,	but	also	in	the	potential	conflicts	between	financing,	equity	and	social	values	
related	to	the	diagnostic	and	therapeutic	challenges	associated	with	its	management.	Dialysis	is	
an	 immediate	 life-saving	therapy,	which	 is	 fairly	easily	technically	accessible,	but	 is	 time,	 labor	
and	 resource	 intensive.	 In	 the	 case	 of	 patients	with	 AKI	 it	 is	 hoped	 that	 dialysis	may	 only	 be	
required	for	days	to	weeks	and	that	kidney	function	would	recover	enough	that	dialysis	could	be	
stopped,	 resulting	 in	 a	 short-term	 dependence	 on	 this	 high-cost	 therapy.	 A	 prevailing	
presumption	in	the	nephrology	community	is	that	dialysis	for	AKI	should	be	accessible	to	all	as	a		





In	 contrast,	 for	 patients	with	 ESKD,	unless	 a	more	 cost-effective	 kidney	 transplant	 is	 possible,	
dialysis	is	required	for	the	remaining	years	of	life	at	significant	continuous	expense.	It	has	been	








NCD	 management	 programmes.	 If	 dialysis	 is	 to	 be	 provided,	 who	 and	 how	 to	 dialyze,	 what	
quality	 standards	 should	 be	 acceptable,	 and	 where	 facilities	 should	 be	 located	 to	 maximize	





needs	 of	 a	 very	 small	 proportion	 of	 patients	 who	 develop	 ESKD	 in	 SSA.	 Transplantation	 also	
	 24
extends	 beyond	 kidney	 transplantation	 alone	 and	 is	 fraught	with	 its	 own	 additional	 layers	 of	
ethical	 challenges.	 As	 such,	 the	 work	 described	 in	 this	 PhD	 focuses	 primarily	 on	 ethical	







across	 the	 globe,	 and	 the	 potential	 consequences	 of	 individuals	 and	 families,	 health	 care	
workers,	the	health	system	and	society,	the	objectives	of	this	PhD	begin	with	an	epidemiologic	
description	 of	 outcomes	 of	 patients	 requiring	 RRT	 in	 SSA	 and	 experiences	 of	 nephrologists	
managing	patients	with	 kidney	disease	under	 current	 circumstances,	proceed	 to	outline	 some	






studies	 confirm	 poor	 access	 to	 care	 and	 high	mortality	 despite	 access	 to	 care,	 especially	 for	









health	 care	 workers	 in	 SSA.	 Given	 the	 expense	 and	 health	 systems	 components	 required	 to	
deliver	equitable	and	sustainable	RRT	in	SSA,	there	is	no	quick	fix	to	this	problem.	Prevention	of	






Building	 on	 the	 findings	 of	 the	 systematic	 reviews	 and	 the	 nephrologist	 survey	 outlined	 in	
Chapters	 1	 and	 2,	 in	Chapter	 4,	 the	 ethical	 challenges	 associated	with	 provision	 of	 dialysis	 in	
resource-limited	settings	are	reviewed	(Paper	5).	Potential	policy	approaches	to	kidney	disease	
are	 discussed	 regarding	 their	 impact	 on	 equity	 and	 justice	 in	 terms	 of	 access	 to	 dialysis,	
efficiency	and	opportunity	costs.	A	framework	of	ethics	developed	for	implementation	research	
is	 described	 which	 may	 be	 useful	 to	 guide	 transparent	 and	 equitable	 decision-making	 and	
planning	regarding	implementation	of	expensive	heath	care	interventions	(Paper	6).		
	
It	 is	hoped	 that	 the	work	presented	here	may	be	useful	 to	 inform	 regional	policy	makers	and	
advocacy	 activities	 about	 the	 realities	 faced	 by	 patients,	 families	 and	 health	 care	 workers	
confronted	with	kidney	disease	in	SSA.	Ultimately	the	goal	is	raise	to	awareness	of	the	need	for	
transparent	 and	 fair	 priority	 setting	 around	 access	 to	 high	 cost,	 but	 life-saving,	 interventions	









Given	 the	many	presumptions	about	access	 to	dialysis	 and	outcomes	 in	 SSA,	 the	 lack	of	 large	
rigorous	 studies,	 and	 the	 relative	 lack	 of	 policies	 regarding	 kidney	 disease	 and	 dialysis,	 two	
systematic	 reviews	were	 conducted	 to	 consolidate	 published	 literature	 on	 the	 topic	 (Paper	 1	
and	Paper	2)	 and	objectively	describe	 the	 clinical	 realities	on	 the	ground.	Outcomes	 captured	




subsequently	 invited	 as	 co-investigators	 to	 extend	 the	 search,	 to	 perform	 a	 rigorous	
collaborative	 systematic	 review	 according	 to	 PRISMA	 guidelines,	 and	 to	 ensure	
representativeness	 and	 coherence	 of	 the	 findings	 with	 their	 experiences.	 These	 papers	 were	
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Outcomes of acute kidney injury in children and adults in 
sub-Saharan Africa: a systematic review
Wasiu A Olowu*, Abdou Niang*, Charlotte  Osafo, Gloria Ashuntantang, Fatiu A Arogundade, John Porter, Saraladevi Naicker, Valerie A Luyckx
Summary 
Background Access to diagnosis and dialysis for acute kidney injury can be life-saving, but can be prohibitively 
expensive in low-income settings. The burden of acute kidney injury in sub-Saharan Africa is presumably high but 
remains unknown. We did a systematic review to assess outcomes of acute kidney injury in sub-Saharan Africa and 
identify barriers to care.
Methods We searched PubMed, African Journals Online, WHO Global Health Library, and Web of Science for articles 
published between Jan 1, 1990, and Nov 30, 2014. We scored studies, and all were of medium-to-low quality. We made 
a pragmatic decision to include all studies to best refl ect reality, and did a descriptive analysis of extracted data. This 
study is registered with PROSPERO, number CRD42015015690.
Findings We identifi ed 3881 records, of which 41 met inclusion criteria, including 1403 adult patients and 
1937 paediatric patients. Acute kidney injury in sub-Saharan Africa is severe, with 1042 (66%) of 1572 children and 
178 (70%) 253 of adults needing dialysis in studies reporting dialysis need. Only 666 (64%) of 1042 children (across 
11 studies) and 58 (33%) of 178 adults (across four studies) received dialysis when needed. Overall mortality was 34% 
in children and 32% in adults, but rose to 73% in children and 86% in adults when dialysis was needed but not 
received. Major barriers to access to care were out-of-pocket costs, erratic hospital resources, late presentation, and 
female sex. 
Interpretation Patients in these studies are those with resources to access care. In view of overall study quality, data 
interpretation should be cautious, but high mortality and poor access to dialysis are concerning. The global scarcity of 
resources among patients and health centres highlights the need for a health-system-wide approach to prevention 
and management of acute kidney injury in sub-Saharan Africa.
Funding None.
Copyright © Olowu et al. Open Access article distributed under the terms of CC BY. 
Introduction
Acute kidney injury is associated with substantial morbidity 
and mortality worldwide, but data have been conspicuously 
missing from the Global Burden of Disease study.1 Acute 
kidney injury refers to any sudden decline in kidney 
function, which can be reversible if detected early enough. 
Acute kidney injury can be community-acquired, resulting 
from an injury or infection before admission to hospital, or 
can be hospital-acquired, arising as a compli cation of 
hospital admission. Community-acquired acute kidney 
injury tends to occur in low-income countries, and in 
young people with few comorbidities, whereas hospital-
acquired acute kidney injury tends to occur in high-income 
settings, and in older people (45–80 years), often with 
several comor bidities.2 The burden of acute kidney injury 
in sub-Saharan Africa is unknown, but mortality is 
presumably high because of poor access to health care. 
In a world meta-analysis,3 the pooled incidence of acute 
kidney injury was 21·0% in adults and 33·7% in children, 
and mortality was 23·3% in adults and 13·8% in children. 
Only one of 154 included studies was from sub-Saharan 
Africa.3 Most studies included patients with 
hospital-acquired acute kidney injury, contrasting with 
most acute kidney injury in sub-Saharan Africa, which is 
community-acquired.3 Mortality was lower in countries 
with higher expenditure on health care, refl ecting 
improved access to health care and dialysis in these 
countries.3 In an update of this analysis, incidence and 
outcomes from 62 African studies were summarised in a 
table, but again excluded from the broader analysis.2 The 
generalisability of these global fi ndings to sub-Saharan 
Africa is therefore unknown.
Despite the absence of data for disease burden, the 
drive towards providing universal dialysis for acute 
kidney injury, which can be life-saving, is growing. In 
much of sub-Saharan Africa, dialysis is paid for out of 
pocket, at an estimated US$300 per episode of acute 
kidney injury for a child, and probably more for an adult.4 
In our experience, many patients cannot meet such costs 
and are forced to decline treatment. If provision of 
dialysis is to be sustainable in sub-Saharan Africa, data 
are needed to inform health policy decisions. In view of 
the present absence of epidemiological data, we have 
undertaken a systematic review to assess reported 
outcomes in patients with acute kidney injury in sub-
Saharan Africa to highlight the real-world context of 
Articles
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acute kidney injury in the region and to identify barriers 
to care that should be tackled to comprehensively address 
this important problem. This systematic review is highly 
relevant to understanding the challenges faced in 
management of acute kidney injury in sub-Saharan 
Africa, which are a crucial component of the disease 
burden.
Methods 
Search strategy and selection criteria 
We did a systematic review using the Preferred 
Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) guidelines (appendix).5 We 
searched PubMed, African Journals Online, the WHO 
Global Health Library, and Web of Science with 
relevant medical subject headings (appendix). We 
selected additional references through bibliographies 
from identifi ed articles. We restricted the search to 
articles in English or French, published between Jan 1, 
1990, and Nov 30, 2014. Outcomes of interest included 
access to dialysis, mortality, and recovery of renal 
function in cohorts of all patients admitted to hospital 
with acute kidney injury, irrespective of cause. We 
included variable defi nitions of acute kidney injury 
(clinical [oliguria, hyperkalaemia, or metabolic 
acidosis]; laboratory [urea or creatinine]; standardised 
diagnostic criteria; and need for dialysis). We excluded 
articles focusing exclusively on cohorts with single 
causes of acute kidney injury (eg, malaria), since 
outcomes would not be generalisable to the broader 
acute kidney injury population.2 We excluded case 
reports. FAA and VAL screened titles and abstracts for 
eligibility. Articles meeting inclusion criteria and 
obtainable as full texts were reviewed in detail. This 
study is registered with PROSPERO, number 
CRD42015015690.
Figure 1: Study selection
*WHO Global Health Library includes African Index Medicus.
3881 records identified
 161 from African Journals Online
 1023 from PubMed
 922 from Web of Science
 1775 from WHO Global Health Library*
261 articles excluded 
 28 specific causes of kidney disease
 1 conference abstract
 8 donors
 6 data not relevant
 65 guidelines, reviews, editorials, or commentaries 
 10 studied prevalence or incidence 
 68 outcomes too specific (eg, peritonitis rates, tuberculosis in dialysis)
 8 papers reported the same populations 
 4 paediatric chronic kidney disease and end-stage renal disease
 46 adult chronic kidney disease and end-stage renal disease
 17 transplant 
3070 titles and abstracts screened 
19 adult acute kidney injury
  9 medium quality 
 10 low quality
22 paediatric acute kidney injury
 11 medium quality 
 11 low quality 
302 full text articles assessed for eligibility
41 articles selected for systematic review
7 studies from 1990–2009 15 studies from 2010–14 9 studies from 1990–2009 10 studies from 2010–14
811 duplicates excluded
2764 records excluded (data not 
 relevant)
33 not available in full text
29 records identified from other 
  sources 
See Online for appendix
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Quality assessment and data extraction
The quality of each study was assessed independently by 
two authors (VAL plus one of: WAO, AN, CO, GA, or 
FAA) using a checklist modifi ed from Stanifer and 
colleagues6 (appendix). Most studies were observational 
case series. Because no study met high-quality criteria 
(predominantly because no study represented all patients 
with acute kidney injury, and many did not describe 
inclusion or exclusion rates or missing data), rather than 
excluding almost all identifi ed articles, we decided not to 
exclude any articles, to minimise bias and refl ect reality as 
much as possible. Half of studies met medium-quality 
criteria (appendix). Data from individual studies were 
extracted into a Microsoft Excel database for analysis.
Data analysis
Because data were not uniform, we reported results with a 
descriptive approach and narrative synthesis.7,8 We 
stratifi ed data into adult and paediatric groups and 
analysed them separately. Where possible, we reported 
pooled estimates of outcome frequencies combining all 
studies, in parallel with means of reported individual study 
frequencies to show variability of reported outcomes.8 We 
analysed diff erences in means with t tests and comparisons 
of proportions using the χ² test. More than half of the 
studies were published since 2010; therefore, to assess 
outcomes and detect changes over time, we further 
stratifi ed data by publication before or after 2010.
We did descriptive statistics using Microsoft Excel and 
Statistics to Use.9
Role of the funding source
There was no funding source for this study.
Results
We identifi ed 3070 studies through the literature search 
once duplicates were excluded. After screening titles and 
abstracts, we assessed 302 studies for eligibility (fi gure 1). 
42 studies10–50 from 13 countries satisfi ed inclusion criteria, 
reporting outcomes in all children and adults admitted to 
hospital with acute kidney injury. Two studies reported on 
the same patient cohort, therefore only the study with the 
most outcomes was included. Eight studies were 
prospective, 32 were retrospective, and one was cross-
sectional. Studies are outlined in detail in the appendix. 
13 adult and six paediatric studies included only patients 
Adult studies Paediatric studies
1990–2009 2010–14 p 1990–2009 2010–14 p
Total number of studies 9 10 ·· 7 15 ··
Countries 6 5 ·· 3 6 ··
Patient inclusion period 1972–2007 1996–2013 ·· 1985–2004 2000–13 ··
Total patients with 
acute kidney injury 
studied (pooled)
639 764 ·· 720 1217 ··
Study duration (years) 5·2 (6·3) 4·9 (5·8) ·· 11·3 (6·3) 4·8 (3·0) ··
Male patients (pooled) 339/601 (56%; n=8) 329/627 (52%; n=6) 0·17 459/713 (64%; n=6) 514/927 (55%; n=9) <0·0001
Male/female ratio 
(means of individual 
studies)
1·5 (0·8) 1·2 (0·3) 0·31 1·9 (0·6) 1·3 (0·6) 0·14
Defi nitions of acute 
kidney injury used 
(number of studies) 
9 9 0·14 6 11 0·023
Clinical 1 0 ·· 1 1 ··
Laboratory (urea or 
creatinine)
5 2 ·· 1 0 ··
Laboratory and clinical 0 0 ·· 4 1 ··
(p)RIFLE, AKIN, or 
ADQI
0 3 ·· 0 4 ··
Dialysis need 3 4 ·· 0 5 ··
Clinical presentations (means of individual studies) 
Oliguria* 59·83% (SD 23·82, n=3) 67·25% (SD 18·58, n=4) 0·66 68·73% (SD 29·00, n=3) 73·02% (SD 8·1, n=6) 0·73
Hyperkalaemia† 30·4% (n=1) 25·10% (SD 23·6, n=3) ·· 13·95% (SD 12·80, n=2) 28·60%  (SD 15·60, n=4) ··
Metabolic acidosis‡ No data 53·87% (SD 20·44, n=3) ·· 20·10% (SD 16·97, n=2) 42·20% (SD 26·51, n=3) ··
Data are number of studies, mean (SD), or percentage of patients (number of studies with outcome). p values reported for time periods 1990–2009 versus 2010–14. 
(p)RIFLE=(paediatric) risk, injury, failure, loss of function, and end-stage renal disease. AKIN=Acute Kidney Injury Network. ADQI=Acute Dialysis Quality Initiative. *Oliguria 
defi ned as urine output <400 mL per 24 h in adults, <300 mL per 24 h or <1 mL/kg/h in children, anuria, or not defi ned. †Defi nitions of hyperkalaemia variable, ≥5·5 mmol/L, 
≥6·5 mmol/L, or not defi ned. ‡Defi nitions of metabolic acidosis variable, ≤10 mmol/L, ≤15 mmol/L, or not defi ned.  
 Table 1: Acute kidney injury study populations
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with acute kidney injury who received or needed dialysis; 
two adult studies included intensive care unit populations; 
and two adult studies included a small proportion of 
paediatric patients. Pooled studies included patients 
enrolled between April, 1972, and December, 2013. 
Study populations are outlined in table 1. Pooled patients 
with acute kidney injury included 1403 adults and 
1937 children. Six adult and nine paediatric studies described 
patients presenting with predominantly community-
acquired acute kidney injury, and two paediatric studies 
reported the proportions of community-acquired acute 
kidney injury to be 72·8% and 82·9%.14,16 In the remaining 
studies, most cases were probably community-acquired. 
Children ranged from birth to age 17 years, and mean age in 
adult studies ranged from 28·7 years to 44·4 years (appendix). 
The pooled proportion of male patients was signifi cantly 
larger than that of female patients (57% men; p=0·005). 
Male predominance did not change in adults, but declined 
signifi cantly in children over time (table 1). Reported 
frequencies of hyperkalaemia, metabolic acidosis, and 
oliguria are outlined in table 1. Acute kidney injury was 
attributed to intrinsic renal disease in 200 (pooled 56%) of 
359 adults (across four studies) and 200 (pooled 41%) of 
491 children (across six studies; data not shown). Detailed 












Glomerular disease 350 (21%) 76 (8%)
Acute glomerulonephritis 183 57
Nephrotic syndrome 115 10
Rapidly progressive acute 
glomerulonephritis
46 4




Nephrotoxin    270 (16%) 182 (18%)
Haemoglobinuria from: 
Plasmodium falciparum malaria 
haemolysis
198 34
G6PD defi ciency haemolysis 18 0
Infection 0 41




Herbal remedies ingestion 6 8
Holy water 0 7
Henna (para-phenylenediamine) 0 12
Unspecifi ed drugs 0 17
Furosemide 5 0
ACE inhibitors 5 0
Cytotoxic drugs 5 0
Unspecifi ed 31 61
Intravascular volume depletion or 
hypoperfusion 
174 (11%) 50 (5%)
Gastroenteritis 169 42
Inadequate volume replacement 
before and after surgery
4 0
Severe haemorrhage 1 0
Unspecifi ed 0 8
Obstructive uropathy 146 (9%) 46 (5%)
Renal stone 60 16





(Continued from previous column)
Congenital anomaly of the kidney and the urinary tract
Posterior urethral valves 32 0
Renal agenesis    4 0




Unspecifi ed 49 17
Vascular disease or haemolysis 116 (7%) 11 (1%)




Purpura fulminans 1 0
Renal vein thrombosis 1 1
Sickle cell crisis 1 0
Haemolysis, other 0 9
Medical, other 0 36 (4%)
Liver disease 0 15
Cardiac 0 8
Malignant hypertension 0 13
Malignancy 40 (2%) 19 (2%)
Birth asphyxia 27 (2%) 0
Obstetric or gynaecological 0 157 (16%)
Septic abortion 0 66
Pre-eclampsia or eclampsia 0 43
Pre-partum or post-partum 
haemorrhage
0 30
Ureter ligation after hysterectomy 0 7
Unspecifi ed 0 11
Surgical 0 54 (5%)
Trauma, burns, or fractures 0 43
Postoperative 0 1
Other 0 10
Unspecifi ed 140 (9%) 88 (9%)
G6PD=glucose-6-phosphate dehydrogenase. ACE=angiotensin converting enzyme. 
*17 paediatric studies. †14 adult studies. 
Table 2: Causes of acute kidney injury in children and adults
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and children, infection, including malaria, accounted for 
more than 30% of acute kidney injury.
Delays of up to 3 weeks between onset of symptoms and 
presentation to hospital were described in three adult 
studies.31,36,38 One paediatric study reported a mean delay of 
6 days between symptom onset and presentation, and two 
studies described delay in presentation among 50–80% of 
children (appendix).11,15,29  
Defi nitions used for diagnosis of acute kidney injury 
have changed over time (table 1). Standardised diagnostic 
criteria for acute kidney injury (risk, injury, failure, loss of 
function, and end-stage renal disease [RIFLE] and 
paediatric RIFLE [pRIFLE]; Acute Kidney Injury Network 
[AKIN]; and Acute Dialysis Quality Initiative) were used 
in 35% of studies that reported defi nitions used published 
after 2010 compared with none before 2010. 
1075 adults and 609 children received dialysis (table 3). 
Haemodialysis predominated among adults (969 [90%] of 
1075) and peritoneal dialysis predominated among children 
(568 [80%] of 709). 19 of the 41 studies included only patients 
who needed or received dialysis and therefore could not be 
used to calculate dialysis indication or access rates. 
Access to dialysis was defi ned as the proportion of 
patients with acute kidney injury who received dialysis 
when indicated (table 3). In four studies, 178 of 253 adults 
needed dialysis, giving a pooled dialysis indication rate of 
70%. Among these 178 adults, the pooled dialysis access 
rate was 33%. The mean dialysis access rate across adult 
studies was 49·1% (SD 42·3). 11 studies reported dialysis 
need in 1042 of 1572 children with acute kidney injury, 
giving a pooled dialysis indication rate of 66% (table 3). 
In these 1042 children, the dialysis access rate was 64%. 
The mean dialysis access rate across studies was 45·0% 
(SD 32·8; range 9·7–100). In pooled analyses, dialysis 
indication rate and dialysis access rate in children 
increased signifi cantly over time (table 3; p<0·0001). 
However, when data from South Africa and Sudan 
(countries with government-sponsored dialysis and 
paediatric acute kidney injury access rates of 100% and 
95%, respectively) were excluded from this analysis, the 
pooled dialysis access rate after 2010 decreased to 31% 
(156 of 509 children received dialysis), which does not 
diff er signifi cantly from the rate before 2010.
One study described a delay of 3·3 days (SD 1·9; 
range 1–9) between admission to hospital and initiation 
of dialysis owing to the search for resources to pay for 
dialysis, others reported patient deaths while the search 
for resources was underway, or patients leaving hospital 
against medical advice because of inability to aff ord 
dialysis (appendix).13,25,45 
Mortality was reported in 17 adult studies and 21 paediatric 
studies (table 4). Of 1077 adults, 346 died, giving a pooled 
mortality of 32%. Of 1842 children, 627 died, giving a 
pooled mortality of 34%. Pooled mortality decreased 
signifi cantly in both adults and children over time, although 
the ranges of individual study mortalities were highly 
variable (p<0·0001). Mortality associated with specifi c 
causes of acute kidney injury is shown in the appendix.
When stratifi ed by whether dialysis, when indicated, was 
received or not, pooled mortality was signifi cantly higher 
in adults (86% vs 30%; p<0·0001) and children (74% vs 
30%; p<0·0001) who did not receive at least one dialysis 
session. Nine studies reported consistent fi ndings in 
adults and children from the same cohort, suggesting this 
may not merely be a centre eff ect (appendix). Mortality in 
children was not diff erent between those who received 
haemodialysis and those who received peritoneal dialysis. 
Overall mortality reported in children with acute kidney 
injury who did not need dialysis was lower than in those 
who received dialysis (16·22% vs 28·54%; p=0·13). 
Major predictors of poor outcomes in several studies 
were late presentation and inability to pay for dialysis.18,36 
Numbers of patients lost to follow-up or leaving against 
medical advice were high in some studies (table 4), 
showing the challenges of patient care and clinical 
research in sub-Saharan Africa. 
Renal recovery, defi ned as independence from dialysis, 
improvement in serum creatinine after acute kidney injury, 
Adult studies Paediatric studies
1990–2009 2010–14 p 1990–2009 2010–14 p
Dialysis distribution ·· ·· <0·0001 ·· ·· 0·57
Haemodialysis 411 (82%; n=8)  558 (97%; n=8) ·· 5 (4%; n=2) 114 (20%; n=5) ··
Peritoneal dialysis 86 (17%; n=2) 17 (3%; n=1) ·· 122 (96%; n=6) 446 (77%; n=8) ··
Both 1 (<1%) 0 ·· 0 22 (4%; n=1) ··
CRRT 2 (<1%) 0 ·· ·· ·· ··
Studies with dialysis received as an inclusion criterion* 5 8 ·· 0 6  ··
Indication for dialysis in acute kidney injury (pooled) 94/132 (71%; n=3) 84/121 (69%; n=1) 0·76 372/608 (61%; n=5) 670/964 (70%; n=6) 0·001
Access to dialysis (pooled) 44/94 (47%) 14/84 (17%) ·· 119/372 (32%) 547/670 (82%)† <0·0001
Access to dialysis (means of individual studies) 59·8% (SD 44·2) 16·7% ·· 34·2% (SD 37·2) 54·0% (SD 28·9) 0·35
Data are number of patients (%) or number of studies. p values for 1990–2009 versus 2010–14. CRRT=continuous renal replacement therapy. *Studies with dialysis required or received as an inclusion criterion 
provided no information on non-dialysed patients or patients with acute kidney injury who did not need dialysis and therefore were excluded from this analysis. †When two studies from South Africa and Sudan 
are excluded, the dialysis access rate decreases to 31% and does not diff er between 1990–2009 and 2010–14. 
Table 3: Indication for dialysis and access to dialysis in children and adults with acute kidney injury 
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or both, was reported in 17 studies (table 4). The pooled rate 
of renal recovery was 130 (55%) of 237 (six studies) in adult 
survivors and 667 (75%) of 886 (11 studies) in child 
survivors. The pooled rate of residual chronic kidney 
disease, defi ned as persistence of renal dysfunction but not 
needing dialysis at time of discharge, was 24 (13%) of 
186 adults (three studies) and 68 (10%) of 676 children (fi ve 
studies). These outcomes were not routinely reported or 
systematically defi ned, and some studies had substantial 
loss to follow-up, so the true rates remain unknown.
Discussion 
The aim of this systematic review was to describe the 
real-world context of patients diagnosed with acute 
kidney injury in sub-Saharan Africa. We identifi ed 
41 studies published during 25 years reporting access to 
dialysis when needed, mortality, and renal outcomes in 
cohorts of all patients with acute kidney injury. 
Most patients presented with severe acute kidney injury, 
with 70% of adults and 66% of children needing dialysis 
(stage 3 acute kidney injury). This dialysis need contrasts 
strongly with the pooled world need for dialysis in patients 
with acute kidney injury of 11%, because 80% of all 
patients worldwide had stage 1 (mild) acute kidney injury.4 
These opposing observations suggest that acute kidney 
injury is a more aggressive disorder in sub-Saharan Africa 
than elsewhere; however, this is more likely to be a result 
of late presentation to hospital and reliance on clinical 
criteria for diagnosis, which might only become apparent 
at an advanced stage. Many studies commented on delay 
in patient presentation, not uncommonly with oliguria 
and advanced uraemia at diagnosis.
When dialysis was needed, the pooled dialysis access 
rate was 33% in adults and 64% in children, although 
rates were as low as 10% in some studies. Results of a 
survey of availability of paediatric services in Nigeria 
showed that more than 50% of facilities did not have 
dialysis capability.51 When patients did gain access to 
dialysis, most adults received haemodialysis, showing the 
absence of peritoneal dialysis in many centres.32,34,36 In 
Adult studies Paediatric studies
1990–2009  2010–14  p 1990–2009 2010–14  p
Overall mortality
Mortality (pooled) 237/639 (37%; n=9) 109/438 (25%; n=8) <0·0001 285/720 (40%; n=7) 342/1122 (30%; 
n=14)
<0·0001
Mortality (means of individual studies) 38·7% (20·6) 29·2% (24·5) 0·40 40·5% (8·3) 30·4% (14·4) 0·11
Mortality without dialysis when needed
Mortality without dialysis when needed 
(pooled)
43/50 (86%; n=2) NA ·· 179/247 (72%; n=4) 45/57 (79%; n=3) 0·32
Mean mortality without dialysis (means of 
individual studies) 
82·4% (12.8) NA ·· 72·9% (18·8) 90·0% (17·3) 0·27
Mortality with dialysis
Mortality with dialysis (pooled) 161/500 (32%; n=8) 78/288 (27%; n=6) 0·13 28/119 (24%; n=5) 184/585 (31%; 
n=10)
0·09
Mean mortality with dialysis (means of 
individual studies) 
28·0% (15·7) 35·1% (26·1) 0·54 16·4% (11·5) 34·6% (20·1) 0·09
Mean mortality haemodialysis (means of 
individual studies) 
27·3% (14·13; n=7) 33·46 % (27·00; n=6) 0·61 57·0% (39·9; n=3)  0·27*
Mean mortality peritoneal dialysis (means 
of individual studies) 
25% (n=1)  NA NA 33·6% (27·4; n=9)  ··
Mortality when dialysis not indicated
Mortality when dialysis not indicated 
(pooled)
23/43 (53%†; n=2) NA ·· 36/232 (16%; n=4) 43/285 (15%; n=4) 0·84
Mortality, acute kidney injury not needing 
dialysis (means of individual studies)
30·3% (42·8) NA ·· 22·2% (17·1) 10·2% (8·4) 0·25
Other outcomes
Recovery of renal function in survivors 
(pooled)
58/78 (74%; n=2) 72/159 (45%; n=4) <0·0001 152/172 (88%; n=3) 515/714 (72%; n=8) <0·0001
Residual chronic kidney disease in survivors 
(pooled)‡
6/73 (8%; n=1) 18/113 (16%; n=2) 0·1 23/143 (16%; n=2) 45/533 (8%; n=3) 0·007
Left hospital against medical advice (pooled) 0 6/62 (10%; n=1) ·· 10/183 (5%; n=2) 33/814 (4%; n=5) 0·4
Lost to follow-up (pooled) 28/264 (11%; n=2) 6/17 (35%; n=1) ·· 116/334 (35%; n=2) 20/700 (3%; n=2) <0·0001
Data are mean % (SD) or mean (%; number of studies with outcome). p values for 1990–2009 versus 2010–14. *Comparison between haemodialysis and peritoneal dialysis in 
children. †One study included high-comorbidity patients in intensive care units. ‡Chronic kidney disease not specifi cally defi ned, generally non-requirement for dialysis but 
non-return of renal function to normal parameters by discharge or loss to follow-up. 
Table 4: Outcomes in children and adults with acute kidney injury
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children, peritoneal dialysis predominated, owing to body 
size limitations and absence of haemodialysis facilities.11,23,28 
Paediatric peritoneal dialysis was some times done with 
modifi ed alternative catheters and fl uids when appropriate 
resources were unavailable.23
The overall pooled mortality was 32% in adults and 
34% in children with acute kidney injury. These rates are 
much higher than the pooled world rates of 23·3% in 
adults and 13·8% in children, possibly showing the 
increased severity of documented acute kidney injury in 
sub-Saharan Africa and low access to dialysis.3 The more 
than two times higher mortality in children in sub-
Saharan Africa compared with worldwide mortality is 
especially concerning. How the overall data might be 
skewed by the high proportion of studies exclusively on 
dialysed patients is diffi  cult to predict. Pooled mortality 
in those who received dialysis was 30% in adults and 
children, lower than the world mortality among dialysed 
patients with acute kidney injury of 46%.2 The lower 
dialysis mortality in sub-Saharan Africa compared with 
elsewhere might refl ect the relative absence of patient 
comorbidities and more frequent community-acquired 
acute kidney injury, despite frequent premature 
discontinuation of dialysis because of cost.38
However, a substantial proportion of patients with 
acute kidney injury in sub-Saharan Africa did not receive 
dialysis when needed and experienced very high mortality 
rates. These poor outcomes show the severity of patient 
illness and delayed presentation, delays imposed by 
searching for funds after admission to hospital, and the 
erratic infrastructure.13,18,29,38,45 However, mortality among 
these undialysed patients was not inevitable, emphasising 
the value of conservative management and prompt 
treatment of underlying disease in the absence of 
dialysis.24 Availability of the needed resources might also 
be inconsistent in sub-Saharan Africa. Resources 
reported during the included studies are listed in the 
appendix. A survey of 66 intensive care facilities in the 
Democratic Republic of the Congo reported that 
crystalloids were available in 100% of units, but that 
availability of antibiotics and other necessities was 
variable.52 Serum creatinine was never available in 75·8% 
of units. Dialysis was not available in any units. 
Most adults and children surviving acute kidney injury 
recovered renal function, although roughly 10% had 
residual renal dysfunction. This high rate of persistent 
renal dysfunction might be a result of the initial severity 
of acute kidney injury, or might highlight the challenges 
in excluding underlying chronic kidney disease without 
access to diagnostic tests. Very few cohorts had long-term 
follow-up, therefore these percentages could be an 
overestimate and some patients might have continued to 
improve over time.
Several barriers to access to care for acute kidney injury 
were identifi ed through this study, as shown in fi gure 2. 
First, the low overall patient numbers reported suggest 
that many patients with acute kidney injury are not 
diagnosed or treated. Second, male patients predominate, 
probably showing some discrimination against women. 
Third, poor patient resources led to delays in admission 
to hospital and use of traditional medicine, which might 
be especially harmful in the setting of dehydration, for 
example, and worsen kidney injury. Fourth, delays occur 
in referral from peripheral health-care sites to sites where 
renal care is available. Finally, delays occur after 
admission to hospital because patients need to search for 
funds to pay for dialysis or because supplies, staffi  ng, or 
resources of the hospital are erratic. Each of these delays 
might have a seemingly obvious cause, but if a holistic 
approach is to be taken to prevent acute kidney injury, 
much research, including clinical, epidemiological, and 
anthropological study, is needed to investigate all 
contributors to such barriers. The expectation that most 
patients can pay for dialysis, even when heavily 
subsidised, is probably unrealistic, since even meagre 
user-fees are a hindrance to access to basic health care in 
low-income settings.53 The predominance of male 
Figure 2: Barriers to care in acute kidney injury
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patients might refl ect a true increased susceptibility to 
renal disease (eg, urogenital abnormalities in boys), but 
more probably refl ects the relative absence of economic 
and decision-making power among women, and is 
consistent with fi ndings in other low-resource regions.54,55 
Although reported observations seem to be mostly 
consistent across studies, this systematic review has 
substantial limitations. In most countries in sub-Saharan 
Africa, access to diagnosis and specialist renal care for 
acute kidney injury is scarce, and is heavily reliant on 
out-of-pocket payments by patients. The patients reported 
in the reviewed studies are therefore those who had the 
resources to be diagnosed with acute kidney injury, some 
of whom were also able to access dialysis. These studies 
do not represent the many patients with acute kidney 
injury in sub-Saharan Africa for whom the needed health 
services are beyond reach.
The observational and historical nature of most studies, 
coupled with a high proportion of missing data, frequent 
patient loss to follow-up, variability in acute kidney injury 
defi nitions, and representation of data from only 
13 countries all diminish the robustness of data 
interpretation. Such weaknesses have led to exclusion of 
these studies from existing meta-analyses, and acute 
kidney injury in sub-Saharan Africa has therefore 
remained a so-called black box in the world scientifi c 
literature on acute kidney injury. Our decision to include 
all obtainable studies was intentional to try to mitigate 
publication bias that would be exacerbated with further 
study selection, and to best capture the reality of daily 
challenges faced by patients and nephrologists in sub-
Saharan Africa. Our inclusion of all comers also 
strengthens the generalisability of the fi ndings to the 
general acute kidney injury population. However, 
descriptive analysis cannot account for diff erent study 
weights or quality, and the conclusions are therefore less 
robust than in a meta-analysis. The severity of reported 
acute kidney injury might show a bias towards testing 
the most symptomatic patients, which could overestimate 
poorer outcomes, although patients who survived the 
delay in presentation to hospital might have a propensity 
to survival. Abstracts of nine acute kidney injury articles 
were not obtainable in full text, but the outcomes 
described suggest consistency with the main fi ndings of 
this study and would therefore be unlikely to alter the 
conclusions.
Highlighting real-world outcomes and challenges, 
despite study limitations, is important to inform health-
systems-wide planning and policy development for acute 
kidney injury in regions where resources are scarce and 
many health-care priorities are competing. The increasing 
number of publications over time highlights growing 
expertise, but also an urgency in the specialty. This study 
also highlights the important limitations of previous 
studies. Study quality scores and checklists should be 
considered prospectively in any ongoing or planned 
research on acute kidney injury in sub-Saharan Africa to 
optimise study design, data collection, and accuracy of 
reporting, so that future studies can further understanding 
of the true burden of acute kidney injury in sub-Saharan 
Africa and reliably inform policy making. 
The published outcomes of acute kidney injury in 
patients in sub-Saharan Africa show the complexities of 
access to timely and appropriate renal care in the region. 
Several barriers to diagnosis and care of acute kidney 
injury are evident, the most consistent of which are 
delays in reaching hospital, cost of care, erratic 
functioning or supply of hospital resources, and female 
sex. If a programme for prevention and treatment of 
acute kidney injury is to be eff ective and sustainable, 
each barrier will need to be understood and overcome.
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Outcomes in adults and children with end-stage kidney disease 
requiring dialysis in sub-Saharan Africa: a systematic review
Gloria Ashuntantang, Charlotte Osafo, Wasiu A Olowu, Fatiu Arogundade, Abdou Niang, John Porter, Saraladevi Naicker, Valerie A Luyckx
Summary
Background The burden of end-stage kidney disease (ESKD) in sub-Saharan Africa is unknown but is probably high. 
Access to dialysis for ESKD is limited by insufficient infrastructure and catastrophic out-of-pocket costs. Most patients 
remain undiagnosed, untreated, and die. We did a systematic literature review to assess outcomes of patients who 
reach dialysis and the quality of dialysis received.
Methods We searched PubMed, African Journals Online, WHO Global Health Library, and Web of Science for articles 
in English or French from sub-Saharan Africa reporting dialysis outcomes in patients with ESKD published between 
Jan 1, 1990, and Dec 22, 2015. No studies were excluded to best represent the current situation in sub-Saharan Africa.
Outcomes of interest included access to dialysis, mortality, duration of dialysis, and markers of dialysis quality in 
patients with ESKD. Data were analysed descriptively and reported using narrative synthesis.
Findings Studies were all of medium to low quality. We identified 4339 studies, 68 of which met inclusion criteria, 
comprising 24 456 adults and 809 children. In the pooled analysis, 390 (96%) of 406 adults and 133 (95%) of 140 children 
who could not access dialysis died or were presumed to have died. Among those dialysed, 2747 (88%) of 3122 adults 
in incident ESKD cohorts, 496 (16%) of 3197 adults in prevalent ESKD cohorts, and 107 (36%) of 294 children with 
ESKD died or were presumed to have died. 2508 (84%) of 2990 adults in incident ESKD cohorts discontinued dialysis 
compared with 64 (5%) of 1364 adults in prevalent ESKD cohorts. 41 (1%) of 4483 adults in incident ESKD cohorts, 
2280 (19%) of 12 125 adults in prevalent ESKD cohorts, and 71 (19%) of 381 children with ESKD received transplants. 
16 studies reported on management of anaemia, 17 on dialysis frequency, eight on dialysis accuracy, and 22 on 
vascular access for dialysis 
Interpretation Most patients with ESKD starting dialysis in sub-Saharan Africa discontinue treatment and die. Further 
work is needed to develop equitable and sustainable strategies to manage individuals with ESKD in sub-Saharan Africa.
Funding None.
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND license.
Introduction
Chronic kidney disease (CKD) is an increasing, but still 
underappreciated, contributor to the global burden of 
disease.1 Best estimates from sub-Saharan Africa suggest 
12–23% of adults have CKD and are therefore at risk of 
developing end-stage kidney disease (ESKD).2–4 Since 
symptoms are largely non-specific and manifest late, 
diagnosis of CKD, especially at an early treatable stage, is 
easily missed.
Once the kidneys fail, renal replacement therapy by 
dialysis or transplantation is the only means of survival. 
Findings from studies in the past 5 years5,6 have suggested 
that between 2·3 million and 3·2 million people die 
yearly as a result of no access to dialysis. Estimation of the 
anticipated incidence of ESKD based on the prevalence of 
hypertension and diabetes suggests that only 1·5% of 
those requiring renal replacement therapy in sub-Saharan 
Africa receive it.5 Others reported a gap between those 
who require and receive dialysis of over 84% in sub-
Saharan Africa.6 There is no African renal registry, but 
reported dialysis incidence tends to be higher than 
prevalence in sub-Saharan Africa, suggesting high 
mortality among patients with ESKD.5–8 Where available, 
haemodialysis predominates because of frequent 
unavailability and higher costs of peritoneal dialysis and 
little availability of transplantation.9,10 In South Africa and 
Sudan, governments provide dialysis for ESKD. In 
South Africa, state-funded dialysis is accessed through a 
rationing process; in Sudan dialysis is offered to all, but at 
a reduced frequency (haemodialysis two instead of 
three times per week).11,12 In other sub-Saharan African 
countries, most expenses are paid out of pocket.12–15 
Therefore, in most of sub-Saharan Africa, patients with 
prevalent ESKD represent the elite few with enough 
resources to access long-term renal replacement therapy.
Dialysis outcomes are associated with the quality of 
dialysis delivered, which depends on the amount (ie, 
dose), duration, and frequency of dialysis; management 
of complications including anaemia; blood pressure; 
phosphate control; and laboratory monitoring. In 
haemodialysis, type of vascular access also affects 
morbidity and mortality.
We did a systematic review to explore outcomes and 
quality of dialysis in patients with incident and prevalent 
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ESKD in sub-Saharan Africa. Understanding the local 
realities of management of ESKD is important to 
highlight the daily clinical and moral dilemmas faced by 
clinicians, patients, and families when dialysis is paid for 
out of pocket, and to inform pragmatic policy 
development about ESKD care in resource-limited 
settings.
Methods
Search strategy and selection criteria
We registered our systematic literature review with 
PROSPERO (CRD42015015690) and completed it 
according to the Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses guidelines.16 We searched 
PubMed, African Journals Online, the WHO Global 
Health Library, and Web of Science from Jan 1, 1990, to 
Dec 22, 2015, with relevant medical subject headings 
(appendix p 1). The search was restricted to publications 
in English and French. Additional references were 
identified through bibliography searches. Criteria for 
inclusion were all studies reporting outcomes related to 
access to dialysis, mortality, duration of dialysis, and 
markers of dialysis quality in patients with ESKD who 
needed or received dialysis in sub-Saharan Africa. 
Articles focusing exclusively on specific outcomes or 
subpop ulations, such as infections, and those reporting 
trans plantation outcomes were excluded, as were case 
reports (appendix p 1). Two authors (FA and VAL) 
screened titles and abstracts for eligibility. Articles 
meeting inclusion criteria and obtainable as full texts 
were reviewed in detail. Incident cohorts were defined as 
those reporting outcomes in patients with a new 
diagnosis of ESKD who needed, but either started or did 
not receive, dialysis. Prevalent ESKD cohorts were 
defined as those reporting outcomes in patients receiving 
long-term dialysis.
Quality assessment and data extraction
Study quality was assessed independently by two authors 
(VAL plus GA, CO, WAO, FA, or AN), as described 
previously (appendix pp 2–3).3,17 All articles meeting 
inclusion criteria were included in an attempt to 
minimise further bias and to reflect the current situation 
in sub-Saharan Africa, as reported previously.17 Individual 
study data were extracted into Microsoft Excel (Redmond, 
WA, USA; appendix p 4). 
Data analysis
In view of the variability in definitions of ESKD, length of 
follow-up, proportions of loss to follow-up, study sizes, 
and outcomes reported per study, data were analysed 
descriptively and reported using narrative synthesis.18,19 
Where possible, outcomes were reported within time-
frames for perspective; however, these data were not 
routinely available. Study populations were stratified by 
participant age (adult or paediatric) and by incident or 
prevalent cohorts. Outcomes were analysed separately 
for adults with incident and prevalent ESKD to test the 
hypothesis that outcomes are improved among patients 
with ESKD in sub-Saharan Africa who can achieve long-
term dialysis. Similarly, in view of more scarce resources 
and probably a lower ability to pay for ESKD care for 
children than adults in sub-Saharan Africa, outcomes in 
adult and paediatric populations were analysed separately. 
Data were reported as pooled estimates of outcome 
frequencies; however, in view of the variability between 
studies, the same outcomes are also reported in parallel 
as means (with SDs) of frequencies reported in individual 
studies, to show the breadth of interstudy variability 
of the various outcomes. Study denominators vary 
depending on the outcomes reported. Adults with 
incident and those with prevalent ESKD are reported 
separately; children were analysed overall because of the 
Research in context
Evidence before this study
Data on epidemiology and outcomes of end-stage kidney 
disease (ESKD) in sub-Saharan Africa are sparse. We did a 
systematic review of the literature to understand outcomes in 
patients with ESKD managed under existing circumstances in 
sub-Saharan Africa. We searched PubMed, African Journals 
Online, the WHO Global Health Library, and Web of Science 
between Jan 1, 1990, and Dec 22, 2015, with relevant medical 
subject headings. Additional references were found through 
screening of reference lists from identified articles. All retrieved 
and selected articles were published in English or French. No 
previous systematic reviews on this topic were identified.
Added value of this study
This study is, to our knowledge, the first to systematically 
analyse outcomes and quality of dialysis received in patients 
with ESKD in sub-Saharan Africa from several countries and 
centres. We found high mortality among patients with 
incident ESKD. Mortality was lower in patients with prevalent 
ESKD who had dialysis, which provides reason for optimism, 
but raises the important ethical question of how such dialysis 
could be sustainable on a broader scale in low-income 
countries with other health priorities and where opportunity 
costs (ie, the proportion of budget allocated to dialysis is not 
available for allocation to other health issues) are high. The 
quality of dialysis delivered is generally low, mostly because of 
economic factors.
Implications of all the available evidence
The increasing numbers of publications from sub-Saharan 
Africa in recent years is testament to the growing expertise in 
the region. As expertise grows, the health system must adapt; 
therefore, studies such as this are important initial steps to raise 
awareness of the clinical problem of ESKD as well as the large 
ongoing knowledge gaps among policy makers and the 
international community.
See Online for appendix
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small number of studies. Statistical analyses were not 
done because of the intrinsic differences between adults 
with incident versus prevalent ESKD and between 
adults and children, rendering comparisons artificial.
Role of the funding source
There was no funding source for this study. All authors 
had full access to all the data in the study and had final 
responsibility for the decision to submit for publication.
Results
4339 records were found, of which 1151 were excluded; 
386 of 3188 screened studies underwent full review 
(figure 1), including one registry report from 
South Africa. No study was of high quality, mainly 
because participants were not representative of the 
larger ESKD population and because of missing data. 
68 studies (56 adult, 12 paediatric) from 15 countries 
satisfied inclusion criteria, 49 of which were published 
from 2010 onwards. 34 of the 68 studies met medium-
quality criteria. 26 adult and ten paediatric studies 
included patients with incident ESKD, 30 adult and 
two paediatric studies included patients with prevalent 
ESKD (appendix pp 5–11), and 37 adult and two paediatric 
studies included only patients who received dialysis. 
Ten studies provided details of missing data. 16 adult 
studies were prospective, seven cross-sectional, and 
33 retrospective. Two paediatric studies were prospective 
and ten retrospective. Study duration ranged from 
0·08 years to 19 years. All 12 paediatric and 26 of the 
adult studies were from academic hospitals; 24 adult 
studies were from city hospitals or haemodialysis units; 
three were from private dialysis units; and three reported 
whole-country data. 24 456 adults (10 354 with incident 
and 14 102 with prevalent ESKD) and 809 children 
(736 incident and 73 prevalent) were included in analyses 
(table 1).12,13
Mean patient ages ranged from 35·6 years (SD 13·2) to 
58·2 years (SD 15·0) in adult studies and from 9·8 years 
(range 3 months to 17 years) to 11·5 years (SD 3·0) in 
paediatric studies. Males predominated among adults 
and children (table 1). The term CKD was often used 
synonymously with ESKD. The definitions of CKD and 
ESKD used are reported in table 1. The causes of CKD 
Figure 1: Study selection
ESKD=end-stage kidney disease. *Includes African Index Medicus. †39 had receipt of dialysis as an inclusion criterion.
4339 records found
185 from African Journals Online
1187 from PubMed
1138 from Web of Science
1829 from WHO Global Health Library*
1151 duplicates or published before 1990
3188 titles and abstracts screened
2831 excluded
2797 did not meet eligibility criteria
34 manuscripts not obtainable as full text
318 excluded
44 specific causes of kidney disease 
1 conference abstract
9 donors 
11 data not relevant 
93 guidelines, reviews, editorials, or 
commentaries 
17 prevalence or incidence data
89 outcomes too specific (eg, peritonitis 
rates, tuberculosis in dialysis)
26 acute kidney injury alone
19 transplantation
9 reported same populations
29 records identified from other sources 
386 full-text articles screened
68 articles selected for systematic review†
12 paediatric ESKD studies
6 low quality
6 medium quality
2 studies of patients with prevalent 
ESKD
10 studies of patients with incident 
ESKD
30 studies of patients with prevalent 
ESKD
26 studies of patients with incident 
ESKD
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and ESKD were reported in 40 adult and 12 paediatric 
studies (appendix p 12).
The proportion of patients with incident ESKD who 
were able to access dialysis is outlined in table 2. Pooled 
analysis showed that 4221 of 8253 adults (51%; 15 studies) 
and 211 of 347 children (61%; eight studies) received at 
least one dialysis session. The mean percent access to 
dialysis across individual studies was 39·1% (SD 25·7) in 
adults and 47·4% (30·6) in children. Of 3692 adults with 
incident ESKD, 2980 (81%) received haemodialysis and 
712 (19%) received peritoneal dialysis (16 studies); these 
numbers were 11 186 (84%) and and 2194 (16%) among 
13 380 adults with prevalent ESKD (26 studies), and 
128 (46%) and 149 (54%) among 277 children (ten studies). 
Dialysis duration was reported in 35 adult and 
eight paediatric studies (table 2). Among those who 
started dialysis, 2572 of 4354 adults (59%; 23 studies) and 
94 of 192 children (49%; six studies) discontinued dialysis. 
In adults, 2508 of 2990 (84%; 13 studies) incident and 
64 of 1364 (5%; ten studies) prevalent patients 
discontinued dialysis after a mean of 6·5 (SD 5·3) 
sessions. The pooled proportion of children discontinuing 
dialysis was 94 of 192 (49%; six studies), and the mean 
percentage was 76·2% (SD 33·6). The proportions of 
adults and children continuing dialysis for at least 
3 months and at least 12 months are shown in table 2. 
The pooled proportion of adults with prevalent ESKD 
remaining on dialysis for at least 3 months was 3029 of 
3575 (85%; ten studies) and the mean of individual study 
frequencies was 63·4% (SD 24·0), compared with a 
pooled proportion of 295 of 3104 (10%; 16 studies) and 
mean of individual study frequencies of 14·1% (SD 12·6) 
in adults with incident ESKD. The durations of dialysis 
received in individual studies are shown in the appendix 
(pp 5–11). Compared with the full cohort, when studies 
from South Africa and Sudan were excluded, the 
proportions of people who discontinued dialysis were 
higher among both adults and children (78% and 86%, 
respectively; appendix p 13).
In the pooled analyses, overall known study mortality 
was higher in adults (3446 [32%] of 10 874; 35 studies) 
than in children (159 [24%] of 656; ten studies) and in 
incident (2966 [39%] of 7677; 17 studies) than in prevalent 
(480 [15%] of 3197; 18 studies) adult cohorts. However, 
overall study mortality might not represent ESKD 
mortality, because some studies included patients with 
CKD who did not require dialysis, and most did not 
account for patients lost to follow-up or leaving hospital 
against medical advice. 27 of 143 children (19%; 
three studies) had left hospital against medical advice, 
whereas 557 of 3087 adults (18%; 12 studies) and 188 of 
675 children (28%; eight studies) were lost to follow-up 
(table 3). We presumed that these patients probably died 
without further treatment. Including these patients and 
those who discontinued dialysis in the pooled analysis, 
known and presumed mortality occurred in 5128 of 
9057 adults (57%; 39 studies) and 266 of 426 children 
(62% 11 studies). Mortality was higher among adults with 
incident (4632 [79%] of 5860; 21 studies) than among 
those with prevalent ESKD (496 [16%] of 3197; 18 studies). 
Adult studies Paediatric studies 
(n=12)
Overall (n=56) Incident ESKD (n=26) Prevalent ESKD (n=30)
Number of countries 14 8 12 4
Patient inclusion period 1976–2014 1976–2013 1987–2014 1995–2013
Total number of patients with CKD or ESKD 24 456 10 354 14 102 809
In South Africa and Sudan only 15 063 2586 12 477 398
Excluding South Africa and Sudan 9393 7768 1625 411
Study duration (years)* 4·0 (4·5) 5·8 (5·1) 2·1 (2·3) 6·1 (2·8)
Sex†
Male 13 655/22 152 (62%) 5682/9401 (60%) 7973/12 751 (63%) 439/748 (59%)
Female 8497/22 152 (38%) 3719/9401 (40%) 4778/12 751 (37%) 309/748 (41%)
Male:female ratio, individual studies† 1·98 (1·09) 1·72 (0·78) 2·20 (1·39) 1·46 (0·34)
Definitions of CKD or ESKD used
Clinical 7 7 0 2
Laboratory (creatinine thresholds) 9 9 0 6
ESKD, glomerular filtration rate <15 mL/min 7 7 0 0
KDIGO or KDOQI 4 4 0 3
Dialysis requirement 41 11 30 2
Not mentioned 1 1 0 3
Data are mean (SD) or n/N (%), unless otherwise specified. CKD=chronic kidney disease. ESKD=end-stage kidney disease. KDIGO=Kidney Disease Improving Global Outcomes. 
KDOQI=Kidney Disease Outcomes Quality Initiative. *Data missing for four studies in adults with prevalent ESKD and one paediatric study. †Data missing for ten studies in 
adults (five incident ESKD and five prevalent ESKD) and four in children. 
Table 1: Study populations
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Leading causes of death were uraemia, volume overload 
(ie, too much water in their bodies that they could not 
excrete because of kidney failure), hypertension, 
discontinuation of dialysis, no vascular access, heart 
failure, stroke, or infections.20–26 
Overall pooled mortality among patients with ESKD 
who received dialysis was similar among adults 
(1302 [31%] of 4228; 25 studies) and children (90 [32%] of 
284; ten studies), but was higher among adults with 
incident ESKD (822 [80%] of 1031; seven studies) 
compared with prevalent ESKD (480 [15%] of 3197; 
18 studies; table 3). Among patients who needed but did 
not receive dialysis, pooled known and presumed 
mortality was similar in adults (390 [96%] of 406; 
three studies) and children (133 [95%] of 140; 
nine studies). Among adults with incident ESKD, the 
difference in known and presumed mortality between 
those who did and did not receive dialysis was small 
(2747 [88%] of 3122, 14 studies vs 390 [96%] of 406; 
three studies). When South Africa and Sudan were 
excluded from the analyses, pooled mortality among 
adults and children who received dialysis increased 
further (appendix p 14). Pooled known and presumed 
mortality was similar between adult patients with 
prevalent ESKD who received peritoneal dialysis 
(121 [19%] of 650; seven studies) or haemodialysis 
(301 [16%] of 1884; nine studies; appendix p 15).
15 adult studies reported use of intravenous iron or 
erythropoietin for renal anaemia (appendix p 16). Access 
to both drugs was scarce, leaving patients mainly reliant 
on blood transfusions (mean 61·5% [SD 15·2]; 
six studies). Use of any intravenous iron (1870 [65%] of 
2898; three studies vs 30 [25%] of 120; one study) or 
erythropoietin (2425 [74%] of 3287; nine studies vs 
65 [19%] of 348; three studies) was higher in prevalent 
versus incident cohorts. Means of individual study 
proportions were generally lower than pooled proportions. 
One paediatric study reported use of erythropoietin for 
less than 1 week in two of 24 children and blood 
transfusion in five of 25 children.27 Use of phosphate 
binders was reported in two of 42 and 19 of 45 patients in 
two adult studies.28,29 Haemodialysis vascular access was 
described in 22 adult studies. Overall, the mean 
proportion of patients with arteriovenous fistula was 
15·6% [SD 9·7] at the start of dialysis, but rose among 
prevalent patients over time (from 16·5% [10·9] to 
61·3% [26·2]; appendix p 16). No study described regular 
laboratory monitoring. Four studies reported use of 
four 2 L exchanges daily for continuous ambulatory 
peritoneal dialysis (usual dose), and one study described 
use of a peritoneal dialysis cycler.30–33 Frequency of 
haemodialysis was described in 17 studies (figure 2).12,24,26,34–47 
Most patients with prevalent ESKD received two 4 h 
sessions per week, but some received dialysis 
Adult studies Paediatric studies
Overall Incident Prevalent
Access to dialysis
Pooled 4221/8253 (51%; 15) 4221/8253 (51%; 15) NA 211/347 (61%; 8)
Individual studies 39·1% (25·7; 16) 39·1% (25·7; 16) NA 47·4% (30·6; 8)
Not dialysed although indicated
Pooled 3277/6797 (48%; 11) 3277/6797 (48%; 11) NA 106/323 (33%; 7)
Individual studies 56·6% (19·5; 11) 56·6% (19·5; 11) NA 41·6% (21·4; 7)
Known to stop dialysis although needed
Pooled 2572/4354 (59%; 23) 2508/2990 (84%; 13) 64/1364 (5%; 10) 94/192 (49%; 6)
Individual studies 51·4% (41·4; 23) 79·7% (27·5; 13) 14·7% (23·0; 10) 76·2% (33·6; 6)
Continued dialysis ≥3 months*
Pooled 3324/6589 (50%; 26) 295/3014 (10%; 16) 3029/3575 (85%; 10) 66/190 (35%; 7)
Individual studies 33·1% (32·9; 26) 14·1% (21·6; 16) 63·4% (24·0; 10) 29·6% (38·2; 7)
Continued dialysis ≥12 months†
Pooled 1598/3560 (45%; 13) 19/1472 (1%; 6) 1579/2088 (76%; 7) 3/6 (50%; 1)
Individual studies 36·4% (38·3; 13) 1·5% (2·3; 6) 66·3% (25·8; 7) No data
Recovery of enough renal function to come off dialysis
Pooled 34/1765 (2%; 9) 5/64 (8%; 3) 29/1701 (2%; 6) 2/20 (10%; 3)
Individual studies 4·9% (7·1; 9) 7·3% (12·6; 3) 3·7% (3·4; 6) 22·2% (38·5; 3)
Transplant received
Pooled 2321/16 608 (14%; 24) 41/4483 (1%; 11) 2280/12 125 (19%; 13) 71/381 (19%; 9)
Individual studies 6·3% (8·4; 24) 1·7% (1·3; 11) 10·3% (9·9; 13) 19·0% (26·6; 9)
Data are n/N (%; number of studies) or mean (SD; number of studies). NA=not applicable. *Countries reporting dialysis duration ≥3 months: Burkina Faso, Cameroon, 
Democratic Republic of the Congo, Ethiopia, Ghana, Malawi, Nigeria, Senegal, South Africa, and Sudan. †Countries reporting dialysis duration ≥12 months: Cameroon, 
Ethiopia, Ghana, Nigeria, Senegal, South Africa, Sudan. 
Table 2: Renal replacement therapy for end-stage kidney disease
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intermittently as resources permitted. Eight adult studies 
reported monitoring of dialysis adequacy, which was 
infrequent and often suboptimum (appendix p 17). The 
delivered dialysis dose tended to be higher among those 
receiving peritoneal dialysis than haemodialysis.
Nine adult and three paediatric studies described 
recovery of enough renal function for patients to 
discontinue dialysis. In pooled analyses, five of 64 adults 
with incident ESKD (8%; three studies) and two of 
20 children (10%; three studies) came off dialysis 
(table 2). 2321 of 16 608 adults (14%; 24 studies) and 71 of 
381 children (19%; nine studies) received a kidney 
transplant. A transplant was received by more adults 
with prevalent than with incident ESKD (2280 [19%] of 
12 125 vs 41 [1%] of 4483). Transplantations were often 
done outside the country (data not shown). When studies 
from South Africa and Sudan were excluded, the 
proportion of patients receiving a transplant decreased 
substantially, to 54 (1%) of 4808 adults and four (3%) of 
158 children (appendix p 13).
Discussion
The public health impact of ESKD does not lie exclusively 
in the numbers of patients affected, but also in the 
diagnostic and therapeutic challenges of management, 
which impose a substantial burden on individuals and the 
health system in resource-limited settings. So far, mostly 
single-centre studies have highlighted the local challenges 
in management of ESKD in sub-Saharan Africa. In this 
systematic review, we show that, even among the few 
people who reach a diagnosis of ESKD in sub-Saharan 
Africa, presumed and known mortality among adults and 
children was high, and was over 95% when patients were 
unable to access dialysis. Among patients who did start 
dialysis, mortality remained high, largely because of late 
presentation, frequent dialysis discontinuation, and 
suboptimum dialysis quality. Overall, only around 10% of 
adults with incident ESKD and 35% of children remained 
on dialysis for at least 3 months. Worldwide, higher 
mortality is noted within the first 120 days of starting 
dialysis compared with later months, which is largely 
attributed to comorbid illness, patient age, withdrawal 
from dialysis, or poor care before dialysis.48 Although 
some of these criteria might explain the differences in 
mortality between patients with incident versus prevalent 
ESKD in sub-Saharan Africa, the attrition described in 
most studies was a result of the inability to pay for dialysis, 
occurring usually within the first 2 weeks of initiation 
(mean cost US$100–150 per haemodialysis session).24,49 
The adult ESKD population in sub-Saharan Africa tends 
to be young with few comorbidities; therefore, when 
patients do manage to pay for long-term dialysis, even 
though dialysis quality might be suboptimal, outcomes 
are much improved, with over 75% of patients with 
prevalent ESKD remaining on dialysis for over 1 year. 
Outcomes in children were generally between those noted 
Adult studies Paediatric studies
Overall Incident Prevalent
Known and presumed mortality*
Pooled 5128/9057 (57%; 39) 4632/5860 (79%; 21) 496/3197 (16%; 18) 266/426 (62%; 11)
Individual studies 53·0% (34·0; 39) 79·6% (19·0; 21) 21·9% (15·9; 18) 70·4% (29·8; 11)
Mortality without dialysis although indicated
Known†
Pooled NA 185/212 (87%; 2) NA 43/51 (84%; 4)
Individual studies NA 80·1% (13·1; 2) NA 81·7% (15·8; 4)
Known and presumed*
Pooled NA 390/406 (96%; 3) NA 133/140 (95%; 9)
Individual studies NA 95·6% (7·6; 3) NA 96·2% (8·0; 9)
Mortality with dialysis
Known†
Pooled 1302/4228 (31%; 25) 822/1031 (80%; 7) 480/3197 (15%; 18) 90/284 (32%; 10)
Individual studies 32·1% (27·1; 25) 60·0% (31·0; 7) 21·2% (15·7; 18) 50·5% (32·2; 10)
Known and presumed*
Pooled 3243/6319 (51%; 32) 2747/3122 (88%; 14) 496/3197 (16%; 18) 107/294 (36%; 10)
Individual studies 48·7% (35·3; 32) 83·0% (19·4; 14) 21·9% (15·9; 18) 57·3% (35·1; 10)
Left hospital against medical advice, 
pooled
ND ND ND 27/143 (19%; 3)
Lost to follow-up, pooled 557/3087 (18%; 12) 443/1633 (27%; 7) 114/1454 (8%; 5) 188/675 (28%; 8)
Data are n/N (%; number of studies) or mean (SD; number of studies). NA=not applicable. ND=no data. *Patients with end-stage kidney disease who were known to have 
died plus those who left hospital against medical advice, were lost to follow-up, or stopped dialysis although indicated and therefore are presumed to have died without 
further treatment. †Patients known to have died. 
Table 3: Mortality in children and adults with end-stage kidney disease
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for adults with incident and prevalent ESKD; however, a 
high proportion of children left hospital against medical 
advice, suggesting that families make affordability 
decisions soon after diagnosis and there is little long-term 
dialysis available for children outside of South Africa and 
Sudan. Prospective studies are needed to identify 
differences in causes of death, reasons for dialysis 
discontinuation, and factors associated with dialysis 
continuation among patients with incident and prevalent 
ESKD and in children with ESKD in sub-Saharan Africa, 
to inform clinical decision making and policy development 
around ESKD care.
This systematic review complements our recent review 
on the outcomes of patients with acute kidney injury in 
sub-Saharan Africa, where access to dialysis and survival 
were also low.17 The numbers of patients with acute 
kidney injury and ESKD who remain undiagnosed are 
unknown. Both reviews show that, even among patients 
who have resources to reach a diagnosis of kidney failure, 
dialysis is largely out of reach. Much attention has been 
focused recently on the diagnosis and management 
(including dialysis) of acute kidney injury because this 
disorder is less costly than ESKD.50 Although this strategy 
might be efficient, this narrow focus raises equity 
questions for patients with other kidney diseases. 
Awareness must be raised about the plight of all patients 
with kidney failure in sub-Saharan Africa.
Recent publications have estimated the large unmet 
need for dialysis and a systematic review addressed the 
scarcity of trained staff in sub-Saharan Africa.5,6,51–55 
Where dialysis is available, even where partial 
government subsidies exist, many patients stop 
treatment and die once their resources are depleted 
because vascular access, laboratory and radiological 
testing, drug treatment, or transportation are not 
covered.33,38,41,56,57 Such high attrition rates raise ethical 
questions about offering patients dialysis when their 
resources are known to be inadequate to sustain 
treatment. However, some patients, being fully informed, 
still wish to try. In countries where full dialysis costs are 
covered by the government, although individual 
outcomes are improved, access is still limited by official 
rationing (South Africa), out-of-pocket costs needed for 
transportation and drugs (Sudan), and insufficient 
dialysis infrastructure to treat all those in need.11,12,22,31
The quality of dialysis delivered is also resource-
dependent, and many patients cannot afford, or dialysis 
centres cannot provide, regular dialysis. Dialysis quality, 
as measured by use of erythropoiesis-stimulating drugs; 
permanent vascular access; dialysis dose; dialysis 
adequacy; and access to transplantation, was poor even 
among those able to afford long-term dialysis. One 
study35 described repeated femoral vein catheterisation as 
the predominant form of dialysis access in 105 of 
Figure 2: Proportion of dialysis sessions received per week in incident and prevalent haemodialysis populations by country
The standard haemodialysis dose is three sessions of 4 h per week, but varied in some studies. Each column represents data from one study or country; studies from 
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120 patients because of cost. Measurement of dialysis 
adequacy was rarely reported. However, when measured 
in Sudan, a proportion of patients achieved target 
adequacy despite the lower haemodialysis dose, and 
dialysis quality might be better with peritoneal dialysis 
under the circumstances.12,45 This finding should provide 
a rationale to advocate more affordable peritoneal dialysis 
for ESKD.10,33,58
Common barriers contributing to mortality in ESKD in 
sub-Saharan Africa are shown in figure 3. The most 
common patient barriers to accessing dialysis and 
achieving adequate dialysis quality are the unaffordable 
costs of dialysis, transportation, drug treatment, vascular 
access, and transplantation workup.12,29,35,49 In view of the 
unexpected low prevalence of HIV as a cause of ESKD, 
some underlying diseases and comorbid conditions might 
also represent barriers.11,49,59 Female sex is a systematic 
barrier to access to ESKD care in sub-Saharan Africa.60 In 
the reviewed studies, young children were under-
represented, potentially because of unwillingness to pay 
and paucity of facilities for infants.61 Infrastructural 
barriers include the scarcity of dialysis facilities, which 
when available are predominantly in urban centres, might 
be dependent on donated outdated equipment that cannot 
be maintained, are often affected by staff and stock 
shortages, and cannot meet the clinical need.33,38,62,63 
Identification of common barriers occurring in daily 
practice is important to stimulate debate about pragmatic 
approaches to prevention, diagnosis, and management of 
ESKD in sub-Saharan Africa.
This systematic review has important limitations and 
several strengths. In view of the scarcity of high-quality 
studies, all papers were included in an attempt to reduce 
further bias by exclusion. The diagnosis of ESKD was not 
uniform across studies and in view of the clinical 
circumstances in much of sub-Saharan Africa, the 
distinction between acute kidney injury and ESKD was 
not always possible. Therefore, some patients with acute 
kidney injury might have been incorrectly diagnosed as 
having ESKD. Erroneous inclusion of patients with acute 
kidney injury could have biased the outcomes towards 
underestimation of mortality in ESKD, especially among 
adults with incident ESKD. Not all studies reported on all 
outcomes; therefore, denominators vary for each 
analysis, but the data presented represent the best 
available and patient numbers are high, which are 
important strengths. The finding that about 40–50% of 
patients in the identified studies received dialysis at least 
once is probably a substantial overestimate of the true 
figure, as reported in 2015.6 Almost all studies were from 
centres with dialysis facilities and therefore represent 
only patients who received a diagnosis of ESKD and had 
reached a dialysis unit. Thus, publication bias exists in 
terms of access to dialysis, but outcomes reported remain 
relevant. The outcomes and dialysis quality measures are 
poor and represent the daily reality of dialysis practice in 
many countries in sub-Saharan Africa. Dialysis duration 
and mortality rates were reported with varying follow-up 
times in individual studies. However, we believe that the 
small proportions of patients remaining on long-term 
dialysis is probably a valid indirect indicator of dialysis 
duration and high early mortality in patients with ESKD. 
Differences between pooled proportions and means of 
individual study frequencies for some outcomes show 
variability between studies. These differences are likely 
to reflect differences in study size, but also probably 
reflect many other factors such as local logistics, 
infrastructure, skill, geographical location, and 
distribution of poverty or affluence of patients included, 
Figure 3: Barriers to care in end-stage kidney disease
Flow diagram showing barriers in access to dialysis contributing to mortality in ESKD in many 
sub-Saharan African countries. Green arrows show factors present to facilitate diagnosis of ESKD or referral for or 
access to dialysis; red arrows show absence of these factors. Most barriers are related to access to care, access to 
diagnosis, out-of-pocket payments needed, and infrastructural resources. ESKD=end-stage kidney disease. Figure 
adapted from Olowu and colleagues.17
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which will have affected study outcomes. The overall 
heterogeneity of the data emphasises the urgent need for 
good systematic data collection on incidence and 
prevalence of ESKD as well as the need to perform and 
publish higher quality studies in the region. Despite the 
data only representing 15 countries in sub-Saharan 
Africa, the consistency of problems encountered and 
poor patient outcomes across studies suggest 
generalisability of these findings. Despite the inherent 
limitations, this systematic review provides important 
insights to encourage and inform policy development 
and health-system-wide planning to address ESKD in 
sub-Saharan Africa.
Dialysis facilities and dialysis populations are 
expanding in sub-Saharan Africa.15 The consequences for 
the individual, in terms of catastrophic expenditure and 
life or death, and for the health system, in terms of 
opportunity costs and equity, cannot be ignored. Few 
countries in sub-Saharan Africa have official policies for 
renal replacement therapy, and some governments are 
reluctant to broach the debate about coverage of renal 
replacement therapy, which is fraught with ethical 
dilemmas. Without formalised criteria or official 
guidelines, access to dialysis is haphazard, often 
depending on luck if facilities are available, and ability to 
pay. The burden of so-called choice between life and 
death is shifted to individual clinicians, patients, and 
families, imposing substantial moral distress.64 However, 
before development of ESKD policies, existing knowledge 
gaps about the local burden of disease, outcomes, 
assessment of current treatment capacity, and the 
socioeconomic implications of kidney disease must be 
filled.65 Engaging in public debate about the justice 
implications of starting expensive programmes such as 
dialysis, which deliver acceptable quality care, in 
environments where opportunity costs are likely to be 
very high is important to develop sustainable and 
equitable solutions for patients with kidney disease.
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Interpretation:	The	studies	reported	 in	Papers	1	and	2	were	the	first	systematic	reviews	to	be	
conducted	on	dialysis	outcomes	 in	SSA.	 Systematic	 reviews	are	 regarded	as	one	of	 the	higher	
forms	of	data	reliability,	although	they	are	highly	dependent	on	the	quality	of	studies	that	are	
included.	 In	 total	109	studies,	 including	a	 total	of	27	879	patients	 from	20	countries,	 reported	
over	25	years,	were	identified	and	reviewed.	Strikingly,	there	were	far	fewer	patients	reported	
on	 with	 AKI	 (3340	 patients)	 compared	 with	 ESKD	 (25	 265	 patients).	 Two	 thirds	 of	 the	 ESKD	
patients	 were	 from	 Sudan	 or	 South	 Africa,	 however,	 where	 governments	 provide	 substantial	
support	for	chronic	dialysis.	Children	were	more	represented	in	the	AKI	studies	(1572	children,	
1042	 adults)	 than	 in	 the	 ESKD	 studies	 which	 overwhelmingly	 included	 adults	 (809	 children,	




Almost	 all	 studies	 were	 of	 low	 to	medium	 quality,	 which	 reflects	 the	 resources	 available	 for	
research	 in	SSA.	Despite	 this,	 given	 that	 these	 studies	 comprised	 the	only	existing	data	at	 the	
time,	 the	studies	were	all	 included	 in	 the	analyses	and	data	was	presented	as	 thoroughly	and	
transparently	as	possible.	Given	the	large	heterogeneity	of	data	presented	across	all	the	studies,	
statistical	 analysis	 was	 limited.	 The	 reviewers	 of	 Paper	 1	 initially	 requested	 a	 meta-analysis,	
which	we	did	perform	and	included	in	our	response	letter	to	the	reviewers,	however	we	strongly	
emphasized	 not	 wanting	 to	 give	 a	 false	 sense	 of	 data	 robustness	 and	 our	 preference	 not	 to	
include	 this	 in	 the	 manuscript.	 The	 reviewers	 agreed.	 In	 seeming	 contrast,	 the	 reviewers	 of	
Paper	2	requested	removal	of	even	the	simple	descriptive	statistics	from	the	manuscript	as	they	
felt	 the	 large	 discrepancies	 in	 outcomes	 between	 patient	 groups	 were	 self-explanatory.	 An	
important	 strength	 of	 these	 systematic	 reviews	 is	 that	 they	 combine	 data	 from	 adult	 and	
pediatric	 cohorts	 and	 are	 therefore	 as	 generalizable	 as	 possible	 to	 the	 population	 of	 patients	
who	are	diagnosed	with	kidney	failure	requiring	dialysis	in	SSA.	A	major	weakness	of	the	reviews	
is	that	they	very	likely	reflect	publication	bias,	represent	only	patients	who	were	able	to	access	
some	 level	 of	 care,	 where	 a	 diagnosis	 of	 either	 AKI	 or	 ESKD	 was	 made	 and	 dialysis	 was	
considered.	How	great	the	proportion	of	patients	remaining	undiagnosed	and	never	reaching	a	
possibility	 of	 dialysis	 remains	 unknown.	 As	 such	 these	 systematic	 reviews	 likely	 represent	 a	
















Patient	number	 1043	 1937	 10354	 14102	 809	
Mortality	without	
dialysis	when	needed	
86%	 73%	 96%	 NA	 95%	
Mortality	with	dialysis
#	















































are	most	 likely	 made	 on	 a	 case-by-case	 basis	 if	 and	 when	 a	 patient	 reaches	 a	 center	 where	
kidney	 disease	 is	 diagnosed	 and	 dialysis	 may	 be	 a	 possibility.	 The	 International	 Society	 of	
Nephrology	 (ISN)	 has	 been	 engaged	 in	 various	 capacity	 building	 activities	 over	 the	 past	 2	
decades	and	has	provided	varying	degrees	of	training	to	close	to	900	fellows	in	nephrology	from	
LMICs,	 including	many	 from	SSA,	most	of	whom	have	 returned	 to	 their	home	 institutions.
70
	A	
recent	 survey	 reported	 that	 the	number	of	nephrologists	 in	SSA	has	 increased	 from	218	 in	17	
countries	 in	 2008	 (70	 and	 55	 working	 in	 Nigeria	 and	 South	 Africa	 respectively)	 to	 539	 in	 36	
countries	 in	 2015	 (162	 and	 108	 in	 Nigeria	 and	 South	 Africa	 respectively).
29
	 A	 critical	mass	 of	





As	 identified	 in	the	2	systematic	reviews	presented	 in	Chapter	1,	because	of	 low	awareness	 in	
the	 community,	 pervasive	 poverty	 and	 lack	 of	 access	 to	 primary	 care,	 patients	 with	 kidney	
disease	 tend	 to	 present	 very	 late	 and	 are	 often	 close	 to	 death.	 Delays	 imposed	 by	
transportation,	searching	for	funds	and	poorly	functional	or	insufficient	infrastructure	may	lead	
to	 death	 before	 dialysis	 can	be	 initiated	 even	 if	 it	would	 have	 been	possible	 (as	 illustrated	 in	
Figure	3,	Paper	2).	In	other	cases,	when	patients	are	extremely	poor,	the	option	of	dialysis	may	
not	even	be	presented	to	them	as	the	nephrologists	and	nurses	feel	the	consequences	for	the	
family	would	 be	 too	 severe.	 	 How	 the	 principles	 of	 biomedical	 ethics	 in	 terms	 of	 respect	 for	





























disease	 in	 sub-Saharan	 Africa	 (SSA)	 when	 they	 require	 costly	 therapy	 for	 survival.
65,66
	 Among	
patients	with	 acute	 kidney	 injury	 (AKI),	mortality	was	 73%	 in	 children	 and	 86%	 in	 adults	who	
required,	 but	 could	 not	 access,	 dialysis.	 	 Among	 adult	 patients	with	 end-stage	 kidney	 disease	
(ESKD)	who	did	begin	dialysis,	84%	discontinued	this	life-sustaining	treatment	largely	because	of	
unaffordable	 out-of-pocket	 costs.	 Physicians	 meet	 these	 patients	 daily	 and	 have	 first-hand	
information	 on	 how	 decisions	 are	 made	 and	 how	 resources	 are	 distributed.	 The	 role	 and	
experiences	 of	 health	 workers	 treating	 these	 patients	 in	 SSA	 have	 however	 not	 been	 well	
explored.	
	
Aim:	The	aim	of	 this	 study	was	 to	get	an	overview	of	 the	challenges	 faced	on	a	daily	basis	by	








experiences	within	 the	 2	 years	 prior	 to	 the	 survey.	 Paper	 copies	 of	 the	 survey	 in	 English	 and	
French	 (the	 2	 official	 languages	 of	 the	 African	 Association	 of	 Nephrology,	 AFRAN)	 were	
distributed	 and	 collected	 at	 the	 AFRAN	 and	 the	 Kenyan	 Renal	 Association	 (KRA)	 meetings	 in	
2017.	At	the	AFRAN	meeting	80	surveys	were	distributed	in	the	conference	bags	for	attendees,	





Results:	Thirty-nine	completed	 responses	were	 received.	Of	 the	 respondents,	80%	were	male,	
61%	 were	 aged	 36-55	 years	 and	 74%	 had	 been	 in	 medical	 practice	 >10	 years.	 Respondents	
represented	 15	 countries	 in	 sub-Saharan	 Africa.	 Most	 respondents	 worked	 in	 government	





patients	with	ESKD	per	week,	but	75%	and	54%	of	 respondents	 reported	 that	<5	patients	per	
week	were	 initiated	on	dialysis	 for	AKI	 or	 ESKD	 respectively.	Overall	 50%	and	78%	 responded	




Concerns	 regarding	 high	 out-of-pocket	 expenses	 were	 reported	 by	 the	 majority	 of	 the	
physicians.	While	84%	of	respondents	were	concerned	that	laboratory	testing	was	unaffordable	
to	 the	 patient	 often	 or	 sometimes,	 82%	 were	 concerned	 that	 medication	 was	 unaffordable	
	 53
(Figure	2),	 89%	 felt	pressured	by	 the	patients’	 financial	 constraints	 and	84%	 felt	pressured	by	









diagnosis	 to	 a	 patient	 and	 having	 to	 restrict	 dialysis	 for	 one	 patient	 because	 another	 patient	





Around	 75%	 of	 respondents	 reported	 that	 patients	 at	 least	 sometimes	 reduced	 dialysis	















Conclusions:	 Physicians	managing	patients	with	 kidney	 failure	 in	 SSA	 frequently	 face	 resource	
scarcity	and	ethical	dilemmas	due	to	patients’	inability	to	pay.	The	level	of	moral	distress	among	
nephrologists	 is	 high,	 but	 when	 compared	 to	 the	 findings	 of	 the	 Ethiopian	 study
71
	 among	
general	physicians,	where	74%	regretted	 their	 choice	of	profession	at	 least	monthly,	 the	 level	
appears	lower.		This	finding	could	be	interpreted	in	multiple	ways:	it	is	possible	that	specialists	
are	 relatively	 shielded	 from	 many	 of	 the	 every-day	 resource	 restraints	 experienced	 by	
generalists,	more	senior	physicians	(specialists)	may	have	recourse	to	more	resources	especially	









Interpretation:	 The	 sample	 of	 nephrologists	 surveyed	 here	 was	 small	 (response	 rate	 around	
40%)	 which	 is	 a	 potential	 limitation	 that	 must	 be	 considered.	 Given	 that	 surveys	 were	
distributed	 in	 conference	bags,	 together	with	other	 leaflets	 it	 is	possible	 that	 some	attendees	
did	not	recognize	the	survey	for	what	it	was.	Planned	participant	information	about	the	survey	
and	 requests	 for	 participation	 during	 the	 plenary	 session	 did	 not	 occur.	 It	 may	 therefore	 be	




is	 it’s	 voluntary	 nature	 and	 that	 it	 was	 anonymous,	 therefore	 increasing	 the	 likelihood	 that	
responses	were	 truthful.	Given	 the	 relative	 consistency	of	 responses,	 in	general	 a	high	or	 low	
percentage	per	 response	was	obtained	 (few	 responses	were	 around	50%),	 it	 is	 likely	 that	 the	
responses	are	representative	of	common	ethical	dilemmas	experienced	 in	nephrology	practice	
in	 SSA.	 The	 clear	 dependence	 of	 the	 ability	 to	 provide	 care	 on	 a	 patient’s	 resources	 is	 an	
important	 concern	 that	 must	 be	 addressed	 if	 moral	 distress	 is	 to	 be	 reduced	 and	 equity	 of	
access	to	dialysis	is	to	improve.		
	
Survey	 responses	 also	 highlight	 the	 tension	 that	 physicians	 feel	 between	 limitations	 of	 the	




most	physicians	did	appear	 to	have	 recourse	 to	colleagues	with	whom	they	could	discuss	and	
work	through	these	dilemmas.	Most	physicians	articulate	that	guidance	on	resource	allocation	












universal	 access	 to	 such	 care.	 Even	 in	 high-income	 settings,	 the	 costs	 of	 RRT	 are	
disproportionately	 high	 relative	 to	 the	 numbers	 of	 patients	 affected,	 however	 given	 the	






Importantly,	 major	 risk	 factors	 for	 kidney	 disease,	 both	 acute	 and	 chronic,	 include	 structural	
factors	such	as	poverty,	unsafe	work,	lack	of	education	and	gender	inequality.	Such	factors	have	
all	 been	 highlighted	 in	 2015	 by	 the	 United	 Nations	 as	 the	 Sustainable	 Development	 Goals	
(SDGs),	 which	 are	 important	 targets	 to	 secure	 overall	 well-being.
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	 Multiple	 public	 health	
measures	such	as	ensuring	access	to	clean	water,	vaccinations,	prevention	of	malaria	and	HIV,	
as	 well	 as	 reducing	 dietary	 salt,	 sugar	 and	 fat	 intake,	 tobacco	 consumption	 and	 improving	
physical	activity	would	all	go	a	 long	way	towards	reducing	the	risk	of	both	AKI	and	CKD/ESKD,	
even	 before	 access	 to	 the	 formal	 health	 system	 would	 be	 required.	 If	 kidney	 disease	 is	
diagnosed	 early,	 AKI	 can	 be	 reversed	 and	 the	 progression	 of	 CKD	 can	 be	 slowed	 with	
appropriate	 cheap	 interventions.	 Prevention,	 early	 diagnosis	 and	 early	 treatment	 of	 kidney	
disease	would	reduce	the	need	for	dialysis	and	transplantation	and	would	therefore	appear	the	
most	 cost-effective	 long-term	 approach	 to	 the	management	 of	 kidney	 disease.	Not	 all	 kidney	
failure	can	be	prevented,	however,	therefore	strategies	must	be	 in	place	to	provide	RRT	when	
required,	but	this	should	not	be	the	only	default	strategy	(as	 is	currently	occurring	 in	much	of	




Consistent	 with	 a	 coherent	 and	 comprehensive	 approach	 to	 maintaining	 kidney	 health	 and	
treating	 kidney	 disease,	 two	 papers	 highlighting	 potential	 public	 health	 approaches	 to	 the	
reduction	 of	 risk	 factors	 for	 kidney	 disease,	 with	 emphasis	 on	 LMIC	 (Paper	 3)	 and	 how	
achievement	of	each	SDG	would	have	relevance	for	kidney	health	(Paper	4)	were	developed	in	
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Chronic kidney disease (CKD) is a global public health
concern and a key determinant of poor health outcomes.
While the burden of CKD is reasonably well defined in
developed countries, increasing evidence indicates that the
CKD burden may be even greater in developing countries.
Diabetes, hypertension, and obesity are major contributors
to the global burden of the disease and are important
traditional CKD risk factors; however, nontraditional CKD
risk factors such as nephrotoxin exposure, kidney stones,
fetal and maternal factors, infections, environmental
factors, and acute kidney injury are also increasingly being
recognized as major threats to global kidney health. A
broad approach to CKD prevention begins with the
identification of CKD risk factors in the population,
followed by the development of appropriate mitigation
strategies. Effective prevention policies rely on an accurate
understanding of the incidence and prevalence of CKD in a
given setting, as well as the distribution and burden of risk
factors. Populations or individuals at CKD risk must be
screened and treated early to prevent the onset of and
delay the progression of the kidney disease. Systematically
collected data should be analyzed at country, province, and
district levels to identify regional disparities and CKD
hotspots and develop targeted prevention strategies.
Race-ethnicity, genetics, sex, socioeconomic status, and
geography are likely modifiers of CKD risk. A
comprehensive, informed approach to prevention that
takes into account all of these factors is therefore required
to successfully tackle the global CKD epidemic.
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C
hronic kidney disease (CKD) is increasingly recognized
as a global public health concern and an important
contributor to morbidity and mortality.1 While the
burden of CKD is reasonably well defined in developed
countries, increasing evidence indicates that the CKD burden
may be even greater in developing countries.1,2 Of the major
contributors to the global burden of disease, diabetes, hy-
pertension, and obesity are traditional risk factors for CKD.1
Nontraditional CKD risk factors such as nephrotoxins (e.g.,
prescription medicines and alternative remedies), kidney
stones, fetal and maternal exposures, infections, environ-
mental exposures, and acute kidney injury (AKI) are also
being increasingly recognized as major threats to kidney
health.3 The burden of CKD that is attributable to nontra-
ditional risk factors is unknown and may even predominate in
low- and middle-income countries (LMICs).
A broad approach to CKD prevention begins with the
identification of the incidence, prevalence, and distribution of
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risk factors, followed by the development of mitigation stra-
tegies. At-risk populations or individuals must be screened
and treated early to prevent onset and delay progression.
Reducing CKD risk is also highly dependent on addressing
the fact that it is both a consequence of and a contributor to
socioeconomic disparities. This review expands on the
recently published International Society of Nephrology (ISN)
CKD roadmap,4 which discusses the globally relevant major
traditional and nontraditional risk CKD factors (outlined in
Table 1), highlights gaps in knowledge, and recommends
strategies to close these gaps and enhance CKD prevention.
Prioritization of CKD and detection and investigation of CKD
hotspots
To understand whether CKD is a priority within a country,
incidence and prevalence, as well as the contribution of
various risk factors for the burden of disease should be
determined. Systematic and reliable data collection is
required. It is important that such data are analyzed at region,
country, province, and district levels to identify local dispar-
ities and CKD hotspots. For example, the global burden of
disease study has identified several hotspots in Central
America where the prevalence of CKD is high and requires
attention.5–7 These include Mexico, where women have one
of the highest disability-adjusted life-year rates for CKD
(related to obesity, diabetes, and hypertension), as well as
pockets in Nicaragua, Guatemala, and El Salvador, where
CKD of unspecified cause is highly prevalent in men, pri-
marily related to nontraditional risk factors.7,8
To illustrate the importance of subregional local analysis,
in Nicaragua, increased CKD rates in male farmers aged <60
years were associated with pesticide exposure, dehydration,
alcohol consumption, and exposure to heavy metals.9 Costa
Rica has reported a higher incidence of CKD among young
sugarcane workers, with clinical and histological findings of
chronic interstitial nephritis.10 In El Salvador, a high preva-
lence of CKD (17%) was observed among male farmers
exposed to toxic pollutants.11,12 Studies in Sri Lanka reported
an association between pesticide poisoning and pollutants,
with repeated episodes of AKI and CKD.13 In India and
Pakistan, a large percentage of CKD cases are of undeter-
mined etiology, potentially related to environmental factors.14
Many knowledge gaps remain regarding these regional epi-
demics of CKD of unspecified cause.5
Gaps. There are no reliable statistics about the prevalence
of CKD in most of the developing world. Improving and
expanding local data collection and processing and research
infrastructure is recommended to ensure a better under-
standing of the burden and regional distribution of specific
CKD risk factors.
Action strategies. Including screening for kidney disease
in established noncommunicable disease (NCD) risk factor
surveys will add significant value to existing efforts to
monitor the prevalence of NCD risk factor, likely at a lower
cost than duplicating efforts with parallel CKD surveillance
programs. Combining such survey data with global
positioning technology will permit the identification of
regional and local variations in CKD occurrence. For
example, the World Health Organization (WHO) STEPwise
approach to surveillance is an NCD household survey that
was launched in 2002.15 To date, 122 countries have partici-
pated.16 Depending on the local resources, the survey collects
behavioral risk factors (step 1); physical measurements,
including blood pressure (BP), height, and weight (step 2);
and biochemical parameters (blood glucose and lipids; step
3).17 Advocacy efforts in Uruguay succeeded in including
serum creatinine and urine protein measurements in the
STEPwise approach to surveillance survey in 2006. This effort
captured the attention of policy makers and resulted in a
policy mandating kidney disease screening in individuals with
hypertension or diabetes at regular health checkups in the
employed population. This program is raising CKD awareness
and will permit tracking of prevention efforts.18
Importantly, surveillance or outreach activities must
include vulnerable groups and ensure equitable representa-
tion of the population. Monitoring activities should integrate
national data at regional and local levels with data obtained in
research and screening activities to optimize efficiency, facil-
itate surveillance, and permit the rapid identification of
geographic hotspots for CKD that require focused attention.19
A task force supported by global experts should be setup to
investigate hotspots rapidly. Investigations should include
standardized data on social, structural, and clinical risk fac-
tors, clinical course, and potential interventions. A guideline-
based approach should be disseminated and adapted in
regions experiencing CKD hotspots. An example is the in-
ternational study group on CKD of unspecified cause in
Mesoamerica, organized by the Central American Program
for Work, Environment, and Health.20 Such efforts require a
multi-sectoral approach with sustainable financing.21
Tackling CKD risk factors: diabetes, hypertension, and obesity
The WHO global action plan for the prevention and control
of NCDs does not include CKD among the four priority
NCDs. However, diabetes, hypertension, and cardiovascular
disease (CVD) are acknowledged to be integrally linked with
CKD. Notably, CKD is an important risk amplifier within
these conditions.22 Across the world, 415 million adults have
diabetes, 1.4 billion adults have hypertension, and 2.1 billion
children and adults are overweight or obese.23–25 The preva-
lence of CKD in adults with type 2 diabetes is approximately
25% to 40%, depending on population factors.26–28 In the
United States, the prevalence of CKD is approximately 30%
among adults with hypertension and 17% among obese
adults.26 The size of the population at CKD risk is influenced
by regional differences in demographics, different approaches
to diagnosis and management, and effectiveness of local in-
terventions to address lifestyle-related risks. Reduction of
lifestyle-related risks is a cornerstone of mitigating the public
health impact of diabetes, hypertension, and obesity. There is
clear evidence that links upstream factors such as poor diet,
poverty, food insecurity, tobacco consumption, and other
r ev i ew VA Luyckx et al.: Prevention of kidney disease
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70% of children with
nephrotoxin-
induced AKI had
CKD at 6 mo
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PEP, HAART Impact of HAART on
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ESKD may be 3%–
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ACEI, angiotensin converting enzyme inhibitor; AKI, acute kidney injury; ARB, angiotensin receptor blocker; ART, antiretroviral therapy; BMI, body mass index; BP, blood pressure; CKD, chronic kidney disease; CKDu, chronic kidney
disease of uncertain etiology; CVD, cardiovascular disease; DM, diabetes mellitus; ESKD, end-stage kidney disease; GDM, gestational diabetes mellitus; GFR, glomerular filtration rate; GN, glomerulonephritis; HAART, highly active
antiretroviral therapy; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; HIC, high-income country; HT, hypertension; HUS, Hemolytic-uremic syndrome; HZ, hazard ratio; ITN, insecticide-treated nets; LBW, low birth weight; LIC,
low-income country; LMIC, low- and middle-income countries; MDR, multi-drug resistance; NSAID, nonsteroidal antiinflammatory drug; OTC, over-the-counter; PEP, postexposure prophylaxis; PPI, proton pump inhibitor; PSGN, post-
streptococcal glomerulonephritis; RDT, rapid diagnostic testing; RR, relative risk among those who experineced preeclampsia versus those who did not for the listed outcomes; Rx, treatment; SDG, sustainable development goal;

































































lifestyle factors with the risk of developing CKD.29–36
Conversely, interventions to manage hypertension and pro-
mote weight loss are associated with reduced risks of devel-
oping CKD and better outcomes among those living with
CKD.2,37–43
Gaps. Epidemiological assessment, followed by prioriti-
zation of CKD risk factors according to their contribution to
the local burden of the disease, is important to determine
where public health care efforts should be focused on
reducing the population burden of CKD. In addition, existing
barriers to the implementation of locally relevant strategies
for the prevention and management of diabetes, hyperten-
sion, and obesity must be identified. Barriers may include
resistance to change in the communities themselves or push
back from industry and others that are potentially affected by
lifestyle modification campaigns.
Action strategies. Population-based studies are needed to
determine the impact of diabetes, hypertension, and obesity
prevention programs on the prevalence and incidence of
CKD. Longitudinal studies are necessary to understand the
impact of prevention programs on the rates of CKD and end-
stage kidney disease (ESKD) and related comorbidities,
including cardiovascular complications and infections.
Studies are required to better understand appropriate risk-
benefit thresholds (target hemoglobin A1c, BP, and weight)
for CKD prevention and management and to understand
interactions between race-ethnicity, genetics, socioeconomic
status, and geography as modifiers of CKD risk and pro-
gression. The impact of tobacco consumption on CKD needs
to be studied further.
Strategies to reduce CKD risk attributable to diabetes,
hypertension, and obesity will be most effectively imple-
mented as part of a broad approach to NCD prevention.
Interventions to reduce lifestyle-related NCD risk factors are
most successful when implemented at both patient and
community levels, supported by legislation and regulation.44
Public health care approaches with the greatest evidence of
effectiveness in reducing NCD risk include economic in-
centives to lower the price of healthy food, taxation on un-
healthy food, education and physical activity programs in
schools, food advertising restrictions and standards, providing
more recreation spaces and facilities, sustained media cam-
paigns for smoking cessation, cigarette packet warnings, re-
strictions on tobacco advertising, higher taxes on tobacco, and
restrictions on smoking in public areas and workplaces.45
Several countries have made efforts to reduce population
consumption of sugary beverages, high-fat foods, and salt
with the endorsement of the Panamerican Health Organiza-
tion and WHO; however, more research is needed to un-
derstand which lifestyle interventions will have the greatest
impact on CKD burden.22,46,47
An example of the importance of rigorous epidemiologic
evidence required to inform policymaking and action is the
ongoing debate on the utility of sodium reduction as a pop-
ulation measure to reduce BP and CVD.48–53 Recent studies
have demonstrated a J- or U-shaped relationship of sodium
intake with BP and mortality.54–56 The benefit of salt reduc-
tion is greater among hypertensive people, but definitive
effects on kidney disease outcomes remain uncertain. Inter-
ventional studies have demonstrated that estimated glomer-
ular filtration rate (eGFR) and albuminuria (proteinuria)
increased with higher salt intake, and a recent study showed
that reduction of sodium intake reduced albuminuria.57 In
the United Kingdom, voluntary food-manufacturing targets
achieved a lower sodium intake of 15% between 2001 and
2011, which was associated with a decrease in mean BP (3
mm Hg) and 40% reduction in deaths owing to stroke and
ischemic heart disease.50,58 However, the respective role of
sodium reduction versus other treatments for hypertension,
dyslipidemia, and CVD are not clearly delineated.50,58
Implementing population-level approaches to reduce
NCDs requires action across multiple sectors of the govern-
ment and society, as well as a commitment of the govern-
ments. This is consistent with the Health in All policy
strategies outlined by WHO, which emphasizes the impor-
tance of multi-sectoral engagement for the successful imple-
mentation of public health care policies.44,46 At the level of
health care departments, health care providers must have the
necessary technology, tools, medicines, and services that are
required for efficient assessment and control of risk factors.
Community engagement and education are crucial to opti-
mize success. Patients themselves are also a key to NCD
prevention. In the chronic care model, patient self-care takes
on great importance, while the roles and responsibilities of
physicians, nurses, and community health care workers are
being redefined through innovative strategies and technolo-
gies.21 Ongoing monitoring and evaluation of policy imple-
mentation will permit a better understanding of barriers to
and facilitators of CKD prevention. This is especially true of
LMICs, where the major barriers are quality, price, and
availability of drug treatments for diabetes and hypertension.
Understanding how such barriers and facilitators vary by
jurisdiction, health care system, race-ethnicity, age, sex, and
socioeconomic status helps to inform the development of
effective local strategies.
Systematic surveillance is recommended for the screening
of diabetes, hypertension, and obesity using, for example, the
STEPwise approach to surveillance survey model. Once in-
dividuals with these conditions are identified, they should be
recognized as being at high risk for CKD and should be
evaluated for eGFR and albuminuria. Clinical guidelines on
BP, blood glucose, and weight and physical activity targets
should be clear and easy to implement to optimize CKD risk
factor management. Screening and early intervention when
CKD is detected were shown to reduce ESKD and be cost-
effective.40,59–61
Nephrotoxins as risk factors for AKI and CKD
Nephrotoxic agents can cause both AKI and CKD.62 Neph-
rotoxin exposure is common in hospitalized patients and may
account for up to 25% of AKI cases.63–65 Common agents
associated with AKI include nonsteroidal antiinflammatory
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drugs, antibiotics, iodinated contrast media, and chemo-
therapeutic drugs.66,67 Clinician and patient education are
important to reduce the risk of nephrotoxicity. Where elec-
tronic medical records exist, alerts to reduce the risk of
nephrotoxic exposure and drug interactions can be acti-
vated.68,69 Electronic medical records can simultaneously be
used to monitor prescription practices, responsiveness to
alerts and prompts, rates of AKI, and barriers to effective
implementation.70,71 In high-income countries, AKI typically
develops during hospitalization and may impact long-term
health. For example, CKD (urinary abnormalities, low
eGFR, or hypertension) was found in 70% of children 6
months after nephrotoxin-induced AKI.72
The list of medications that can induce CKD is steadily
expanding. The mechanisms range from interstitial inflam-
mation to glomerular and tubular injury.73–75 Strategies
should be implemented to reduce nephrotoxin-induced AKI
and CKD, as well as to emphasize the risks of medication
overuse and dose adjustments for eGFR. Detection of medi-
cations that lead to CKD is challenging given the long lag
time. As recently described for proton pump inhibitors,
linkage between clinical and prescription databases can
identify novel associations between CKD and medications,
which enables ongoing surveillance.73
The use of culturally traditional and alternative remedies is
common worldwide, reaching over 80% of the population in
many regions.76 The rates of associated AKI and CKD are
unknown, although up to 30% of AKI in sub-Saharan Africa
may be related to traditional remedy use.77 In Europe and
North America, the market for alternative remedies generates
billions of dollars per year.78 Remedy production is often un-
regulated, leading to high interproduct variability and under-
appreciated risk of kidney injury.79 In LMICs, traditional
remedies are often the only affordable means of health care.
Given the large number of people worldwide using these
remedies, toxicity cannot be universal but instead may relate to
individual susceptibility, which remains underinvestigated.76
Gaps. The true risk of nephrotoxicity of commonly used
medications or remedies is uncertain given the unknown
denominators of use. Some medications are known to be
nephrotoxic, especially in particular circumstances such as
nonsteroidal antiinflammatory drugs with volume depletion.
The magnitude of risk, which compounds are most toxic and
under which circumstances, and how to best use these
compounds safely if no alternatives exist remain unknown. In
LMICs, traditional medicines are used for many reasons other
than medical ones; therefore, a better understanding of the
role that remedies play in people’s lives is required.80 Further
studies are required to identify potentially toxic remedies, risk
factors that may exacerbate nephrotoxicity, herb-medication
interactions, and potentially beneficial compounds.81–87
Action strategies. In settings with electronic medical re-
cords, the use of medicines and alternative remedies should
be captured. These databases will permit the monitoring of
prescription practices to establish a true denominator of
subjects who are at risk and to permit surveillance for
determining associations with nephrotoxicity and potential
exacerbating factors. Screening protocols should be developed
to identify nephrotoxic effects of medications to improve
consistency in case/compound identification and compara-
bility of outcomes. When nephrotoxicity is suspected, at-
tempts should be made to analyze culprit remedies, and
detailed case reports should be published. Education of health
care practitioners is important to foster regular prescription
reviews. Guidelines should emphasize the measurement of
eGFR prior to the prescription of potentially nephrotoxic
medications, with electronic warnings for medication in-
teractions and risks. Shared pharmaceutical prescription da-
tabases will avoid repeat prescriptions or drug interaction
potential. Research should continue to develop effective
alternative agents with reduced nephrotoxicity.
To reduce the use of nephrotoxic remedies, it is important
to ensure that individuals have access to essential medical care
and medication. Where alternative remedy use is widespread,
strategies should be identified to minimize exposure to
nephrotoxins. Such approaches should be customized based
on the region, economic realities, and community perspec-
tives to improve safety without alienating groups or chal-
lenging fundamental beliefs. Engagement with traditional
healers is crucial to foster collaboration, educate on kidney
disease, and learn about potentially beneficial remedies. The
public and health care workers (HCWs) must be educated
about nephrotoxicity and drug interactions relevant to herbal
remedies and over-the-counter preparations.87 Clinicians
should be encouraged to ask about alternative remedy use. A
global free web–based adverse event reporting site (across
income settings) should be developed to gather data and
study associations of remedy use with rates of CKD.
Given easy access to alternative remedies, governments
should develop policies about the accuracy of advertising and
health claims touted on the Internet and require efficacy data
similar to that required for pharmaceuticals. Policies should
enforce minimum standards of safety, manufacturing, label-
ing, and adverse event reporting on the alternative remedy
industry.
Kidney stones and CKD risk
Kidney stone disease is now recognized as a chronic health
condition that is associated with CKD and ESKD risks.88–92
The association between kidney stones and CKD is partly
explained by shared risk factors such as diabetes,93–95
obesity,96,97 hypertension,94,97,98 metabolic syndrome,99,100
and CVD.101–103 However, kidney stones may also directly
contribute to the development and progression of CKD via
urinary tract obstruction and/or infection, nephrocalcinosis,
and oxalate nephropathy.88,104,105 The worldwide prevalence
of kidney stones among adults is 5% to 9% and is apparently
increasing, with variations between regions and coun-
tries.106,107 The rising global rate of kidney stones may be
contributing to the overall CKD burden related to dietary
factors, obesity, global warming, and environmental and
occupational exposures (e.g., high ambient temperatures,
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contact with zinc or cadmium).90,97,105,107 Individuals who
have experienced a single stone event are at an increased risk
for a symptomatic stone recurrence (up to 50% within the
first 5 years).105 Therefore, prevention among these in-
dividuals is an important strategy to reduce further stone
formation and CKD risks.90 Higher fluid intake, avoidance of
low dietary calcium and sweetened beverages and the
reduction of dietary sodium and red meat intake reduce stone
formation risk.108–110
Gaps. A better understanding of regional risk for kidney
stones is important to prioritize stone prevention and reduce
CKD risk. The regional impact of climate change on kidney
stones is unknown. Long-term surveillance should permit a
better understanding of the impact of stone prevention stra-
tegies (lifestyle habits and medication) and treatments (e.g.,
lithotripsy and surgery) on the risks of new-onset and pro-
gressive CKD. Health care costs for kidney stone disease
require further studies. The effectiveness and cost-
effectiveness of prevention strategies across populations are
unknown.
Action strategies. Tracking mechanisms and research
should be developed to determine the relationships between
kidney stones and the incidence, prevalence, progression, and
complications of CKD in regional contexts. Environmental or
occupational hotspots should be detected through surveil-
lance. Understanding stone types and risk factors (e.g., ge-
netics, infections, and diet) are important to inform local
prevention strategies. Together with public health care stra-
tegies to reduce diabetes, hypertension, and obesity, surveil-
lance activities should include impact on the rates of kidney
stones and those of stone-related CKD to identify high-risk
groups for targeted prevention and cost-effectiveness.90 In
areas with a high risk for stone formation, public and HCW
education campaigns should increase awareness and
emphasize simple prevention strategies (e.g., fluid intake and
dietary modification). Where occupational exposure is
detected as important, engagement with policy makers and
employers is important to modify work conditions.111
Maternal, fetal, and childhood health as CKD risk factors
Low birth weight (LBW), small for gestational age, and pre-
term birth (PTB) impact the number of nephrons an indi-
vidual starts life with and are increasingly being recognized as
CKD risk factors.112,113 In 2010, over 43 million babies in 139
LMICs were born too soon or too small, suggesting many
children are born with a CKD risk.114 Developmental pro-
gramming for CKD results from many structural, environ-
mental, social, and physical factors that impact maternal and
fetal health throughout pregnancy, as well as the child’s
nutrition and growth.112 Recent evidence also indicates high
birth weight (especially an infant of a diabetic mother), in
addition to LBW and PTB, to be a risk factor for obesity,
hypertension, diabetes, and CKD.115–119 Early onset of dia-
betes in offspring exposed to diabetes in utero in part explains
the higher CKD risk in these individuals.115,120 Childhood
obesity is also an important risk amplifier for CKD after LBW,
small for gestational age, or PTB.121 Preterm babies are at an
increased risk for AKI related to reduced nephron number,
frequent nephrotoxin exposure, and comorbidities, which
increase their subsequent CKD risk.122,123 Not only the
children of troubled pregnancies are at long-term risk of
CKD, however. Women who develop pre-eclampsia/
eclampsia have a higher life-time risk of hypertension,
CKD, and CVD, and those who experience gestational dia-
betes mellitus have an increased risk for developing dia-
betes.124–126 Preeclampsia occurs in 1% to 5% of pregnancies
worldwide, and gestational diabetes mellitus occurs in around
2% to 6% of pregnancies in Europe, but in up to 25% in some
LMICs.125–127 Many individuals at a long-term CKD risk can
be identified early in prenatal clinics and delivery rooms.
Gaps. The contribution of maternal and fetal risk factors
to the CKD burden is unknown. In vivo counting of nephron
number is not yet possible and poses an obstacle to further
understanding the impact of developmental programming in
the kidney. Variability of nephron number between racial and
ethnic groups and geographic locations is largely unknown.
Tracking fetal size by fundal height, ultrasound, and Doppler
velocimetry can detect intrauterine growth restriction, but the
impact of interventions during pregnancy or soon after birth
on CKD risk is unknown. Similarly, the impact of PTB on
CKD requires longitudinal studies. The impact of high birth
weight on CKD risk has rarely been studied. Better methods
to screen for and treat preeclampsia and its consequences
require further studies.
Action strategies. The impact of fetal and early life
development on the risk of adult NCDs is underappreciated.
Monitoring the incidence of LBW, high birth weight, PTB,
and fetal growth restriction is required to understand the
burden with regard to the region and to raise awareness of
potential long-term risks. Identification of regional and de-
mographic disparities in birth weights or PTB within coun-
tries requires specific interventions or intensification of
prevention efforts. Babies must be weighed at birth or soon
thereafter, and the birth weight and gestational age should be
documented in an enduring health record, which is often not
done in LMICs.114,128 Similarly, neonatal AKI should also be
documented as a future CKD risk factor and should trigger
follow-up. Education of the public, HCW, and traditional
birth attendants is required to raise awareness of the long-
term risks of LBW, growth restriction, PTB, gestational dia-
betes mellitus, and preeclampsia for mother and child. Both
require early and ongoing education on healthy lifestyles and
lifelong follow-up. Engagement with mothers, communities,
traditional birth attendants, and HCW is important to
encourage optimal feeding of LBW, high birth weight, small
for gestational age, and preterm children to ensure healthy
growth while avoiding obesity. Ensuring access to essential
health care and medications is crucial to optimize child and
maternal health.
Given the attention focused on improvements in maternal
and child health initiated by the millennium development
goals and sustainable development goals, most countries have
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some form of data reporting or monitoring.129 Policies
should not focus only on maternal health during pregnancy
and at delivery but should also include access to family
planning, equity, and education for women, reduction of
poverty, and access to better nutrition. Monitoring women
throughout pregnancy is important to detect and manage
problems early. Innovative programs have improved prenatal
clinic visits and deliveries attended by skilled birth atten-
dants.130 Such programs should be utilized to improve
documentation of birth circumstances, maternal preeclamp-
sia, or gestational diabetes mellitus, thereby identifying in-
dividuals who require long-term follow-up and to initiate
lifestyle education peripartum. In LMICs, engagement with
traditional birth attendants is important to build trust and
educate them to detect and refer problem cases. Women with
preeclampsia should undergo long-term follow-up to deter-
mine the impact of interventions to reduce long-term CVD
and CKD risks.
Infections as CKD risk factors
CKD and AKI are considered as NCDs, but infections are an
important cause of both conditions, especially in LMICs.
Infections are also a common cause of AKI world-
wide.64,131,132 The three diseases, namely HIV, malaria, and
tuberculosis (TB), that received much attention under the
millennium development goals can cause CKD. In 2015, 36.7
million people were living with HIV.133 The risk of HIV ne-
phropathy (HIVAN) varies from <10% to almost 50% in
Africa.134 HIVAN is a well-recognized form of CKD that can
be prevented and treated with access to effective antiretroviral
therapy.134,135 However, the impact of antiretroviral therapy
on kidney disease is not straightforward. Although antire-
troviral therapy reduces the incidence and rate of HIVAN
progression to ESKD, it also reduces the competing risk of
death; therefore, the prevalence of HIVAN-ESKD tends to
increase in treated populations.134 Antiretroviral therapy does
not reduce the incidence and/or rate of progression of non-
HIVAN forms of CKD.134 Kidney disease prevention in HIV
infection is also affected by comorbidities such as diabetes and
viral hepatitis and therefore requires additional management
and health screening programs.134,135 In 2015, 241 million
cases of malaria were reported worldwide. AKI secondary to
malaria occurs in up to 40% of adults with severe infection.136
Although kidney function typically recovers in survivors, se-
vere AKI may eventually lead to CKD.136–138 A Sri Lankan
study also reported an association of malaria with CKD of
unknown cause.139 Malaria-associated AKI can be prevented
by widespread vector control, use of insecticide-treated bed
nets, and access to rapid diagnosis and treatment.136 In 2014,
9.6 million people became infected with TB.140,141 Genito-
urinary TB may be a cause of CKD through miliary
involvement or urinary obstruction and may occur in 27% of
cases with extrapulmonary TB.142,143 HIV and TB infections
frequently coexist; therefore, the combined kidney risk,
exacerbated by medication toxicities and interactions, may be
higher.
Many infections other than HIV, malaria, and TB increase
CKD risk. Impetigo is frequent in adults and children living
in disadvantaged conditions. CKD risk among adults with
impetigo is high, strongly supporting proactive prevention
and early treatment of skin infections as a possible means to
reduce CKD risk.144 The worldwide prevalence of hepatitis B
(HBV) was 331 million people in 2013 and that of hepatitis C
was 148 million.145 The global risk of HBV-associated CKD is
likely to be under 10%, whereas the risk of hepatitis C-
associated CKD is likely to be higher.146,147 HBV- and hepa-
titis C-associated CKD may be unrecognized contributors to
chronic glomerulonephritis, which is a leading cause of ESKD
in LMICs. Other infections such as leptospirosis and schis-
tosomiasis are neglected tropical diseases associated with
CKD.137,148 Given the direct associations among infections,
AKI, and CKD, it is likely that strategies to prevent infection
will reduce the global CKD burden.
Gaps. The magnitude of regional CKD burden related to
specific infections is unknown. How increasing the effec-
tiveness and reach of public health care interventions could
reduce the CKD burden needs to be further studied. The
impact of the successful treatment of malaria on the incidence
of malaria-associated AKI should be tracked, as fewer people
may develop endemic immunity and may be more susceptible
to severe disease.
Action strategies. Many guidelines mention CKD as a risk
factor for infections, but few recognize CKD as a complica-
tion. A survey of existing guidelines is necessary to gauge the
current level of awareness and intervention for infection as a
CKD risk factor. HBV vaccination, for example, successfully
reduced the incidence of childhood HBV-associated mem-
branous nephropathy.149 Efforts should be made to ensure
access to vaccinations to reduce infection-associated risks of
AKI and CKD. Short- and long-term surveillance for kidney
disease in regions where these vaccines are implemented
should be conducted to determine the impact. Where the
CKD burden associated with a specific infection is high,
research is required to develop locally effective and sustain-
able methods to prevent and treat these infections. Such
strategies require partnerships with local policy makers,
public health care practitioners, governmental organizations,
and communities to raise awareness and develop imple-
mentation strategies. HCWs and communities should be
educated about the risks of AKI and CKD associated with
infections to support prompt diagnosis, institution of i.v.
fluids and antibiotics, and avoidance of nonsteroidal antiin-
flammatory drugs and other nephrotoxins. Governments
should suppress the use of counterfeit drugs, which
contribute to increasing disease severity and risk of AKI in
infections.
AKI as a CKD risk factor
Worldwide, approximately 20% of patients admitted to hos-
pitals develop AKI.150 This statistic is largely derived from
high-income countries where the majority of AKI is hospital
acquired. The true AKI incidence in LMICs is less well known
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but is likely at least as high.150,151 Worldwide, it is estimated
that 2 million people die of AKI annually.152 The number of
AKI survivors is unknown, and a considerable proportion will
develop CKD.153–155
Gaps. The actual CKD risk after AKI is not known. Risk
modifiers and the long-term impact of AKI prevention on
CKD burden are unknown.
Action strategies. Regionally adapted strategies should be
promoted to avoid AKI. Given that most AKI cases in high-
income countries are hospital acquired, efforts to reduce
AKI incidence should focus on increasing awareness among
clinicians and encouraging proactive patient management.
Strategies may include electronic medical record alerts for
AKI risk and medication prescriptions.68,69,156 In LMICs, the
majority of AKI cases are community acquired, suggesting
that prevention should start before hospital admission. Stra-
tegies include implementation of public health care measures
to reduce the risk of infections and use of nephrotoxins;
ensure access to clean water; reduce poverty, accidents, and
trauma; improve maternal health; and provide access to
essential health care and medication. Education campaigns
should be conducted in communities and among HCWs to
increase awareness of AKI risk, avoid nephrotoxins, and seek
health care promptly.157 Once patients present to a hospital,
guidelines and facilities should be available to institute an
appropriate therapy. Long-term follow-up of patients with
AKI is required to determine the true burden of subsequent
CKD and potential risk modifiers.
Conclusions
Morbidity and mortality owing to CKD are increasing
worldwide, and CKD is progressively being recognized as an
important contributor to the global burden of the disease.1,8
Major contributors to the CKD burden are the growing fre-
quencies of diabetes, hypertension, and obesity, which are
well-established traditional risk factors for CKD. Public health
care policies directed to address many lifestyle factors that
contribute to these conditions are expected to positively
impact CKD risk. Systematic screening for CKD in at-risk
individuals is required for timely intervention when needed
and to understand the impact of such policies on CKD
incidence. The contribution of nontraditional CKD risk fac-
tors, including nephrotoxin exposure, kidney stones, fetal and
maternal factors, infections, environmental factors, and AKI,
to the global CKD burden is unknown. Moreover, many
nontraditional risk factors may predominate in LMICs. The
impact of reducing nontraditional CKD risk factors requires
further studies. Mitigation of nontraditional CKD risk factors
will require advocacy efforts to support policy development,
implementation of strategies to reduce disparities, improve
access to essential health care and maternal and child health,
reduce environmental exposures, prevent AKI, better under-
stand traditional remedy use, and prevent infections.2,3,158
Race-ethnicity, genetics, sex, socioeconomic status, and
geography likely modify the impact of CKD risk factors.
Effective coordination within health care systems, and
importantly in the era of the sustainable development goals, a
broad multi-sectoral approach are required to identify and
tackle achievable goals to reduce CKD risk factors and thereby
the global burden of CKD.
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The global burden of kidney disease and the sustainable development 
goals
Valerie A Luyckx,a Marcello Tonellib & John W Staniferc
Introduction
The 17 sustainable development goals (SDGs) were adopted by 
the United Nations, as successors to the millennium develop-
ment goals, with the broad goal of achieving healthy people 
living on a healthy planet.1 Although only SDG 3, that is, to 
ensure healthy lives and promote well-being for all at all ages, is 
specifically focused on health,1 achievement of all of the SDGs 
should have health benefits via impacts on the environment, 
governance and society.
The Global action plan for the prevention and control 
of noncommunicable diseases 2013–2020 (hereafter called 
the 2013 action plan) outlined an approach to reduce the 
combined mortality from four major categories of noncom-
municable disease, i.e. cancer, cardiovascular disease, chronic 
respiratory disease and diabetes, by 25% by 2025.2 Previously, 
these four categories had been prioritized in the 2008–2013 
action plan because, collectively, they were believed to ac-
count for about 60% of global deaths and it was anticipated 
that a large proportion of these deaths could be prevented 
through elimination of shared risk factors, e.g. alcohol and 
tobacco use, poor diets and inadequate exercise.3 Although 
laudable, the 2013 action plan has been criticized for failing 
to acknowledge the broader drivers of the noncommuni-
cable disease epidemics, other important noncommunicable 
diseases and the so-called causes of the causes of noncom-
municable diseases and failing to place sufficient emphasis 
on the need for coordinated multisectoral action.4 We argue 
that kidney disease represents one of the important noncom-
municable diseases missing from the 2013 action plan and 
that, given the many social and structural factors that directly 
affect risks and outcomes of kidney disease, multisectoral 
action to achieve the SDGs will help prevent and control 
such disease (Table 1).1
Global burden
Although often considered a comorbidity of diabetes or hy-
pertension, kidney disease has numerous complex causes.5 
Importantly, such disease has an indirect impact on global 
morbidity and mortality by increasing the risks associated 
with at least five other major killers: cardiovascular diseases, 
diabetes, hypertension, infection with human immunode-
ficiency virus (HIV) and malaria. For example, the Global 
Burden of Disease (GBD) 2015 study estimated that 1.2 million 
deaths, 19 million disability-adjusted life-years (DALYs) and 
18 million years of life lost from cardiovascular diseases were 
directly attributable to reduced glomerular filtration rates.6,7
The GBD 2015 study also estimated that, in 2015, 1.2 
million people died from kidney failure, an increase of 32% 
since 2005.7 In 2010, an estimated 2.3–7.1 million people 
with end-stage kidney disease died without access to chronic 
dialysis.8 Additionally, each year, around 1.7 million people are 
thought to die from acute kidney injury.9 Overall, therefore, 
an estimated 5–10 million people die annually from kidney 
disease. Given the limited epidemiological data, the common 
lack of awareness and the frequently poor access to labora-
tory services, such numbers probably underestimate the true 
burden posed by kidney disease. It is therefore possible that, 
each year, at least as many deaths are attributable to kidney 
disease as to cancer, diabetes or respiratory diseases, three of 
the four main categories targeted by the 2013 action plan.2,10,11 
In addition, the estimated number of DALYS attributable to 
kidney disease globally increased from 19 million in 1990 to 33 
million in 2013.12 In 2016, the DALYs associated with chronic 
kidney disease, along with those associated with cardiovas-
cular disease, cancers, diabetes and neurological disorders, 
were found to have increased significantly between 1990 and 
2015.6 A report from the GBD 2016 study highlighted the 
Abstract Kidney disease has been described as the most neglected chronic disease. Reliable estimates of the global burden of kidney 
disease require more population-based studies, but specific risks occur across the socioeconomic spectrum from poverty to affluence, 
from malnutrition to obesity, in agrarian to post-industrial settings, and along the life course from newborns to older people. A range of 
communicable and noncommunicable diseases result in renal complications and many people who have kidney disease lack access to 
care. The causes, consequences and costs of kidney diseases have implications for public health policy in all countries. The risks of kidney 
disease are also influenced by ethnicity, gender, location and lifestyle.  Increasing economic and health disparities, migration, demographic 
transition, unsafe working conditions and environmental threats, natural disasters and pollution may thwart attempts to reduce the morbidity 
and mortality from kidney disease. A multisectoral approach is needed to tackle the global burden of kidney disease. The sustainable 
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Table 1. The 17 sustainable development goals and their relevance to kidney health, 2015
Goal Description Relevance to kidney health Relevant 
SDG 3 targets
1 End poverty in all its forms 
everywhere
• Improvements in access to nutrition, personal safety and health care should 
enhance the prevention, detection and management of kidney disease
• Should reduce the incidence of catastrophic health expenditure resulting from 
treatment for kidney disease
3.8
2 End hunger, achieve food security 
and improved nutrition and 
promote sustainable agriculture
• Improvements in maternal nutrition and reductions in the frequencies of low 
birth weight and preterm birth should reduce the risk of CKD
• Reductions in the incidence of obesity should cut the risk of CKD, diabetes and 
hypertension
3.1, 3.2
3 Ensure healthy lives and promote 
well-being for all at all ages
• Should improve screening for, and the prevention, diagnosis and treatment of, 
kidney disease
• Public health programmes to promote community education, healthy lifestyles 
and vaccinations could also reduce the risk of AKI and CKD
All
4 Ensure inclusive and equitable 
quality education for all and 
promote life-long learning
• Should improve awareness and kidney-health-related knowledge
• May reduce use of nephrotoxic remedies and preparations
3.4, 3.5
5 Achieve gender equality and 
empower women and girls
• Reductions in the numbers of teenage pregnancies and increases in pregnancy 
spacing may reduce the incidence of the low birth weight, prematurity and 
pregnancy-related complications that are all risk factors for CKD
• There should also be improvements in overall family health
3.1, 3.7
6 Ensure access to water and 
sanitation for all
• There should be reductions in the incidence of the waterborne diseases and 
diarrhoeal illnesses that are major causes of AKI and in the incidence of the 
schistosomiasis that can cause CKD
• There should also be reductions in water pollution that can cause CKD
3.9
7 Ensure access to affordable, 
reliable, sustainable and modern 
energy for all
• Should broaden opportunities to use mobile health in prevention and 
treatment and in community and health worker education
• Improvements in access to electronic information sharing and data collection 
could lead to improvements in the epidemiology, monitoring and surveillance 
of kidney disease
3.9
8 Promote inclusive and sustainable 
economic growth, employment 
and decent work for all
• Improvements in personal access to health care, dignity and wealth could lead 
to improvements in the prevention and early treatment of kidney disease
• Improvements in the retention of health-care workers could reduce the so-
called brain drain
• Task shifting in health care could be facilitated
3.b, 3.c
9 Build resilient infrastructure, 
promote sustainable 
industrialization and foster 
innovation
• Could support innovations to improve the affordability and sustainability of 
access to diagnosis, facilitate early treatment and secondary prevention and 
foster cheaper and more efficient means to prevent, diagnose and treat both 
AKI and CKD
• Could also facilitate investigation of the potential benefits of, or risks posed by, 
traditional remedies for kidney disease
3.b
10 Reduce inequality within and 
among countries
• Could improve equity in the prevention, diagnosis and care of all forms of 
kidney disease
• Could improve access to expensive therapies, e.g. dialysis, hepatitis C therapy 
and transplantation
• Could improve geographical access to all forms of kidney care
3.1, 3.2, 3.7, 
3.8, 3.b, 3.d
11 Make cities inclusive, safe, resilient 
and sustainable
• Improved warning and protection from disasters could reduce crush-injury-
related AKI
• Levels of preparedness in mass disasters, including for patients with AKI, CKD or 
ESKD, should improve
• Urban planning to eliminate food deserts and increase physical activity could 
help reduce diabetes and obesity-related kidney disease
• Reductions in exposure to alcohol, drugs and tobacco could also reduce the 
risk of kidney disease
3.5, 3.6, 3.d
12 Ensure sustainable consumption 
and production patterns
• Promotion of the environmentally friendly and sustainable local production of 
dialysis supplies could reduce dialysis costs, create jobs and support the local 
economy
• Any reductions in the need for dialysis should reduce the carbon footprint from 
dialysis
• There may also be adverse effects on kidney health as increasing access to 
cars and unhealthy processed foods could lead to an increasing prevalence of 
obesity and access to cigarettes may also increase
3.4, 3.5, 3.9
(continues. . .)
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important omission of focus on chronic 
kidney disease and suggested that “the 
SDG agenda offers at best a minimal 
platform for drawing attention to the 
health care and monitoring needs of 
[chronic kidney disease].”13
Kidney disease is associated with 
a tremendous economic burden. High-
income countries typically spend more 
than 2–3% of their annual health-care 
budget on the treatment of end-stage 
kidney disease, even though those re-
ceiving such treatment represent under 
0.03% of the total population.14 In 2010, 
2.62 million people received dialysis 
worldwide and the need for dialysis was 
projected to double by 2030.8 Globally, 
the total cost of the treatment of the 
milder forms of chronic kidney disease 
appears to be much greater than the total 
cost of treating end-stage kidney disease. 
In 2015, in the United States of America, 
for example, Medicare expenditures on 
chronic and end-stage kidney disease 
were more than 64 billion and 34 bil-
lion United States dollars, respectively.15 
Much of the expenditure, morbidity and 
mortality previously attributed to diabe-
tes and hypertension are attributable to 
kidney disease and its complications.12,16
Worldwide, important risk fac-
tors for kidney disease include diar-
rhoeal diseases, HIV infection, low birth 
weight, malaria and preterm birth, all of 
which are also leading global causes of 
DALYs.12 Risks of kidney disease span 
the life-course and environmental, in-
fection and lifestyle etiologies.17 If risk 
factors are identified early, acute kidney 
injury and chronic kidney disease can 
be prevented and, if kidney disease is 
diagnosed early, worsening of kidney 
function can be slowed or averted by 
inexpensive interventions, several of 
which are on the World Health Orga-
nization’s (WHO’s) so-called best buys 
list for noncommunicable disease man-
agement.18 Such interventions include 
counselling for cardiovascular disease, 
diabetes and hypertension, drug therapy, 
tobacco control, promotion of physical 
activity and the reduction of salt intake 
through legislation and food labelling. 
The timely identification and manage-
ment of acute kidney injury and chronic 
kidney disease represent the most ef-
fective strategy to address the growing 
global burden sustainably.4,5 By advocat-
ing for a multisectoral approach, as a 
means to achieving the SDGs, it should 
be possible to reduce the incidence of 
kidney disease globally.19 We discuss 
the kidney-health-related opportunities 
offered by attempts to achieve each SDG 
(Table 1).
SDGs and kidney health
SDGs 1, 3.8, 3.b and 10
In high-income countries, lower so-
cioeconomic status is associated with 
greater risk of end-stage kidney disease 
because of behavioural and metabolic 
risk factors and reduced access to care.20 
In low- and middle-income countries, 
the burden posed by such poverty-
related kidney disease is even greater, 
because of associated infections, hazard-
ous work, poor education and poor ma-
ternal health. In all countries, poverty is 
associated with lack of social protection 
and transportation, poor housing and 
unemployment.20 Lack of transporta-
tion restricts access to care even when 
treatment costs are not a major barrier.20 
Poverty and lower socioeconomic status 
have been specifically identified as inde-
pendent risks for both incident chronic 
kidney disease and the more rapid pro-
gression of such disease.20 In low-income 
countries where treatment costs have to 
be paid directly by patients, a month’s 
supply of essential medications for the 
treatment of chronic kidney disease can 
cost up to 18 days’ wages21 and the corre-
sponding out-of-pocket costs of dialysis, 
for acute kidney injury or end-stage 
kidney disease, are much higher.22,23 In 
South Africa, where limited access to 
dialysis is government-funded, patients 
who are otherwise eligible for dialysis 
are frequently declined access because 
of their socioeconomic circumstances.24 
For those who do access dialysis, the 
financial burden is exacerbated because 
they cannot be employed while receiv-
ing dialysis or travelling to and from 
the provider.
Goal Description Relevance to kidney health Relevant 
SDG 3 targets
13 Take urgent action to combat 
climate change and its impacts
• Global warming may have contributed to an epidemic of Central American 
nephropathy and to CKD of unknown origin that appears related to 
dehydration and toxin exposure
• The adverse effects of climate change on the transmission of pathogens 
causing infectious disease and poverty may increase the risk of CKD
3.2, 3.3, 3.d
14 Conserve and sustainably use the 
oceans, seas and marine resources
• Exposure to marine pollution may increase the risk of CKD 3.9, 3.d
15 Sustainably manage forests, 
combat desertification and halt 
and reverse land degradation and 
halt biodiversity loss
• Any reduction in the leaching of toxins from industrial waste into ground water 
could reduce the risk of the CKD associated with such pollution
3.9, 3.d
16 Promote just, peaceful and 
inclusive societies
• Any reduction in armed conflict could reduce the risk of AKI associated with 
crush injuries and major trauma and improve food security
• The incidence of low birth weight, which is a risk factor for CKD, tends to 
increase during wars
• Among prisoners and other marginalized populations, improvements in equity 
and justice could facilitate the prevention, diagnosis and treatment of kidney 
disease
3.d
17 Revitalize the global partnership 
for sustainable development
• Improved global partnerships for health-care financing and regulation and 
health-related development and research could accelerate our understanding 
of kidney disease, reduce inequities in kidney care and reduce so-called 
transplant tourism
3.d
AKI: acute kidney injury; CKD: chronic kidney disease; ESKD: end-stage kidney disease; SDG: sustainable development goal.
(. . .continued)
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Promotion of universal health 
coverage should reduce the financial 
hardship of patients with kidney disease 
and improve access to kidney care.25 The 
goal of eradicating poverty spans all 
of the other SDGs and is fundamental 
to improving kidney health. In turn, 
achievement of each SDG promises to 
promote equity and reduce poverty.20
SDG 2
Many low-income countries have 
problems with undernutrition and 
overnutrition, both are risk factors for 
kidney disease. Malnutrition predis-
poses young children to infections, e.g. 
diarrhoeal diseases and pneumonia, 
that are important risk factors for acute 
kidney injury.22 Among girls and female 
adolescents, undernutrition leads to 
underweight mothers and low-birth-
weight offspring.26 Low birth weights, 
preterm births and pregnancies affected 
by diabetes and pre-eclampsia, which, 
combined, may represent up to 20% 
of pregnancies worldwide, are all as-
sociated with increased lifetime risk of 
chronic kidney disease in both mothers 
and children.26 Obesity increases the 
lifetime risk of end-stage kidney dis-
ease17 and maternal obesity is associated 
with adverse outcomes in pregnancy,26 
including the gestational diabetes and 
preterm births that are associated with 
increased risk of chronic kidney disease.
Adequate nutrition is a key tool 
for reducing the burden of chronic 
kidney disease. Groups with very low 
incomes often live in areas where ac-
cess to healthful foods is very limited 
or non-existent.20 Some population-level 
strategies, e.g. public education about 
healthful food choices, regulation of the 
fat, salt and/or sugar contents of food 
and the regulation of programmes for 
the provision of public and/or school 
meals, can all improve kidney health.27 
Reduction in dietary salt is proposed as 
a cost-saving best buy with great poten-
tial to avert deaths from kidney disease. 
Similarly, a tax on high-sugar beverages, 
as introduced in Mexico, where chronic 
kidney disease is the second leading 
cause of death, can lead to sustained 
decreases in the purchase of taxed drinks 
and may reduce diabetes-related kidney 
disease over time.28
SDG 3
SDG 3 has many l inks to better 
kidney health (Table 2 available at: 
http://www.who.int/bul let in/vol-
umes/96/6/17-206441) including opti-
mization of fetal development, preven-
tion of infections, reduction of the mor-
tality and morbidity of cardiovascular 
disease and mitigation of environmental 
exposures. The Global Kidney Health 
Atlas has provided an overview of the 
main gaps in kidney care globally: an 
absence of relevant policies, shortages 
of essential medications, reliable epi-
demiological data, relevant workforce 
capacity, infrastructure and research 
capacity and a persistent reliance on out-
of-pocket payments.29 The Atlas empha-
sizes the need for a health-system-wide 
approach to kidney care and provides a 
baseline against which to measure prog-
ress. Work towards reducing the global 
burden of kidney disease will contribute 
to achieving SDG 3 (Table 2).
SDGs 4 and 5
Because they are, in general, responsible 
for most child care and housework, 
women in low- and middle-income 
countries may face greater challenges if 
they have chronic kidney disease – and 
other noncommunicable diseases, than 
men with similar health problems.30 
Heavy demands on their time may ex-
plain why, even though chronic kidney 
disease is more common among women 
than men, fewer women than men re-
ceive dialysis.30 Child marriage and lack 
of access to family planning contribute 
to poor maternal health and increased 
risk of obstetrical complications, includ-
ing acute kidney injury.31 Among urban 
adults in the United States, both gender 
and race appeared to affect glomerular 
filtration rates.32 Achievement of equity 
for women worldwide should reduce the 
burden of kidney disease.
SDG 6
Globally, almost 800 million people 
lack access to safe water and 2.5 billion 
lack access to optimal sanitation.33 In 
low- and middle-income countries, 
waterborne and pestilent diseases as-
sociated with poor hygiene and sanita-
tion are major causes of acute kidney 
injury and chronic kidney disease.34 
Enteric diarrhoeal deaths, associated 
with lack of safe water, cause over 1 
million deaths annually.13 Most of these 
deaths occur in children younger than 
five years and many can be attributed 
to dehydration-related acute kidney 
injury.13 Non-enteric diseases caused by 
waterborne pathogens, e.g. leptospirosis 
and schistosomiasis, are also major 
causes of kidney disease in low- and 
middle-income countries.34
Local availability of clean water 
would be expected to reduce the risk of 
diarrhoea-related acute kidney injury.35 
Beyond infection-related kidney com-
plications from contaminated water and 
poor sanitation, additional challenges 
exist. Water containing organic perfluo-
roalkyl acids and heavy metals has been 
associated with chronic kidney disease 
in several settings and pesticide-con-
taminated well water may contribute to 
the risk of some chronic kidney disease 
observed in Sri Lanka.36 Dehydration, in 
conjunction with heat stress, may have 
contributed to the epidemic of chronic 
kidney disease observed among young, 
economically productive male labour-
ers in Central America and South-East 
Asia.36 The global burden of kidney dis-
ease should be reduced by ensuring the 
availability of clean water and adequate 
sanitation.
SDGs 7 and 12–15
Climate change, degradation of bio-
diversity, forest and land, and loss of 
marine resources, all likely increase 
the risk of kidney disease through 
multiple mechanisms, e.g. increases in 
food insecurity, the incidences of heat-
related illness and infectious diseases 
and pollution.37 Deforestation and land 
degradation can bring humans into 
greater contact with vector-borne and 
waterborne pathogens, such as enteric 
bacteria and other pathogens that can 
directly cause kidney disease, e.g. those 
causing dengue fever, leishmaniasis, 
leptospirosis, malaria, schistosomiasis, 
trypanosomiasis and yellow fever.38
Reducing the global burden of 
kidney disease in turn will also be criti-
cal for mitigating some of the environ-
mental impacts of dialysis. Each year, 
for example, the haemodialysis given 
to more than 2 million people requires 
160 billion litres of water and generates 
over 900 000 tonnes of, predominantly 
plastic waste.39 Clean, local production 
of dialysis supplies, the reprocessing 
of dialysis filters, the reuse of dialysis 
water, solar-powered dialysis and water-
less dialysis are all promising strategies 
that could creduce the environmental 
footprint of dialysis as well at its costs.39
SDGs 8, 10 and 17
Within low- and middle-income coun-
tries, access to dialysis is highly inequi-
table.8 Despite its relative cost–effective-
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ness, access to transplantation is even 
more inequitable because of cultural, 
financial and legislative barriers and 
infrastructural limitations.40 In the face 
of extreme social inequalities and a 
demand for transplants that markedly 
exceeds the supply, the trafficking of kid-
neys and other human organs remains a 
major concern.40
Disparities in the burden of kidney 
disease, which are particularly complex, 
arise from biological, environmental, 
genetic, lifestyle and sociocultural 
factors20 and need to be addressed via 
multilevel, systematic interventions.34 
An example of the complexities involved 
has been described in the United States. 
There, in general, compared with other 
patients with similar disease, patients 
with chronic kidney disease from eth-
nic and racial minorities have delayed 
referral for care, lower incomes, report 
poorer physician–patient relationships 
and have less access to health care in 
general.20 The pervasive disparities 
in kidney disease will have to be ad-
dressed before SDGs 8, 10 and 17 can 
be achieved.
SDGs 3.6, 3.d, 9 and 11
Rapidly occurring urbanization has 
contributed to the rise of kidney disease 
and other noncommunicable diseases 
in low- and middle-income countries.41 
In addition to the commonly associated 
lifestyle changes, e.g. a switch to high-
calorie, sodium-rich diets and decreased 
physical activity, rapid urbanization has 
led to crowded cities with environmen-
tal pollution, a limited infrastructure 
and poor levels of sanitation and waste 
disposal.42 Such urbanization also means 
that more and more people are living in 
settings where a growing prevalence of 
noncommunicable diseases, e.g. diabe-
tes, hypertension and obesity, is juxta-
posed with environmental toxins and 
numerous infectious diseases.42 These 
changes portend a synergistic growth 
in the global burden of kidney disease. 
There may already be evidence of such 
growth in the ever-higher ranking of 
chronic kidney disease among lead-
ing cause of deaths, across all country 
income categories, between 1990 and 
2016.13
By building resilient infrastructure 
while promoting sustainable industrial-
ization, it should be possible to enhance 
health-care access while simultaneously 
reducing the risk of kidney disease. In 
low- and middle-income countries, 
urban planning, to improve hygiene 
and sanitation and reduce population 
densities and the transmission of the 
pathogens causing enteric infections, 
schistosomiasis and tuberculosis, should 
reduce the incidence of acute kidney 
injury and chronic kidney disease.17 
At the same time, by promoting the 
development of parks, paths and effi-
cient transport systems, urban planning 
could increase general levels of physical 
activity and so help reduce the risk of 
obesity-related kidney disease.42
The effective prevention of chronic 
kidney disease will require engagement 
with the corporate sector, whose inter-
ests may be in conflict with those of pub-
lic health.43 Novel strategies are required 
to create incentives for the corporate 
sector to promote public health.44 Even 
under optimal circumstances, kidney 
disease cannot always be prevented 
and strategies to reduce the economic, 
physical and social burdens of end-stage 
kidney disease are needed. Innovative 
mechanisms to reduce dialysis costs and 
make dialysis less dependent on electric-
ity and water could multiply opportuni-
ties for access to dialysis, especially in 
low- and middle-income countries.39 
Innovation is also required to improve 
access to transplantation. Although opt-
out or presumed-consent strategies have 
been proposed as a way of increasing the 
supply of organs from deceased donors, 
they remain contentious.
Acute kidney injury after a road-
traffic collision may result from rhabdo-
myolysis and multi-organ failure as well 
as blunt or penetrating kidney injury.45 
Natural disasters are associated with 
increased rates of crush-injury-induced 
acute kidney injury and frequently lead 
to life-threatening interruptions of treat-
ment among those with end-stage kid-
ney disease.46 Similarly, forced migrants 
with chronic or end-stage kidney disease 
can face dangerous interruptions in their 
treatment or receive inadequate care,47 
even in a high-income country such as 
the United States.48 Continued action on 
reducing the burden of road-traffic inju-
ries and supporting efforts to integrate 
noncommunicable disease management 
into humanitarian relief efforts should 
help to reduce the burden of chronic 
and end-stage kidney disease.46
SDG 16
Exposure to armed conflict can result 
in acute kidney injury caused by crush 
injury and rhabdomyolysis and the 
severity of injuries sustained in combat 
strongly correlates with the subsequent 
risk of chronic kidney disease.49 Kid-
ney disease is common in incarcerated 
populations and, in terms of their kid-
ney health, prisoners may face a triple 
burden: of excess risk of kidney disease 
and its risk factors, of barriers to preven-
tive care for established chronic kidney 
disease and of the suboptimal manage-
ment of end-stage kidney disease.50 As 
an important step towards improving 
global health, much work is required 
globally to reduce conflict and dispari-
ties and enhance peace.
Policy perspective
The net health burden of kidney disease 
is substantial, growing and driven by 
complex interactions, between commu-
nicable and noncommunicable diseases, 
that are shaped by upstream environ-
mental and socioeconomic disparities. 
Although kidney disease, whether acute, 
chronic or end-stage, can be extremely 
costly, it is also potentially preventable 
and adverse outcomes can often be 
delayed or prevented by inexpensive 
interventions. Kidney disease is highly 
prevalent, spans the life course and has 
substantial financial implications. Our 
response to such disease requires a sys-
tematic policy approach, to strengthen 
all relevant aspects of the health sys-
tem and to facilitate integration of the 
promotion of kidney health within a 
comprehensive horizontal programme 
for the prevention and treatment of 
noncommunicable diseases (Table 2).
Within each country, the local bur-
den and prevalence of kidney disease 
and its risk factors and the local capac-
ity to identify and manage such disease 
must be determined, as a prerequisite 
for fair priority setting and appropri-
ate policy development. Diagnosis of 
kidney disease is often hampered by a 
lack of awareness among health-care 
workers and at-risk communities and 
by inadequate and often erratic access 
to laboratory testing. Broad policies are 
increasingly being adopted globally to 
curb dietary intakes of fat, salt and sugar. 
Such policies all promise to reduce the 
burden of chronic kidney disease. The 
burden of acute kidney injury could be 
reduced through the ongoing commit-
ment to reduce the transmission of the 
pathogens causing infectious diseases.
We need universal health coverage 
to tackle kidney disease successfully 
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and ensure effective screening, preven-
tion and early treatment. Effective and 
transparent policies to govern access 
to care for end-stage kidney disease 
should only be developed after there has 
been a thorough attempt to determine 
the local health priorities, especially in 
resource-poor settings. Engagement 
with all relevant stakeholders and in-
novative financing strategies will be 
required to maximize equitable access 
to care. The bidirectional and synergistic 
interplay between kidney disease and 
all of the SGDs must be acknowledged 
in the development of a multisectoral 
approach. Policies that foster domes-
tic and international collaboration, 
improve occupational and road safety, 
limit organ trafficking, promote access 
to education and gender equality, reduce 
unemployment and tackle the predicted 
adverse effects of climate change may 
all reduce kidney disease and/or the 
disparities in the care for such disease. 
However, as noted by the United Na-
tions Secretary-General in December 
2017, in the control and prevention 
of noncommunicable diseases, “politi-
cal commitments have not often been 
translated into concrete action.”51 On 
its own, policy-making is insufficient. 
Monitoring the impact of policies on 
kidney disease and the risk factors for 
such disease needs to be integrated into 
existing surveillance activities. Health 
workers and communities must be 
empowered to advocate for, and hold 
policy-makers accountable for, kidney 
health, as an important step towards 
achievement of the SDGs. ■
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ملخص
العبء العاملي ملرض الكىل وأهداف التنمية املستدامة
ُوصف مرض الكىل بأنه املرض املزمن األكثر عرضة لإلمهال. وال 
ملرض  العاملي  العبء  حلجم  موثوقة  بتقديرات  اخلروج  إىل  سبيل 
الرشائح  إىل  املستندة  الدراسات  من  املزيد  إجراء  دون  من  الكىل 
الطيف  أنحاء  خمتلف  يف  تقع  حمددة  خماطر  هناك  أن  إال  السكانية، 
االجتامعي االقتصادي، ما بني الفقر إىل الثراء، ومن سوء التغذية 
الصناعية،  بعد  ما  إىل  الزراعية  البيئات  ويف  الزائدة،  الِسمنة  إىل 
وهناك  املسنني.  حتى  حديًثا  املولودين  من  بدًءا  احلياة  مدار  وعىل 
إصابة  إىل  تؤدي  التي  السارية  وغري  السارية  األمراض  من  عدد 
الكىل  يتسنى للعديد من املصابني بمرض  الكىل بمضاعفات، وال 
سبل احلصول عىل الرعاية. كام أن ملسببات أمراض الكىل وتبعاهتا 
مجيع  يف  العمومية  الصحة  سياسة  عاتق  عىل  تقع  تبعات  ونفقاهتا 
األصل  بعوامل  الكىل  بمرض  اإلصابة  خماطر  تتأثر  كام  البلدان. 
يؤدي  وقد  احلياة.  ونمط  واملوقع  االجتامعي  والنوع  العرقي 
واالنتقال  اهلجرة،  وعوامل  والصحية،  االقتصادية  الفوارق  تزايد 
البيئية،  والتهديدات  اآلمنة،  غري  العمل  وظروف  الديموغرايف، 
الساعية  املحاوالت  تقويض  إىل  والتلوث  الطبيعية،  والكوارث 
الكىل.  مرض  عن  الناجتة  والوفيات  اإلصابة  نسب  من  احلد  إىل 
العاملي  العبء  مع  للتعامل  القطاعات  متعدد  هنج  اتباع  ويلزم 
ملرض الكىل. وتؤكد أهداف التنمية املستدامة عىل أمهية اتباع هنج 
توجيه  عىل  نعمل  ونحن  الصحة.  مع  للتعاطي  القطاعات  متعدد 
التنمية املستدامة القادرة عىل  اإلجراءات نحو حتقيق مجيع أهداف 
حتسني مستويات فهم مرض الكىل وقياسه والوقاية منه وعالجه يف 
مجيع الفئات العمرية. كام يمكن هلذه اإلجراءات أن تعزز من سبل 
التطوير يف جمال العالج، وحتد من حجم العبء الناتج عن املرض 




















Charge mondiale de la maladie rénale et objectifs de développement durable
La maladie rénale est décrite comme la maladie chronique la plus 
négligée. Si d’autres études en population sont nécessaires pour 
établir des estimations fiables de la charge mondiale de la maladie 
rénale, les risques spécifiques sont présents dans l’ensemble du spectre 
socioéconomique, à la fois en situation de pauvreté et de richesse, 
de malnutrition et d’obésité, dans des environnements agricoles et 
postindustriels, et à tous les âges, aussi bien chez les nouveau-nés 
que chez les personnes âgées. Diverses maladies transmissibles et non 
transmissibles entraînent des complications rénales et de nombreuses 
personnes atteintes de maladie rénale n’ont pas accès aux soins. Les 
causes, les conséquences et les coûts de la maladie rénale ont une 
incidence sur la politique de santé publique dans tous les pays. Le risque 
de développer une maladie rénale est également influencé par l’origine 
ethnique, le sexe, le lieu et le mode de vie. L’accroissement des disparités 
économiques et sanitaires, les migrations, la transition démographique, 
les conditions de travail dangereuses, les menaces environnementales, 
les catastrophes naturelles et la pollution sont susceptibles de faire 
échouer les tentatives de réduction de la morbidité et de la mortalité 
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liées à la maladie rénale. Une approche multisectorielle est nécessaire 
pour faire face à la charge mondiale de la maladie rénale. Les objectifs 
de développement durable (ODD) soulignent l’importance d’une 
approche multisectorielle en matière de santé. Nous établissons une 
cartographie des actions à entreprendre pour atteindre tous les ODD qui 
sont susceptibles d’améliorer la connaissance, la mesure, la prévention 
et le traitement de la maladie rénale dans toutes les tranches d’âge. Ces 
actions peuvent également favoriser les innovations thérapeutiques et 
réduire la charge de cette affection pour les générations futures.
Резюме
Глобальное бремя хронической болезни почек и цели в области устойчивого развития
Хроническая болезнь почек известна как одно из тех хронических 
заболеваний, которым уделяется меньше всего внимания. 
Надежные оценки глобального бремени хронической 
болезни почек требуют проведения исследований, более 
ориентированных на популяционный уровень, но определенные 
риски возникают во всем социально-экономическом спектре: 
от нищеты до богатства, от недоедания до ожирения, от 
аграрного до постиндустриального сегментов общества, а 
также в течение всей жизни от новорожденных до взрослых 
людей. Ряд инфекционных и неинфекционных заболеваний 
приводит к осложнениям, затрагивающим почки, а многие люди 
с хронической болезнью почек не имеют возможности получить 
медицинскую помощь. Причины, последствия и расходы, 
связанные с заболеваниями почек, имеют значение для политики 
общественного здравоохранения во всех странах. Риск развития 
хронической болезни почек также зависит от этнической 
принадлежности, пола, территории проживания и образа жизни.  
Рост диспропорций в области экономики и здравоохранения, 
миграция населения, демографические изменения, небезопасные 
условия труда и экологические угрозы, стихийные бедствия 
и природное загрязнение могут помешать попыткам снизить 
заболеваемость хронической болезнью почек и связанную с 
ней смертность. Для решения проблемы глобального бремени 
хронической болезни почек необходим многосекторальный 
подход. Цели в области устойчивого развития подчеркивают 
важность многосекторального подхода к здравоохранению. 
Авторы составили план действий по достижению всех целей 
в области устойчивого развития, которые могут улучшить 
понимание аспектов хронической болезни почек во всех 
возрастных группах, а также исследование, профилактику и 
лечение этой болезни. Эти действия могут также способствовать 
инновациям в области лечения и уменьшить бремя этого 
заболевания для будущих поколений.
Resumen
La carga global de la insuficiencia renal y los objetivos de desarrollo sostenible
La insuficiencia renal se ha descrito como la enfermedad crónica más 
olvidada. Serían necesarios más estudios basados en la población para 
obtener estimaciones fiables de la carga mundial de la insuficiencia renal, 
pero existen riesgos específicos en todo el espectro socioeconómico 
desde la pobreza hasta la prosperidad, desde la desnutrición hasta 
la obesidad, en contextos agrarios y postindustriales, y a lo largo de 
la vida desde recién nacidos hasta la tercera edad. Una variedad de 
enfermedades contagiosas y no contagiosas producen complicaciones 
renales y muchas personas que padecen una insuficiencia renal no 
tienen acceso a la atención. Las causas, las consecuencias y los costes 
de las insuficiencias renales tienen implicaciones para la política de salud 
pública en todos los países. Los riesgos de la insuficiencia renal también 
están influenciados por la raza, el sexo, la ubicación y el estilo de vida.  
El aumento de las disparidades económicas y de salud, la migración, 
la transición demográfica, las condiciones de trabajo inseguras y las 
amenazas ambientales, los desastres naturales y la contaminación 
pueden frustrar los intentos de reducir la morbilidad y la mortalidad 
por insuficiencia renal. Se necesita un enfoque multisectorial para 
abordar la carga mundial de la insuficiencia renal. Los Objetivos de 
Desarrollo Sostenible (ODS) hacen hincapié en la importancia de un 
enfoque multisectorial de la salud. Planificamos las acciones para 
alcanzar todos los ODS con el potencial de mejorar la comprensión, 
la medición, la prevención y el tratamiento de la insuficiencia renal en 
todos los grupos de edad. Estas acciones también pueden fomentar 
innovaciones en el tratamiento y reducir la carga de dicha enfermedad 
en las generaciones futuras.
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Table 2. Relevance of the targets of sustainable development goal 3 to kidney disease, 2015
Target Description Relevant kidney 
condition
Strategies or actions to reduce risk  
of kidney disease
Policies facilitating improved  
kidney health
3.1 By 2030, reduce global 
maternal mortality to 
less than 70 deaths per 




• Improve access to antenatal care and 
institutional deliveries and the recognition 
of pregnancy complications, e.g. 
eclampsia, pre-eclampsia and peripartum 
haemorrhage
UHC 
Promotion of gender equity 
Public health promotion of healthy lifestyles 
through education and regulation of 
unhealthy food and tobacco consumption 
Promotion of the consumption of healthy 
food
• Identify, during antenatal care or at 
delivery, mothers at risk, for education 
and follow-up to reduce long-term risk of 
maternal CKD and cardiovascular disease 
associated with pre-eclampsia
3.2 By 2030, end preventable 
deaths of neonates and 
children under 5 years 
of age, with all countries 
aiming to reduce neonatal 
mortality to no more 
than 12 deaths per 1000 
live births and mortality 
among children under 
5 years of age to no more 
than 25 deaths per 1000 
live births
Perinatal AKI • Reduce prematurity UHC 
Education of health-care workers 
Enhancement of the capacity and 
infrastructure for detection and surveillance
• Avoid or reduce perinatal use of 
nephrotoxins, e.g. aminoglycoside 
antibiotics and non-steroidal anti-
inflammatory drugs




• Reduce prematurity and low birth weight, 
which are both risk factors for low nephron 
numbers
UHC to improve access to prevention and 
screening services 
Public health promotion of healthy lifestyles 
through education and regulation of 
unhealthy food and tobacco consumption 






• Improve sanitation and access to 
vaccinations and medical care
Development of public health policy to 
improve disease surveillance and response to 
outbreaks
3.3 By 2030, end the 
epidemics of AIDS, 
malaria, neglected 
tropical diseases and 
tuberculosis, and combat 
hepatitis, waterborne 
diseases and other 
communicable diseases
HIV nephropathy • Provide equitable access to services for the 
prevention and treatment of HIV infection
UHC 
Enactment of protections for women victims 
of domestic violence and sexual assault 
Taking action, including legal, policy and 
regulatory reforms, to ensure full political 
enfranchisement for women 
Legislation for the protection of sex workers
Malaria-associated 
AKI, black water 
fever
• Prevent and provide early treatment of 
malaria and combat both availability 
of fake medication and emergence of 
resistance to antimalarials
Development of public health policy to 
improve disease surveillance and response to 
outbreaks 
Reforming of pharmaceutical supply chains 
and enhancement of regulations to combat 
fake medicines
CKD – a risk factor 
for tuberculosis
• Increase awareness of risk Development of public health policy to 
improve disease surveillance and the 
effectiveness of diagnosis and treatment 
Development of innovative interventions to 
improve labour conditions and conditions in 
prisons







• Improve access to vaccination and 
treatment for hepatitis B and C
Provision of public education and UHC 
Development of care models integrating 
traditional healers. Legislation on alcohol 
consumption to reduce high-risk drinking
• Reduce hepatitis-associated inflammation 
and immune-complex deposition




• Prevent and treat Hantavirus, leptospirosis 
and scrub typhus
Development of public health policy to 
improve disease surveillance and the 
effectiveness of diagnosis and treatment
Urinary obstruction • Reduce schistosomiasis Development of public health policy to 
improve disease surveillance and response to 
outbreaks
• Diagnose and treat kidney tuberculosis 
adequately, to reduce long-term 
obstruction of urinary tract
(continues. . .)
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Target Description Relevant kidney 
condition
Strategies or actions to reduce risk  
of kidney disease
Policies facilitating improved  
kidney health
3.4 By 2030, reduce by one 
third premature mortality 
from noncommunicable 
diseases through 
prevention and treatment 
and promote mental 
health and well-being
CKD • Prevent and screen for CKD, improve access 
to early diagnosis and effective treatment 
for CKD, provide equitable access to 
treatment for kidney failure, i.e. dialysis and 
transplantation, and strengthen access to 
options for lifestyle improvement
UHC 
Enactment of protections for women victims 
of domestic violence and sexual assault 
Taking action, including legal, policy and 
regulatory reforms, to ensure full political 
enfranchisement for women 
Promotion of healthy lifestyles through 
education and regulation of unhealthy food 
consumption 
Adoption and implementation of FCTC 
Enhancement of capacity and infrastructure 
for detection and surveillance 
Development of care models integrating 
traditional healers. Enhancement of 
occupational safety standards 
Development of transparent policies 
governing access to expensive therapies such 
as dialysis and transplantation
• Reduction in CKD could reduce morbidity 
and mortality associated with some other 




• Reduce CKD, this should reduce the 
burdens posed by global hypertension and 
cardiovascular disease and the associated 
mortality
AKI • Prevent AKI through improved access 
to sanitation and vaccination, decrease 
reliance on toxic traditional remedies, 
improve access to early diagnosis and 
effective treatment for AKI and provide 
equitable access to dialysis
• Reduction in AKI could reduce morbidity 
and mortality associated with some other 
conditions, e.g. heart failure, liver disease, 
sepsis and surgery
3.5 Strengthen the 
prevention and treatment 
of substance abuse, 
including narcotic drug 





• Reduce low birth weight associated with 
alcohol use, smoking and substance abuse 
in pregnancy
UHC 
Enactment of protection for women victims 
of domestic violence and sexual assault 
Taking action, including legal, policy and 
regulatory policy reforms, to ensure full 
political enfranchisement for women 
Promotion of urban safety 
Legislation and regulation of alcohol 
consumption 
Adoption and implementation of FCTC 
Legislation for the protection of sex workers






• Reduce infections transmitted by 
intravenous drug use
Rhabdomyolysis • Prevent rhabdomyolysis by increasing 
awareness and providing treatment for 
drug withdrawal and delirium tremens
3.6 By 2020, halve the 
number of global deaths 
and injuries from road 
traffic accidents
AKI • Prevent trauma-related crush injury or 
blunt kidney trauma
Enforcement of existing traffic laws and 
reform of traffic laws to reduce road trauma 
Promotion of occupational safety 
Development and building of infrastructure 
and safe roads, with capacity to absorb urban 
growth
CKD • Prevent accident-related losses in 
employment, increases in poverty and 
reductions in access to health care
3.7 By 2030, ensure 
universal access to 
sexual and reproductive 
health-care services, 
including for family 
planning, information 
and education, and 
the integration of 
reproductive health into 




• Empower women, increase spacing 
of pregnancies and reduce teenage 
pregnancies
Promotion of access to education for all and 
family planning, gender equity and UHC 
Strengthen legislation on access to safe 
abortion and the protection of sex workers• Reduce risk of low birth weight and 
preterm birth, as these can adversely affect 
kidney health of the child
3.8 Achieve UHC, including 
financial risk protection, 
access to quality essential 
health-care services and 
access to safe, effective, 
quality and affordable 
essential medicines and 
vaccines for all
AKI, CKD • Provide universal access to basic health 
care and services for the diagnosis, 
prevention and treatment of all kidney 
disease and its risk factors, e.g. diabetes 
and hypertension
Promotion of innovative financing, regulation 
of the pricing of medical products and UHC 
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Target Description Relevant kidney 
condition
Strategies or actions to reduce risk  
of kidney disease
Policies facilitating improved  
kidney health
3.9 By 2030, substantially 
reduce the number of 
deaths and illnesses 
from hazardous 
chemicals and air, water 
and soil pollution and 
contamination
CKD of unknown 
origin, observed in 
Egypt, India and Sri 
Lanka, and Balkan 
nephropathy
• Reduce exposure to environmental toxins 
that may be associated with CKD, e.g. 
aristolochic acid and cadmium and others
Promotion of environmental protection and 
safety 
Promotion of sustainable agriculture and 
fishing 
Commitment to combat climate change
3.a Strengthen the 
implementation of WHO’s 
FCTC in all countries, as 
appropriate
CKD • Reduce tobacco smoking, a risk factor 
for cardiovascular disease and mortality, 
haematuria, low birth weight and 
proteinuria
Adoption and implementation of FCTC
3.b Support the research 
and development of 
vaccines and medicines 
for the communicable 
and noncommunicable 
diseases that primarily 
affect developing 
countries, provide access 
to affordable essential 
medicines and vaccines, 
in accordance with the 
Doha Declaration on the 
TRIPS Agreement and 
Public Health, which 
affirms the right of 
developing countries 
to use to the full, the 
provisions in the TRIPS 
Agreement regarding 
flexibilities to protect 
public health and, in 
particular, provide access 
to medicines for all
AKI • Provide and support the uptake of vaccines 
that can prevent diarrhoeal illness, sepsis 
and other infections that can cause AKI 
and can prevent low birth weight in 
pregnancy
Promotion of budget allocation for locally 
relevant research 
Strengthening and empowerment of local 
research ethics committees 
Utilization of TRIPS Agreement exemptions 
Enhancement of the regulation of generic 
medication 
Monitoring of medication supply and use 
Promotion of health technology assessments 
Development of transparent policies 
governing access to expensive therapies, e.g. 
dialysis and transplantation 
Development of innovative financing models 
to reduce costs of dialysis and transplantation 
Implementation and enforcement of the 
Istanbul Declaration against organ trafficking 
Development of legislation regarding brain 
death and organ donation 
Opt-out or presumed-consent policies for 
organ donation
• Support prompt access to the intravenous 
fluid and appropriate antibiotics that can 
prevent AKI and glomerulonephritisd
• Vaccination in pregnancy can reduce the 
risk of low birth weight
• Vaccination during pregnancy can reduce 
the incidence of low birth weight
CKD • Provide affordable and sustainable access 
to basic medications for CKD, diabetes and 
hypertension and so reduce burden of 
end-stage kidney disease
ESKD • Devise innovative ways to deliver cheaper 
dialysis worldwide
Transplantation • Promote safe and altruistic kidney 
donation by living donors. Improve supply 
from deceased donors where permissible. 
Stop organ trafficking
3.c Substantially increase 
health financing 
and the recruitment, 
development, training 
and retention of the 
health workforce in 
developing countries, 
especially in least 
developed countries and 





• Improve awareness and capacity to 
diagnose, prevent and treat kidney disease
Development of innovative financing models 
to reduce costs of dialysis and transplantation 
Promotion of the education, licensing and 
registration of health-care workers and 
researchers 
Promotion of the fair remuneration of health-
care workers 
Legislation to define the scope of practice 
of community health workers and any 
associated task shifting
• Train and retain health-care workers with 
knowledge of kidney disease
3.d Strengthen the capacity 
of all countries, in 
particular developing 
countries, for early 
warning, risk reduction 
and management of 
national and global health 
risks
Crush syndrome • Improve disaster planning and responses 
to earthquakes and other major disasters
Promotion of international collaboration to 
respond to natural disasters 
Commitment to equality and peace 
Promotion of democracy 
Strengthening of intersectoral 
communication and collaboration
CKD • Promote peace
• Prevention of wars should reduce both the 
burden of kidney disease associated with 
low birth weight and malnutrition and the 
conflict-related disruption of care
AIDS: acquired immunodeficiency syndrome; AKI: acute kidney injury; CKD: chronic kidney disease; ESKD; end-stage kidney disease; FCTC: Framework Convention on 
Tobacco Control; HIV: human immunodeficiency virus; HUS: haemolytic uraemic syndrome; TRIPS: Trade-related Aspects of Intellectual Property Rights; UHC: universal 




Papers	3	and	4	 take	a	very	concrete	approach	to	prevention	of	kidney	disease.	 In	Paper	3	 the	
approach	was	 to	 try	 to	estimate	 the	burden	of	kidney	disease	attributable	 to	each	risk	 factor.	
Risk	 factors	 were	 identified	 through	 literature	 search	 and	 consensus	 within	 an	 expert	 group.	
Strategies	for	primary	and	secondary	prevention	and	advocacy	messaging	were	highlighted	for	
each	risk	factor.	The	novelty	of	this	paper	was	the	comprehensiveness	of	this	approach.	In	Paper	
4	 the	 goal	was	 to	 illustrate	 the	 necessity	 of	multi-sectoral	 co-operation	 and	 collaboration	 for	
health,	 using	 the	 example	 of	 kidney	 disease,	 which	 lends	 itself	 well	 to	 this	 given	 that	 it	 is	
impacted	by	many	structural	and	environmental	 factors.	The	message	of	the	SDGs	 is	the	need	
for	 a	 “health	 in	 all	 policies”	 approach	 such	 that	 “no	 one	 is	 left	 behind”.
73
	 Highlighting	 the	
potential	 health	 benefits	 of	 achieving	 the	 non-health	 focused	 SGDs	 across	 the	 spectrum	 of	
kidney	 disease	 is	 novel,	 and	 is	 intended	 to	 be	 a	 practical	 illustration	 of	 the	 value	 of	 this	
approach.		
	
It	 is	 likely	that	policy	makers	are	generally	aware	of	the	broad	concepts	outlined	 in	Chapter	3,	




directed	 to	NCDs,	 and	 kidney	disease	has	not	been	on	 the	priority	 list.
13,74
	Numbers	 and	data	
therefore	 have	 not	 been	 enough	 to	 motivate	 a	 change	 in	 resource	 allocation	 or	 tangible	
prioritization	 of	 NCDs.	 There	 are	 many	 possible	 reasons	 why	 NCDs	 as	 a	 whole	 have	 been	
relatively	 neglected,	 in	 part	 due	 to	 the	 higher	 profile	 of	 diseases	 such	 as	 HIV,	 malaria	 and	
tuberculosis,	but	also	the	silent	comprehension	that	there	is	no	quick	fix	for	NCDs.	NCDs	require	
strong	 health	 systems,	 horizontal	 integrated	 disease	management	 programmes	 and	 sustained	
attention.	 It	 could	be	 argued	 that	 kidney	disease	 is	 an	 extreme	example	of	 the	 complexity	 of	
managing	NCDs,	given	that	it	is	amenable	to	prevention,	can	be	controlled	for	prolonged	periods	













	 However,	 the	 egalitarian	 perspective	 of	 providing	 dialysis	 to	 all,	 at	 a	 high	 cost,	














place	 regarding	 access	 to	 dialysis,	 disadvantaged	 and	 vulnerable	 patients	 are	 de	 facto	 being	
abandoned	by	 the	health	 system	whether	 this	 is	 admitted	or	 not.	How	governments	 can	 and	
should	 approach	 the	 “problem”	 of	 provision	 of	 dialysis	 within	 their	 health	 systems	 and	 their	
budgets	is	unclear.	There	are	a	limited	number	of	policy	options	that	can	be	pursued	in	terms	of	




have	 recently	 set	 an	 example	 of	 performing	 thorough	 health	 technology	 assessments	 (HTA),	




implementation	 to	 determine	whether	 the	 intended	 goals	 have	 been	 reached,	whether	 there	
have	 been	 unanticipated	 harms	 and	 to	 identify	 the	 need	 for	 policy	 revision.	 Implementation	
research	(IR)	is	gaining	prominence	as	the	most	appropriate	way	to	investigate	how	best	to	get	
known	 effective	 health	 interventions	 into	 practice	 and	 scaled	 up	 in	 low	 resource	 settings.	 A	
	 92
broad	 approach	 to	 the	 ethical	 implications	 of	 the	 planning,	 implementation	 and	 post-
























Ethical Challenges in the Provision of Dialysis in
Resource-Constrained Environments
Valerie A. Luyckx, MBBCh, MSc,*,† Ingrid Miljeteig, MD, PhD,‡,§ Addisu M. Ejigu, MD,||
and M. Rafique Moosa, MBBCh, FCP, MD, FRCP¶
Summary: The number of patients requiring dialysis by 2030 is projected to double worldwide, with the
largest increase expected in low- and middle-income countries (LMICs). Dialysis is seldom considered a high
priority by health care funders, consequently, few LMICs develop policies regarding dialysis allocation. Dialysis
facilities may exist, but access remains highly inequitable in LMICs. High out-of-pocket payments make
dialysis unsustainable and plunge many families into poverty. Patients, families, and clinicians suffer significant
emotional and moral distress from daily life-and-death decisions imposed by dialysis. The health system’s
obligation to provide financial risk protection is an important component of global and national strategies to
achieve universal health coverage. An ethical imperative therefore exists to develop transparent dialysis
priority-setting guidelines to facilitate public understanding and acceptance of the realistic limits within the
health system, and facilitate fair allocation of scarce resources. In this article, we present ethical challenges
faced by patients, families, clinicians, and policy makers where dialysis is not universally accessible and
discuss the potential ethical consequences of various dialysis allocation strategies. Finally, we suggest an
ethical framework for use in policy development for priority setting of dialysis care. The accountability for
reasonableness framework is proposed as a procedurally fair decision-making, priority-setting process.
Semin Nephrol 37:273-286 C 2017 Elsevier Inc. All rights reserved.
Keywords: Dialysis, priority setting, ethics, accountability for reasonableness, rationing, low- and
middle-income countries
C
hronic kidney disease (CKD) mortality
increased by 82% between 1990 and 2013,
with CKD being one of a few diseases world-
wide in which mortality failed to decrease.1 The true
prevalence of acute kidney injury (AKI) and CKD in
most low- and middle-income countries (LMICs) are
unknown, but are likely at least as high as in high-
income countries (HIC).2–4 Because the symptoms are
nonspecific until advanced stages of the disease and
awareness and diagnostic possibilities in many LMICs
are poor, early diagnosis of kidney disease, when
simple interventions could be effective, is often
missed. Social determinants play an important role in
the risk for kidney disease and its progression in
LMICs as outlined in Table 1. Dialysis and trans-
plantation are the only means of surviving chronic
kidney failure. Little is known about the need for
dialysis among patients with AKI in LMICs, but AKI
tends to be more severe than in HICs, most likely
owing to delays in presentation to the hospital, and few
patients can afford dialysis.5,6 For patients with end-
stage kidney disease (ESKD), the global country
prevalence of dialysis ranges from 0.1 (or zero) to
more than 2,000 per million population (pmp), show-
ing a vast inequity in dialysis access.7 The global need
for dialysis is projected to double by 2030, largely in
LMICs.8 Recent estimates have suggested that 2.3 to
3.2 million people die annually because of an inability
to access dialysis or sustain the treatment.8,9
Many ethical dilemmas are raised by the facts that the
global burden of renal disease remains undefined, access
to early diagnosis and effective management is sub-
optimal, access to life-saving renal replacement therapy
(RRT; dialysis or transplantation) is highly inequitable,
and the costs of RRT are prohibitive for individuals and
health systems in LMICs. Technology has a global
reach, but in LMICs given the costs and infrastructure
required, demand outstrips the capacity for equitable
access, aggravated by the lack of clear policies about
allocation of limited dialysis resources. Thus, priority-
setting dilemmas regarding RRT under resource-limited
conditions must be addressed: should lines be drawn on
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Table 1. Differences in Kidney Disease Between High- and Low-Income Countries
Countries Acute Kidney Injury End-Stage Kidney Disease
HIC LMIC HIC LMIC
General mean age
(y)
460 25-50 460 20-50










environmental exposures, diabetes, unknown
Multimorbidity Often present Often absent Often present Often absent
Access to dialysis Yes Limited Yes Limited
Financing dialysis State, insurance Often out of pocket State, insurance Often out of pocket
Financing medication State, insurance Often out of pocket State, insurance Often out of pocket
Preventive strategies Increased awareness,
avoid hypotension,
avoid nephrotoxins
Increased awareness, reduce infection rates,
vaccinations, reliable availability of antibiotics
and intravenous fluids, reduce use of traditional
remedies, improve antenatal and maternal






Increased awareness; improve access to early
detection and essential medications; reduce
infection rates; reduce use of traditional
remedies; manage blood pressure, diabetes,
and HIV; reduce poverty; improve nutrition;
improve gender equality, education, and work
conditions; reduce environmental exposures
Abbreviation: HIV, human immunodeficiency virus.

















whom to treat; how patients who should be dialyzed can
be dialyzed; and if patients are dialyzed, how much self-
payment, if any, is acceptable?
In this article, we use country examples derived from
the literature and our experience to highlight ethical
concerns and dilemmas at the patient/family, health-
provider, and policy-making levels that relate to the
treatment of renal failure in LMICs where dialysis is
not universally accessible. By using the four ethical
principles of justice, beneficence, nonmaleficence, and
autonomy, we systematize some potential ethical con-
sequences of four possible RRT policy strategies and
suggest ethical frameworks for use in policy development
and fair decision making regarding priority setting relat-
ing to RRT. For simplicity, the discussion will be limited
to dialysis as it relates to both AKI and ESKD because
this is the predominant form of RRT in most LMICs. The
ethical challenges surrounding transplantation and access
to diagnosis and primary and secondary prevention of
kidney disease are discussed elsewhere.3,10–15
ACCESS TO DIALYSIS IN LMICS
In LMICs, the clinical problem of kidney disease is
aggravated by a lack of awareness among communities
and health care workers (HCWs) of the risk and
seriousness of the disease, and limited diagnostic
facilities.14 Even among patients who are diagnosed,
the mortality from AKI and ESKD is high because of
many barriers to dialysis access.6,8,13,16,17 Provision of
dialysis varies between regions and countries, from
universal access in some Latin American countries to
none in many Asian and sub-Saharan African coun-
tries.18,19 Dialysis access in LMICs mainly, but not
exclusively, is a function of economics. In general,
more prosperous nations can afford more, and dialysis
rates are highest in countries with universal health
coverage (UHC).18,19 Some Latin American countries,
however, have committed themselves to universal
dialysis coverage despite lower health expenditures,
indicating the political will to provide financial risk
protection from kidney disease, which is a health
priority in the region.19 In sub-Saharan Africa very
few countries have dialysis facilities, and where these
are available few have policies in place regarding
access to dialysis.
Policy makers are hesitant to address the controver-
sial topic of how limited dialysis resources should be
allocated. Much of the dialysis in LMICs currently is
delivered in the private sector and high out-of-pocket
(OOP) costs often lead to financial ruin of the family,
discontinuation of treatment, and death once resources
are exhausted.6,16,20,21 Even when funded or subsi-
dized by governments, dialysis facilities in LMICs tend
to be located in cities, often are small, have poorly
maintained equipment (at times donated by well-
wishers without adequate technologic support), have
frequent staff and stock shortages, and unreliable water
and electricity supplies, and therefore struggle to meet
the clinical need.12,22–24 Even in the few state-
supported facilities access to dialysis is haphazard
and inequitable in the absence of formalized guide-
lines, and the burden of choosing between life and
death is borne by individual patients, families, and
clinicians, causing significant emotional and moral
distress.
Affordability of Dialysis in LMICs
Advocacy is mounting globally for universal access to
dialysis for AKI because it is anticipated to be life-
saving but temporary (and therefore to cost much less
than life-long treatment for ESKD).2 The costs asso-
ciated with dialysis for AKI in LMICs, however, often
remain prohibitive; for example, 5 days of dialysis for
a child in Nigeria costs several times the monthly
minimum wage.6 In some countries (eg, Ghana,
Tanzania, and Nigeria), short-term dialysis for AKI is
included under national health insurance schemes, in-
patient government-funded services, or is funded by
non-governmental organizations (NGOs).25–28 Under
these circumstances, however, if a patient fails to
recover kidney function or requires longer treatment,
the OOP costs become unaffordable and dialysis
actively must be discontinued.25–27 In India, dialysis
may be provided free of charge in some government-
funded hospitals, but patients must purchase medications
and disposables, the cost of which often is prohibitive.29
Certain governments or charities (eg, Guinea, Cameroon,
Senegal, and India) substantially subsidize the cost of
chronic dialysis, and OOP costs may be reduced to US
$2.30 per day for peritoneal dialysis (PD) and US $1.50
to $3.20 for a hemodialysis (HD) session, depending on
the country.30–32 Even these prices generally are unaf-
fordable long term, however, and often exclude the costs
of transportation, medications, or account for time lost at
work.20,29,33 Protection from financial risk is therefore an
important consideration in reducing inequitable access to
dialysis worldwide.
THE EVOLUTION OF ETHICAL CHALLENGES IN
DIALYSIS ACCESS
Dilemma of Distributive Justice
When HD first was introduced as a treatment for
ESKD in the 1960s, access was restricted severely
because of limited availability and high costs. The
evolution of ethical challenges imposed by dialysis in
the United States, the first country to provide chronic
HD, likely mirrors the experience of most countries.34
Initially, existing resources failed to meet the clinical
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need. Dialysis was more accessible to patients would
could pay OOP, but fair allocation of the few existing
dialysis slots was difficult.34 Rationing decisions were
made by a small group of individuals, colloquially
known the “Life or Death Committee.”35 Case-by-case
decisions were based on the members’ consciences and
a patient’s perceived social worth, rather than any firm
philosophical or ethical principles. Reporting of this
rationing process in the media led to a public outcry
and after much lobbying and advocacy, the Social
Security Amendment Act was passed in 1972, under
which all ESKD patients would receive Medicare
benefits and gain access to dialysis.35,36 This was a
contentious, complex decision.36,37
Since the US establishment of chronic dialysis
programs, HICs have progressed to supporting universal
access to dialysis at varying rates. Throughout the
evolution of dialysis, however, as the technical, cost,
and access barriers progressively were overcome, the
demand for dialysis and the budgets have escalated
considerably beyond expectation.13 Approximately 2%
of national health care budgets in HICs are spent on
ESKD, which impacts less than 0.2% of the popula-
tion.13 The disproportionately high costs of ESKD when
compared with costs for other diseases that may affect
larger numbers of people now are bringing the ethical
challenges of dialysis full circle back toward justice and
fairness of resource allocation as sustainability questions
for growing ESKD programs are raised.34,38,39
Trade-Offs Between Beneficence and Nonmaleficence
Despite the concern of increasing costs, in HICs people
now rarely die of renal failure, instead they die with
renal failure, on dialysis, from other comorbidities.34,40
Given the technical advances in health care the ques-
tion now no longer is whether we can keep people
alive, but at times whether we should: whether we are
truly improving quality or merely quantity of life?40,41
In recognition of the fact that quality of life on dialysis
may not always be optimal, there is an increasing
awareness that comprehensive supportive care may be
a superior alternative, especially for older ESKD
patients.40 In LMICs, however, patients needing dial-
ysis are younger and otherwise generally healthy
(Table 1), and therefore lack of access to dialysis
clearly leads to harm.
Dilemma of Respecting Patient Autonomy
Bioethics in HICs focus strongly on preserving patient
autonomy, given that individual patient decisions are
unlikely to impose major opportunity costs on the
broader health system.42 Since cost restrictions on
dialysis were lifted, individual patient autonomy has
been the over-riding ethical principle in determining
whether dialysis is initiated or not. This luxury of
patient choice, however, largely is attainable only in
settings where dialysis costs are covered through UHC
or insurance schemes. In lower-income settings,
patients paying OOP cannot truly be considered to
have autonomy because explicit or implicit rationing or
personal circumstances may impose a decision against
the patient’s will.
ETHICAL CHALLENGES FROM THE PATIENT/FAMILY
PERSPECTIVE
Most patients who develop AKI or ESKD in LMICs
are younger, economically active, and may be the
family’s sole breadwinner.6,28,43,44 Patients often
present late with profound uremia as the first clinical
presentation of kidney disease.6,16 Women and chil-
dren generally are under-represented, likely owing to
their low economic power.20,25,45,46 The decision to
seek care for kidney failure is complex. As outlined in
Figure 1, the patient/family/HCW are required to make
multiple resource-dependent decisions that ultimately
impact survival.6 The search for resources involves use
of a family’s own funds, sale of property, and incurring
debts, yet with no guarantee of survival.16,47–49 In
Thailand, before ESKD was included under UHC,
some households used up to 74% of their income to
sustain a single family member on dialysis.50 Families
coped by reducing dialysis frequency and reducing
food, education, and other expenditures. This study
was pivotal in informing Thai policy on extending
dialysis to the whole population to protect families
from financial risk.50 In patients with ESKD a cost-
benefit thought processes occurs before each dialysis
session and imposes significant moral dilemmas as
choices are made on how to allocate the meager
household resources, often at the expense of other
family members’ needs.
Given that most patients who commence dialysis in
LMICs where OOP payments are required discontinue
after a few sessions, the question arises as to how well
patients realize the full implications of dialysis. Many
studies from India and Africa have shown that despite
patients being fully informed about ongoing costs
required, only a small proportion of patients can
sustain even short-term dialysis.6,16,51 Patients and
families initially are desperate to preserve life, but
soon “reality dawns and emotions and resources are
exhausted” and the family must contend with the loss
of a loved one and a deeper descent into poverty.21
A Nigerian study reported that 27% of households
incurred a catastrophic health expenditure (CHE) after
an average health expense of US $19.60 in a month.52
A CHE is defined as an expense that risks or sends a
household into, or further into, poverty or household
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OOP in excess of 40% of household income after
covering the cost of basic needs.53–55 The majority of
households in Nigeria therefore would experience CHE
from one dialysis session, which costs approximately
US $150.51 An Indian study of ESKD patients referred
for transplantation found that 72% experienced some
form of financial crisis as a consequence.49 Of concern,
more than 10% of patients on the eve of transplant
regretted embarking on such expensive treatment and
said they would not do it again given the choice.49
These data underscore the urgent need for financial risk
protection for patients with ESKD.56
Many studies from LMICs report a significant
proportion of patients with AKI or ESKD disappearing
and leaving the hospital against medical advice.6,16,57
This is often a desperate act when families realize they
are faced with the impossible choice of paying for care
or letting their loved one die. A sense of shame likely
accompanies many of these decisions. The ethical
dilemma of parents declining life-saving dialysis for
children in LMICs is very different from that in
Western countries where, at times, physicians appeal
to the courts to enforce treatment for a child when a
parent refuses.58,59 Parents in LMICs attempt to act in
the best interest of the child; however, once a decision
must be made about a catastrophically expensive
treatment, they must weigh their own and the rest of
the family’s livelihoods against that of the sick child.
Such choices create much distress and anxiety, the
long-term impact of which remains unknown.47,60
ETHICAL CHALLENGES OF DIALYSIS AT THE
CLINICAL LEVEL
An analysis of factors limiting access to dialysis among
children in Nigeria reported that despite 33 of 51
families being willing to pay, only six children
received dialysis.22 The majority did not receive
dialysis because of a malfunction or lack of dialysis
equipment (22 children), shortage of staff (3 children),
or the staff being reluctant to dialyze for fear of
impoverishing the family (3 children).22 Both material
and human resources are important factors restricting
access to dialysis in LMICs. Ethiopia, for example, has
Figure 1. Barriers to care in AKI. Outcomes shown for each pathway (survival or death) are the most likely
outcomes, but are not inevitable. Copyright © 2016 Olowu et al. Open Access article.
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approximately 100 million inhabitants but has only
three pediatric and nine adult nephrologists, providing a
nephrologist to population ratio of 0.12 pmp. The
average ratio in Europe is approximately 20 pmp.61
Measurement of serum creatinine is not always possible
outside of cities. If a patient requires dialysis the only
option is referral to Addis Ababa or a few other towns,
and most costs are OOP (Table 2). There are presently
15 HD units providing dialysis in Ethiopia. Acute PD
recently was initiated in one public hospital but there is
no chronic PD. There are 115 HD machines in the
whole country, 24 of which belong to the public sector,
mainly providing acute dialysis. There are 356 patients
on chronic HD, of which only 8 are in the public sector.
Most patients are dialyzed once or twice weekly
(A.M.E.). The internationally recommended HD dose
is 4 hours, three times a week.
When resources are available but limited, HCWs
often struggle to balance the conflicting roles of
advocating for the patient and protecting the hospitals’
resources.62 A recent nationwide survey of 587 Ethio-
pian physicians investigated the toll of moral distress
imposed by this conflict, which is outlined in Table 3.62
Most agreed there was a lack of official guidance on
allocation of available resources and the first-come, first-
served strategy was used most commonly.62 More than
80% of respondents reported that in the prior 6 months
they had been unable to obtain dialysis for patients in
need. Half of the physicians reported consciously
considering the hospital’s costs when screening patients
for dialysis.62 The lack of explicit rationing guidelines
leads to such implicit case-by-case rationing, which is
highly variable and exacerbates inequities between
patients with similar needs.63 This underscores the
ethical imperative for the development of explicit and
transparent guidelines to reduce this variability and
reduce the moral distress experienced by HCWs.63
Reduction of Quality of Care as a Survival Technique?
In many LMICs, once a patient commences dialysis
further ethical challenges arise in clinical management
either because of limited institutional resources or the
patient’s ability to pay. Clinicians agonize over delib-
erately providing suboptimal dialysis by restricting the
duration or frequency of HD, reducing the number of
Table 2. Ethiopian Dialysis Costs
Item Cost89
Public hospital dialysis*
AKI Free for 1 month
ESKD–poorest population segment Not available†
ESKD–others (OOP) $23 per HD session
Venous catheter for first dialysis session (OOP) $46
Transport, syringes, diagnostic testing, medications (OOP) Extra costs as required
Private hospital dialysis
HD, AKI, and ESKD (OOP) $68 per session ($10,680/y)
First dialysis session including catheter, procedures, tests (OOP) $137-$228
Arteriovenous fistula (OOP) $365-$456






1 month of blood pressure medication
Travel to and from dialysis within the city
Transplant surgery (OOP)
Including 1 week pretransplant and 2 weeks post-transplant in India and transport costs $20,000
For comparison
Specialist physician working full time in government hospital $456 per month
Manual worker in rural/semi-urban area around the capital $45 per month
Per capita health expenditure Ethiopia (2013)‡ $25 per person per year
Earnings below poverty line poverty-line (r%1.25/d) 44% of the population
Out-of-pocket expenditures on health (National Health Account Ethiopia 2014) 34% for adult interventions
48% for child interventions
Data in Table 2 are from a personal communication with AME.
*Only available in selected public hospitals.
†Except for very few awaiting kidney transplantation in one center.
‡WHO global health observatory data repository.
V.A. Luyckx et al.278
daily PD exchanges, use of temporary catheters long
term to reduce costs, and knowing patients cannot
afford the medication required (eg, erythropoie-
tin).12,16,22,29,51,64–66 Recent debate has considered
whether it is ethically acceptable to provide less-
effective medication to more people for certain dis-
eases (eg, human immunodeficiency virus), rather than
restricting more expensive state-of-the-art medication
to fewer people.67 On balance, it would seem less
harmful overall to treat more patients with an accept-
able second-line treatment rather than fewer patients
with a first-line regimen.67 Such an approach may be
feasible when the choice of medication can be adapted
safely within a budget to achieve the desired amount of
coverage. This reasoning, however, cannot be extrapo-
lated easily to dialysis. Dialysis resources are much
more limited and less divisible and therefore there is
less room for compromise, and outcomes of any such
strategy would need to be monitored closely.
In Sudan, all patients who present with kidney failure
are offered dialysis.23,68 To accommodate as many people
as possible, chronic HD is offered for 4 hours twice a
week, knowing that patients will be underdialyzed.23,64,69
Evaluation of the program found that patients with
clinical indications, such as volume overload, and more
children in practice received dialysis three times a
week.69 The Sudanese therefore have taken an egalitarian
approach to maximize the number of people treated, but
those who are worse off or children may be prioritized
further. This approach, which also is used in other LMICs
to reduce patient costs, is ethically defensible based on
the principle of justice and financial risk protection, but
the major concern is whether there may be a risk of
systematic harm related to underdialysis.29,31,33,70,71
When the HD dose is reduced to twice a week, if
dialysis continues regularly as in Sudan and in China,
survival and quality of life may be acceptable; this
compromise appears feasible.69,72 In practice, however,
further reducing dialysis frequency is common among
patients who struggle to remain alive with limited
resources.16,29,50 The majority of patients cannot con-
tinue for more than a few sessions, a trend that has not
improved despite the growing number of dialysis units
in many LMICs.6,16,28,51 The role of the HCW beyond
ensuring fully informed consent, in restricting access to
dialysis if it is clear the patient’s resources are
insufficient to sustain reasonable health, is unclear.
Some programs only accept patients for long-term
dialysis if they are able to make several months'
prepayment, which may be a practical strategy to
reduce CHEs and an attempt to ensure sustainability.
One could argue that focusing on the quality of dialysis
may not be relevant in practice when the only actual
choice is between any dialysis (life) and no dialysis.1
Ethically, however, it is questionable whether there is, or
should be, a minimum standard for dialysis, and whether
this is a determination that the state, physician, or patient
should make.21 In LMICs, a patient’s choosing to dialyze
infrequently, based on being less worse off when receiving
poor dialysis compared with no dialysis, is an exercise of
their autonomy. However, this presents a challenge for the
HCWs and may impact other patients. HCWs cannot
control how often a patient comes for dialysis or their
access to medication and therefore may feel helpless and
frustrated when confronted with the ongoing deterioration
of a patient’s condition.66
There are, therefore, many dilemmas faced by HCWs
caring for patients with kidney disease in LMICs. In the
Ethiopian physician study described earlier, 88% of
physicians were so troubled by the lack of resources that
they had daily or weekly regrets about their choice of
profession.62 It is likely that many of these chal-
lenges drive the brain drain of health professionals from
LMICs to better-resourced countries. The potential
impact on the entire health system therefore is
significant.
Table 3. Proportions of Ethiopian Physicians Experiencing Resource-Related Dilemmas
Rationing dilemmas Often (%) Sometimes (%) Rarely (%) Never (%) NA (%) Total
Limitation of resources required me to make a difficult choice 55 39 5 1 0 551
The preferred course of treatment was not pursued because
of a patient’s ability to pay
40 43 12 5 0 547
There was significant disagreement among health care
personnel on continuing treatment of the patient due to
lack of resources
19 38 30 11 2 541
You felt that the patient’s need of treatment was not in
agreement with the patient’s family needs or welfare
13 48 29 8 2 549
You were restricting treatment to a patient to give those
resources to someone who could benefit more (i.e. hospital
bed, ventilator, medication)
14 32 18 33 3 538
Adapted from Defaye et al62 under the Creative Commons License (http://creativecommons.org/licenses/by/4.0/) with additional
unpublished data (Miljeteig et al, unpublished data).
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ETHICAL CHALLENGES OF DIALYSIS FROM THE
HEALTH SYSTEMS/POLICY PERSPECTIVE
The Challenge of Priority Setting
UHC is defined by the World Health Organization as
“all people receiving quality health services that meet
their needs without being exposed to financial hardship
in paying for the services.”73 In addition, there is a
growing realization that the right to health may be
considered fundamental in the realization of global
human rights.74 At first glance it therefore would seem
consistent with these goals that dialysis treatment for
patients with kidney failure is a human right and
should be covered under UHC. The reality, however,
is that every health system has a limited budget, much
more constrained in LMICs than in HICs, and entitle-
ment to the fulfillment of an individual’s right to health
must be balanced against the resources available and
respect the concept of fairness to other individuals.74,75
The three core goals of UHC are to expand priority
health services, to extend health coverage to more
people, and to reduce financial hardship as a conse-
quence of seeking health care.73 The realization of
human rights also involves addressing the social and
structural determinants of health including poverty,
education, gender equity, safety, and infrastructure.
Policy makers therefore are faced with the difficult task
of determining which conditions should have priority
and why, and how to allocate resources. Important
trade-offs must be considered between implementing
strategies that maximize aggregate population health
and those that specifically address the needs of the
worst off patients.74
Patients with kidney failure are dying because of a
lack of access to treatment; however, the costs of
treatment for a single patient per year may be several
hundred times the individual per-capita health expen-
diture of a country, and many times the per-capita
income per year.76 The opportunity costs of dialysis
therefore are extremely high in terms of financial costs
and lives lost. In many LMICs, basic and highly cost-
effective health services such as skilled birth attend-
ance or treatment of childhood pneumonia or diarrhea
are not available for the majority of the population.
Cost effectiveness in terms of quality-adjusted life-
years gained per dollar is a major concern for policy
makers when comparing and prioritizing interventions
in designing essential health care packages. The
development of kidney disease, however, may in part
be the result of poor public health practices and the
lack of UHC or other structural factors, and the state
could be considered partly responsible. In addition,
vertical equity demands that patients should have
access to treatment according to their needs. The views
on state assistance for dialysis in LMICs, however, are
very divergent. Some experts consider provision of
coverage for dialysis to be an “unacceptable trade-
off73” in a health system in which UHC and meeting
more urgent health needs have yet to reach all
individuals.75 Others have suggested that patients with
kidney failure can be considered worse off because
they would die imminently without dialysis and almost
universally experience catastrophic financial hardship
by paying OOP.38,50 Viewed through the lens of
distributive justice, however, as a compromise, the
possibility of rationing expensive therapies may be
necessary. Rationales underlying potential fair strat-
egies for rationing the scarce resources are expertly
reviewed elsewhere.70 In all cases, clear and trans-
parent policies are needed to allocate scarce resources
and ensure delivery of fair and appropriate care.
Restrictive policy thresholds governing access to dial-
ysis may be acceptable to the population if the policy-
making process is clear and transparent and fosters
public trust in the governance process.
Framework and Methodology to Support Decision
Making for Fair Distribution of Resources
Marckmann et al77 have proposed a practical trans-
parent ethical framework for public health policy
making based on ethical foundations. Underlying this
framework is the recognition that public health policy
making should be systematic, transparent, consistent,
and ethically justifiable.77 They chose to base their
approach on the coherenist ethical principles of justice,
beneficence, nonmaleficence, and autonomy in contrast
to using the more polarizing ethical frameworks of
utilitarianism/egalitarianism or favoring the worst
off.77 Their approach begins with the consideration
of 5 normative criteria (Table 4): anticipated improve-
ments in the health of the target population; possible
negative consequences; autonomy implications; equity
implications; and the anticipated efficiency in terms of
cost effectiveness, which are a prerequisite to build
ethical justification for a decision-making process.77 In
Table 4 we present a crude analysis of ethical consid-
erations raised under these five criteria as they relate to
four possible dialysis allocation strategies: state provi-
sion of dialysis for all, state provision of dialysis for
AKI only, state rationing of dialysis, or no state
coverage of dialysis. This analysis is not comprehen-
sive and we do not suggest which strategy would be
most appropriate under specific circumstances. This
rudimentary analysis, however, can be a starting point
for transparent discussions by policy makers and other
stakeholders involved in decisions regarding imple-
menting or scaling-up dialysis. The depth and breadth
of discussions then must be tailored to the relevant
contexts.
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Table 4. Potential Ethical Challenges Raised by Four Possible Policy Strategies for Universal Coverage of Dialysis in LMICs
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Universal coverage of
dialysis for all patients
with AKI and ESKD
Decreased mortality
and morbidity6,38
Improved quality of life
Increased productivity
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High total and opportunity costs of
dialysis
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Cost-saving strategies may reduce
dialysis quality (less reduction of
mortality and morbidity)
OOP for medication, transportation,
re-location may remain high and
prohibitive91
Unanticipated escalation of costs if
costs not contained up front38
May reduce overall expenditure on
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Inequities among renal
patients still may remain
if gender, religious,
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of adults who care
for others
May reduce brain-drain
because HCWs may be
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No health benefit for ESKD patients
OOP costs for medication,
transfusions, loss of work for
accompanying caregivers may
remain high91
High opportunity costs of dialysis in
some health systems
Inequity within health system90
May still be barriers, unanticipated
cost escalations38
Potentially reduced funds for public
health and prevention92
If coverage only permits a limited
number of treatments this may
pose dilemmas if AKI patients do
not recover within the covered
time period (or if ESKD was
misdiagnosed as AKI)
High OOP and potential CHE for
families deciding to continue
treatment elsewhere
Moral distress for clinicians
withholding dialysis from ESKD
If AKI policies rely on NGOs or
outside drivers initially,
sustainability over the long term
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Inequities still may remain




Relies on equitable and
appropriate access to
diagnosis of AKI
More data are required on
cost effectiveness of
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Table 4 (continued )
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at a reduced dose
Decreased mortality
and morbidity for
patients able to pay
subsidy long term
Higher risk of CHE for patients not
included
State subsidy even if high still may
be prohibitive30,32,71
High opportunity costs even of
limited dialysis
Justice issues within health system
if other expensive treatments are
not covered90
Moral distress of patients, families,
and health care workers when
withholding treatment84,85
Still may be barriers, unanticipated
escalation of costs38
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(requires a policy rather
than ignoring the issue)
Patients without
personal resources
to pay out of pocket
or have health
insurance likely die
High risk of CHE, financial risk with
no guarantee that life will be
saved (likely worse for ESKD
versus AKI)
Moral distress of patients, families,
and HCWs needing to make
individual life-and death
decisions62
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Marckmann et al77 advocated use of the methodo-
logic approach of Accountability for Reasonableness
(A4R) as proposed by Daniels and Sabin80 in using
their framework, which emphasizes fairness in health
care priority settings to operationalize their frame-
work.78,79 The A4R framework is applicable at all
levels of decision making in the health system (micro,
meso, and macro), and requires that decisions be made
based on relevant values, principles, or evidence;
includes active stakeholder engagement in a trans-
parent process; and is open to appeals and review
mechanisms (Table 5).74 Unlike other priority setting
processes that emphasize what decisions should be
made, the A4R framework directs the inquiry at how
and why decisions should be made, and therefore is
amenable to local adaptation.81 In Table 5 we broadly
outline how A4R may apply to decision making
around dialysis. These considerations do not represent
a comprehensive analysis and will require further
contextualization, but are put forward as important
steps required to ensure a fair and legitimate decision-
making process.
Use of the Accountability for Reasonableness
Framework for Allocation of Dialysis in South Africa
South Africa is a middle-income country and has a
two-tiered health system in which dialysis is freely
available to the 16% of the population who have
private insurance; the remaining 84% are dependent
on the state for health care and dialysis.82 The state
provides dialysis for all patients with AKI but rations
dialysis for ESKD. The principle of dialysis rationing
was tested in the constitutional courts in 1997 when a
41-year-old man with diabetes and heart disease was
refused dialysis.83 The court ruled from a utilitarian
perspective that, despite the patient’s right to life, the
state could not fulfill its other constitutional health
responsibilities should it provide dialysis for all.83 In
South Africa at the time, selection of patients for
dialysis was performed by committee (as occurred
early on in the United States) and followed consensus
guidelines proposed by the National Department of
Health. The process was unregulated and had no
formal accountability or oversight. Upon review of
the process clear biases emerged, most disturbing of
which was the favoring of white over African
patients.84 In view of the perceived unfairness, the
lack of accountability, and the real risk of litigation, the
nephrology community decided to review allocation of
the scarce resource. A utilitarian approach, rather than
prioritization of social justice, was believed more
appropriate for the challenges faced. The normative
approach, similar to that described by Marckmann
et al,77 based on the HCWs everyday moral values
and convictions, was used. Procedurally, the guidelines
were developed using the dictates of A4R, based on
criteria that were supported wherever possible by
relevant local evidence and the prevailing clinical
realities. All relevant stakeholders including patients,
clinicians, civil society, hospital management, bioeth-
icists, and legal experts were engaged in an iterative
process. Criteria were grouped broadly into medical
and social categories, which both impacted outcome
decisions. The process was lengthy and challenging;
draft guidelines underwent numerous iterations and
finally were adopted as Western Cape Government policy
in 2010.85 In addition to the guidelines, a hierarchical
allocation system also was developed that took resource
availability into consideration. The ability of patients to
pay was never a consideration. The outcomes of this
process currently are under review, however, preliminary
Table 5. Application of A4R Framework for Fair Dialysis Policy Making74
A4R Condition Relevance to Dialysis
1. Publicity condition All decisions and rationales for limiting dialysis availability should be accessible to the public
Transparency is crucial
Facilitates social learning curve and understanding among public of rationing and rationales
2. Relevance condition Clear understanding of whether kidney disease is a health priority in the country (numbers affected,
numbers at financial risk, potential to meet the needs fairly)
Rationale for limiting access to dialysis should be reasonable and clearly explained, acceptable to “fair-
minded people”
Decisions should be based on accurate data relating to burden of kidney disease, costs, opportunity
costs, equity concerns, and potential financial risk
Decisions should be reached in collaboration with all relevant stakeholders to enhance legitimacy and
understanding (policy makers, health care workers, civil society, and others)
3. Revision and appeals
condition
Possibilities to appeal rationing decisions must be available
Facilitates iterative learning and adaptation of policies
4. Regulative condition Regular official evaluation and by the public to ensure all conditions of A4R are met
Encourages accountability, social learning of the A4R process
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data show that race no longer features in patient selection
(MRM, personal communication).
The importance of this approach is that all relevant
stakeholders participated in the process, which
improves understanding and legitimacy.80 The guide-
lines are available to the general public and therefore
are transparent.85 Patients or their families who were
aggrieved by decisions were invited to lodge appeals.
Health services in South Africa are under increasing
pressure and growing numbers of patients with end-
stage renal disease were being refused treatment. This
resulted in increasing reviews and complaints, includ-
ing a formal complaint to the Human Rights Commis-
sion. Having the policy guidelines in place allowed the
Commission to make a no-fault finding against the
Western Cape Government. The experience of patients
awaiting the decision of whether they are accepted for
dialysis or not has not been studied systematically, but
is distressing and adequate psychosocial and palliative
care support is crucial to navigate this process.86
Rationing is always challenging, the transparent proc-
ess at least optimizes fairness and removes the full
responsibility of individual life-and-death decisions
from doctors and patients at the bedside.
CONCLUSIONS
The ethical dilemmas arising from managing patients
with kidney disease in resource-limited environments
are many. The current burden of disease and the
limited health budgets in LICs make progress in
improving universal access to RRT a major chal-
lenge.87 To begin to tackle the ethical challenges,
which largely are rooted in poverty and vulnerability,
the burden of disease in terms of patient numbers and
societal impact must be quantitated. Simultaneously,
and to facilitate accurate data collection, education of
communities and HCWs about kidney disease as well
as up-scaling of diagnostic capacity are crucial. Where
dialysis is occurring, cost data and patient outcomes
must be tracked to inform priority setting and policy
development. Anthropologic studies are required to
understand patient and family experiences, their under-
standing of kidney disease, and the process of decision
making regarding seeking care. Potential solutions to
the challenges of sustainability and achieving justice
for patients with kidney disease will be highly complex
and very context-specific. Policy makers must take into
account the relevant normative concerns and follow
transparent procedures as outlined in A4R to ensure
fair decision making regarding provision of dialysis in
LMICs. If states choose to support dialysis in some
form, clear and fair eligibility criteria must be estab-
lished. Policy decisions must consider a minimum
quality of care that should be mandated within the
state support. If state support for dialysis is deemed
unaffordable, activities in the private sector still should
be monitored to assess the impact of CHE. Policy
decisions should be communicated to the public clearly
and adequate palliative care facilities should be in
place. Provision of guidance and support also should
be considered for patients, family members, and HCWs
faced with daily dilemmas at the bedside such that
respect, dignity, and humanity of all concerned are
preserved at all times.
ACKNOWLEDGMENTS
The authors thank Professor G. T. Obrador Vera for
insightful discussions.
REFERENCES
1. GBD 2013 Mortality and Causes of Death Collaborators.
Global, regional, and national age-sex specific all-cause and
cause-specific mortality for 240 causes of death, 1990-2013: a
systematic analysis for the Global Burden of Disease Study
2013. Lancet. 2015;385:117-71.
2. Mehta RL, Cerda J, Burdmann EA, et al. International Society
of Nephrology's 0by25 initiative for acute kidney injury (zero
preventable deaths by 2025): a human rights case for nephrol-
ogy. Lancet. 2015;385:2616-43.
3. Stanifer JW, Muiru A, Jafar TH, Patel UD. Chronic kidney
disease in low- and middle-income countries. Nephrol Dial
Transplant. 2016;31:868-74.
4. Mills KT, Xu Y, Zhang W, et al. A systematic analysis of
worldwide population-based data on the global burden of
chronic kidney disease in 2010. Kidney Int. 2015;88:950-7.
5. Mehta RL, Burdmann EA, Cerda J, et al. Recognition and
management of acute kidney injury in the International Society
of Nephrology 0by25 global snapshot: a multinational cross-
sectional study. Lancet. 2016;387:2017-25.
6. Olowu WA, Niang A, Osafo C, et al. Outcomes of acute kidney
injury in children and adults in sub-Saharan Africa: a system-
atic review. Lancet Glob Health. 2016;4:e242-50.
7. Thomas B, Wulf S, Bikbov B, et al. Maintenance dialysis
throughout the world in years 1990 and 2010. J Am Soc
Nephrol. 2015;26:2621-33.
8. Liyanage T, Ninomiya T, Jha V, et al. Worldwide access to
treatment for end-stage kidney disease: a systematic review.
Lancet. 2015;385:1975-82.
9. Anand S, Bitton A, Gaziano T. The gap between estimated
incidence of end-stage renal disease and use of therapy. PLoS
One. 2013;8:e72860.
10. Danovitch GM, Chapman J, Capron AM, et al. Organ traffick-
ing and transplant tourism: the role of global professional
ethical standards-the 2008 Declaration of Istanbul. Transplan-
tation. 2013;95:1306-12.
11. Garcia GG, Harden P, Chapman J. The global role of kidney
transplantation. Saudi J Kidney Dis Transpl. 2012;23:215-22.
12. Mani MK. The management of end-stage renal disease in India.
Artif Organs. 1998;22:182-6.
13. Couser WG, Remuzzi G, Mendis S, Tonelli M. The contribu-
tion of chronic kidney disease to the global burden of major
noncommunicable diseases. Kidney Int. 2011;80:1258-70.
14. Garcia-Garcia G, Jha V, World Kidney Day Steering Commit-
tee. CKD in disadvantaged populations. Kidney Int.
2015;87:251-3.
15. Brouwer ED, Watkins D, Olson Z, Goett J, Nugent R, Levin C.
Provider costs for prevention and treatment of cardiovascular
V.A. Luyckx et al.284
and related conditions in low- and middle-income countries: a
systematic review. BMC Public Health. 2015;15:1183.
16. Parameswaran S, Geda SB, Rathi M, et al. Referral pattern of
patients with end-stage renal disease at a public sector hospital
and its impact on outcome. Natl Med J India. 2011;24:
208-13.
17. Francis ER, Allen AK, Herrera-Anazco P, et al. Establishing a
higher priority for chronic kidney disease in Peru. Lancet Glob
Health. 2016;4:e17-8.
18. White SL, Chadban SJ, Jan S, Chapman JR, Cass A. How can
we achieve global equity in provision of renal replacement
therapy? Bull World Health Org. 2008;86:229-37.
19. Obrador GT, Rubilar X, Agazzi E, Estefan J. The challenge of
providing renal replacement therapy in developing countries:
the Latin American perspective. Am J Kidney Dis. 2016;67:
499-506.
20. Garcia-Garcia G, Monteon-Ramos JF, Garcia-Bejarano H, et al.
Renal replacement therapy among disadvantaged populations in
Mexico: a report from the Jalisco Dialysis and Transplant
Registry (REDTJAL). Kidney Int Suppl. 2005;97:S58-61.
21. Kher V. End-stage renal disease in developing countries.
Kidney Int. 2002;62:350-62.
22. Olowu WA. Renal failure in Nigerian children: factors limiting
access to dialysis. Pediatr Nephrol. 2003;18:1249-54.
23. Elamin S, Obeid W, Abu-Aisha H. Renal replacement therapy
in Sudan, 2009. Arab J Nephrol Transplant. 2010;3:31-6.
24. Odubanjo MO, Oluwasola AO, Kadiri S. The epidemiology of
end-stage renal disease in Nigeria: the way forward. Int Urol
Nephrol. 2011;43:785-92.
25. Antwi S. State of renal replacement therapy services in Ghana.
Blood Purif. 2017;39:137-40.
26. Callegari J, Antwi S, Wystrychowski G, Zukowska-
Szczechowska E, Levin NW, Carter M. Peritoneal dialysis as
a mode of treatment for acute kidney injury in sub-Saharan
Africa. Blood Purif. 2013;36:226-30.
27. Van Biljon G. Causes, prognostic factors and treatment results
of acute renal failure in children treated in a tertiary hospital in
South Africa. J Trop Pediatr. 2008;54:233-7.
28. Ajayi S, Raji Y, Bello T, Jinadu L, Salako B. Unaffordability of
renal replacement therapy in Nigeria. Hong Kong J Nephrol.
2016;18:15-9.
29. Jha V. Current status of end-stage renal disease care in South
Asia. Ethn Dis. 2009;19: (Suppl 1), 2009S1-27-32.
30. Niang A, Cisse MM, Mahmoud SM, Lemrabott AT, Ka el HF,
Diouf B. Pilot experience in Senegal with peritoneal dialysis for
end-stage renal disease. Perit Dial Int. 2014;34:539-43.
31. Bah AO, Lamine C, Balde MC, Bah ML, Rostaing L.
Epidemiology of chronic kidney diseases in the Republic of
Guinea; future dialysis needs. J Nephropathol. 2015;4:127-33.
32. Khanna U. The economics of dialysis in India. Indian
J Nephrol. 2009;19:1-4.
33. Dreyer G, Dobbie H, Banks R, et al. Supporting Malawi's
dialysis services with the international community. Br J Renal
Med. 2012;17:24-6.
34. Butler CR, Mehrotra R, Tonelli MR, Lam DY. The evolving
ethics of dialysis in the United States: a principlist bioethics
approach. Clin J Am Soc Nephrol. 2016;11:704-9.
35. Alexander S. They decide who lives, who dies: medical miracle
and a moral burden of a small committee. Life Magazine. Nov
9, 1962.
36. Rettig RA. Special treatment–the story of Medicare's ESRD
entitlement. N Engl J Med. 2011;364:596-8.
37. Schreiner GE. How end-stage renal disease (ESRD)-Medicare
developed. Am J Kidney Dis. 2000;35 (Suppl 1):S37-44.
38. Tantivess S, Werayingyong P, Chuengsaman P, Teerawattananon
Y. Universal coverage of renal dialysis in Thailand: promise,
progress, and prospects. BMJ. 2013;346:f462.
39. Kahrass H, Strech D, Mertz M. The full spectrum of clinical
ethical issues in kidney failure. findings of a systematic
qualitative review. PLoS One. 2016;11:e0149357.
40. Davison SN, Levin A, Moss AH, et al. Executive summary of
the KDIGO controversies conference on supportive care in
chronic kidney disease: developing a roadmap to improving
quality care. Kidney Int. 2015;88:447-59.
41. Hussain JA, Flemming K, Murtagh FE, Johnson MJ. Patient
and health care professional decision-making to commence and
withdraw from renal dialysis: a systematic review of qualitative
research. Clin J Am Soc Nephrol. 2015;10:1201-15.
42. Azetsop J, Rennie S. Principlism, medical individualism, and
health promotion in resource-poor countries: can autonomy-
based bioethics promote social justice and population health?
Philos Ethics Humanit Med. 2010;5:1.
43. Jha V. ESRD burden in South Asia: the challenges we are
facing. Clin Nephrol. 2015;83 (Suppl 1):7-10.
44. Lou-Meda R. ESRD in Guatemala and a model for preventive
strategies: outlook of the Guatemalan Foundation for Children
with Kidney Diseases. Ren Fail. 2006;28:689-91.
45. Ulasi I. Gender bias in access to healthcare in Nigeria: a study
of end-stage renal disease. Trop Doct. 2008;38:50-2.
46. Harambat J, Ekulu PM. Inequalities in access to pediatric ESRD
care: a global health challenge. Pediatr Nephrol. 2016;31:353-8.
47. Miljeteig IMA, Berhane F, Dessie E, Onarheim KH. Priorities
at the bedside: experiences of catastrophic health expenditures in
Ethiopia. Global health priority-setting: beyond cost-effectiveness.
In press 2017.
48. Yilma Z, Mebratie A, Sparrow R, et al. Coping with shocks in
rural Ethiopia. J Dev Studies. 2014;50:1009-24.
49. Ramachandran R, Jha V. Kidney transplantation is associated
with catastrophic out of pocket expenditure in India. PLoS One.
2013;8:e67812.
50. Prakongsai P, Palmer N, Uay-Trakul P, Tangcharoensathien V,
Mills A. The implications of benefit package design: the impact
on poor Thai households of excluding renal replacement
therapy. J Int Dev. 2009;21:291-308.
51. Ekrikpo UE, Udo AI, Ikpeme EE, Effa EE. Haemodialysis in an
emerging centre in a developing country: a two year review and
predictors of mortality. BMC Nephrol. 2011;12:50.
52. Onwujekwe O, Hanson K, Uzochukwu B. Examining inequi-
ties in incidence of catastrophic health expenditures on different
healthcare services and health facilities in Nigeria. PLoS One.
2012;7:e40811.
53. Kruk ME, Mbaruku G, Rockers PC, Galea S. User fee
exemptions are not enough: out-of-pocket payments for 'free'
delivery services in rural Tanzania. Trop Med Int Health.
2008;13:1442-51.
54. Storeng KT, Baggaley RF, Ganaba R, Ouattara F, Akoum MS,
Filippi V. Paying the price: the cost and consequences of
emergency obstetric care in Burkina Faso. Soc Sci Med.
2008;66:545-57.
55. Xu K, Evans DB, Kawabata K, Zeramdini R, Klavus J, Murray
CJ. Household catastrophic health expenditure: a multicountry
analysis. Lancet. 2003;362:111-7.
56. Tangcharoensathien V, Pitayarangsarit S, Patcharanarumol W,
et al. Promoting universal financial protection: how the Thai
universal coverage scheme was designed to ensure equity.
Health Res Policy Syst. 2013;11:25.
57. Odetunde OI, Okafor HU, Uwaezuoke SN, Ezeonwu BU, Ukoha
OM. Renal replacement therapy in children in the developing
world: challenges and outcome in a tertiary hospital in southeast
Nigeria. ScientificWorldJournal. 2014;2014:903151.
58. Gillam L, Sullivan J. Ethics at the end of life: who should make
decisions about treatment limitation for young children with
life-threatening or life-limiting conditions? J Paediatr Child
Health. 2011;47:594-8.
Ethical challenges of dialysis 285
59. Dare T. Parental rights and medical decisions. Paediatr
Anaesth. 2009;19:947-52.
60. Miljeteig I, Sayeed SA, Jesani A, Johansson KA, Norheim OF.
Impact of ethics and economics on end-of-life decisions in an
Indian neonatal unit. Pediatrics. 2009;124:e322-8.
61. Sharif MU, Elsayed ME, Stack AG. The global nephrology
workforce: emerging threats and potential solutions! Clin
Kidney J. 2016;9:11-22.
62. Defaye FB, Desalegn D, Danis M, et al. A survey of Ethiopian
physicians' experiences of bedside rationing: extensive resource
scarcity, tough decisions and adverse consequences. BMC
Health Serv Res. 2015;15:467.
63. Kapiriri L, Martin DK. Bedside rationing by health practi-
tioners: a case study in a Ugandan hospital. Med Decis Making.
2007;27:44-52.
64. Abdelwahab HH, Shigidi MM. Barriers to adequate urea clearance
among hemodialysis patients in developing countries: an example
from the Sudan. Saudi J Kidney Dis Transpl. 2015;26:144-8.
65. Ulasi II, Ijoma CK. The enormity of chronic kidney disease in
Nigeria: the situation in a teaching hospital in South-East
Nigeria. J Trop Med. 2010;2010:501957.
66. Keshaviah P. Resource limitations and strategies for the treat-
ment of uremia. A dialysis unit in the Himalayan foothills.
Blood Purif. 2001;19:44-52.
67. Persad GC, Emanuel EJ. The ethics of expanding access to
cheaper, less effective treatments. Lancet. 2016;388:932-4.
68. Abdelwahab HH, Shigidi MMT, Ibrahim LS, El-Tohami AK.
Barriers to kidney transplantation among adult Sudanese patients
on maintenance hemodialysis in dialysis units in Khartoum State.
Saudi J Kidney Dis Transplant. 2013;24:1044-9.
69. Elamin S, Abu-Aisha H. Reaching target hemoglobin level and
having a functioning arteriovenous fistula significantly improve
one year survival in twice weekly hemodialysis. Arab J Nephrol
Transplant. 2012;5:81-6.
70. Persad G, Wertheimer A, Emanuel EJ. Principles for allocation
of scarce medical interventions. Lancet. 2009;373:423-31.
71. Halle MP, Takongue C, Kengne AP, Kaze FF, Ngu KB.
Epidemiological profile of patients with end stage renal disease
in a referral hospital in Cameroon. BMC Nephrol. 2015;16:59.
72. Bieber B, Qian J, Anand S, et al. Two-times weekly hemo-
dialysis in China: frequency, associated patient and treatment
characteristics and quality of life in the China Dialysis Out-
comes and Practice Patterns study. Nephrol Dial Transplant.
2014;29:1770-7.
73. World Health Organization. Making fair choices on the path to
universal health coverage. Final report of the WHO Consulta-
tive Group on Equity and INversal Health Coverage[cited 2016
June 30]. Available from: http://apps.who.int/iris/bitstream/
10665/112671/1/9789241507158_eng.pdf?ua=1.
74. Daniels N, Sabin JE Setting limits fairly. Learning to share
resources for health, 2 ed New York: Oxford University Press,
2008.
75. Norheim OF. Ethical perspective: five unacceptable trade-offs
on the path to universal health coverage. Int J Health Policy
Manag. 2015;4:711-4.
76. Luyckx VA, Naicker S, McKee M. Equity and economics of
kidney disease in sub-Saharan Africa. Lancet. 2013;382:103-4.
77. Marckmann G, Schmidt H, Sofaer N, Strech D. Putting public
health ethics into practice: a systematic framework. Front
Public Health. 2015;3:23.
78. Rawls J. A theory of justice. Cambridge, MA: Harvard
University Press, 1971.
79. Daniels N. Justice, health, and health care. Am J Bioeth.
2001;1:2-16.
80. Daniels N, Sabin J. The ethics of accountability in managed
care reform. Health Aff (Millwood). 1998;17:50-64.
81. Daniels N. Meeting health needs fairly. Cambridge: Cambridge
University Press, 2008.
82. Kevany S, Benatar SR, Fleischer T. Improving resource
allocation decisions for health and HIV programmes in South
Africa: bioethical, cost-effectiveness and health diplomacy
considerations. Glob Public Health. 2013;8:570-87.
83. Sidley P. South African row over denial of dialysis. BMJ.
1997;315:1562.
84. Moosa MR, Kidd M. The dangers of rationing dialysis treat-
ment: the dilemma facing a developing country. Kidney Int.
2006;70:1107-14.
85. Moosa MR, Team RST. Guideline: priority setting approach in
the selection of patients in the public sector with end-stage
kidney failure for renal replacement treatment in the Western
cape province. Available from: https://assets.documentcloud.
org/documents/19489/moosa-priority-setting-policy-final-feb-24-
2010-final.pdf. Accessed 01.08.15.
86. Gibson D. The liminality of kidney failure in South African
state hospitals. Anthropol S Afr. 2011;34:74-81.
87. Benatar SR, Gill S, Bakker I. Global health and the global
economic crisis. Am J Public Health. 2011;101:646-53.
88. Jha V, Garcia-Garcia G, Iseki K, et al. Chronic kidney disease:
global dimension and perspectives. Lancet. 2013;382:260-72.
89. GBD 2013 Risk Factors Collaborators, Forouzanfar MH,
Alexander L, et al. Global, regional, and national comparative
risk assessment of 79 behavioural, environmental and occupa-
tional, and metabolic risks or clusters of risks in 188 countries,
1990-2013: a systematic analysis for the Global Burden of
Disease Study 2013. Lancet. 2015;386:2287-323.
90. Rettig RA. The policy debate on patient care financing for
victims of end-stage renal disease. Law Contemp Probl.
1976;40:196-230.
91. El-Tigani MA, Abdelraheem MB, Mohamed RM, Hassan EG,
Watson AR. Chronic renal failure in Sudanese children:
aetiology and outcomes. Pediatr Nephrol. 2009;24:349-53.
92. Schmidt H, Gostin LO, Emanuel EJ. Public health, universal
health coverage, and sustainable development goals: can they
coexist? Lancet. 2015;386:928-30.
93. Abdelraheem M, Ali el T, Osman R, et al. Outcome of acute
kidney injury in Sudanese children - an experience from a sub-
Saharan African unit. Perit Dial Int. 2014;34:526-33.
94. Norheim OF, Baltussen R, Johri M, et al. Guidance on priority
setting in health care (GPS-Health): the inclusion of equity
criteria not captured by cost-effectiveness analysis. Cost Eff
Resour Alloc. 2014;12:18.
95. Teerawattananon Y, Mugford M, Tangcharoensathien V. Eco-
nomic evaluation of palliative management versus peritoneal
dialysis and hemodialysis for end-stage renal disease: evidence
for coverage decisions in Thailand. Value Health. 2007;10:
61-72.




















Developing the ethics of implementation
research in health
Vijayaprasad Gopichandran1*† , Valerie A. Luyckx2†, Nikola Biller-Andorno2, Amy Fairchild3, Jerome Singh4,
Nhan Tran5, Abha Saxena6, Pascal Launois7, Andreas Reis6, Dermot Maher7 and Mahnaz Vahedi7
Abstract
Implementation research (IR) is growing in recognition as an important generator of practical knowledge that can
be translated into health policy. With its aim to answer questions about how to improve access to interventions
that have been shown to work but have not reached many of the people who could benefit from them, IR
involves a range of particular ethical considerations that have not yet been comprehensively covered in
international guidelines on health research ethics. The fundamental ethical principles governing clinical research
apply equally in IR, but the application of these principles may differ depending on the IR question, context, and
the nature of the proposed intervention. IR questions cover a broad range of topics that focus on improving health
system functioning and improving equitable and just access to effective health care interventions. As such, IR
designs are flexible and often innovative, and ethical principles cannot simply be extrapolated from their
applications in clinical research. Meaningful engagement with all stakeholders including communities and research
participants is a fundamental ethical requirement that cuts across all study phases of IR and links most ethical
concerns. Careful modification of the informed consent process may be required in IR to permit study of a needed
intervention. The risks associated with IR may be difficult to anticipate and may be very context-specific. The
benefits of IR may not accrue to the same groups who participate in the research, therefore justifying the risks
versus benefits of IR may be ethically challenging. The expectation that knowledge generated through IR should be
rapidly translated into health policy and practice necessitates up-front commitments from decision-makers to
sustainability and scalability of effective interventions. Greater awareness of the particular ethical implications of the
features of IR is urgently needed to facilitate optimal ethical conduct of IR and uniform ethical review.
Introduction
Implementation research (IR) is growing in importance
and recognition: there is an increasing funding from a
range of donors/sponsors for this research area, leading
scientific journals have established sections promoting
the publication of such research, and it contributes in-
creasingly to the evidence-base used by the World
Health Organization (WHO), which promotes, supports,
publishes, and evaluates such research [1]. With its aim
to answer questions about how to improve access to in-
terventions that have been shown to work but have not
reached many of the people who could benefit from
them, IR involves a range of particular ethical consider-
ations that have not yet been comprehensively covered
in most international guidelines on health research
ethics [2, 3]. The draft of the Council for International
Organizations of Medical Sciences (CIOMS) guidelines
which is currently under revision as well as its commen-
tary does briefly allude to ethical considerations in the
conduct of cluster randomized trials (CRT), but thus far
there has been no comprehensive discussion or guideline
regarding the application of ethical principles in IR in
general or in relation to study designs beyond CRTs [4].
In response to the need for more clarity and guidance
about the ethical implications throughout the IR process,
Special Programme for Research and Training in
Tropical Diseases (TDR) and the Global Health Ethics
unit in collaboration with the Alliance for Health Policy
and Systems Research at the World Health Organization
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are developing a training tool, the Ethics in Implementa-
tion Research Toolkit, as a practical guide for IR re-
searchers and ethics committees to facilitate optimal
study design, conduct, and review. The training tool was
developed through a consultative process launched in
Geneva in which IR experts, philosophers, ethics com-
mittee members, and public health practitioners met to
identify the ethical issues in IR, define the course con-
tent and the format of the training workshops. The tool
was further developed through small group work with
the support of an expert in adult training methods. The
tool has been validated in two pilot workshops in Asia
and Africa. The list of experts who contributed to the
development of the Toolkit, apart from the authors of
this manuscript, can be found in the Acknowledgements
section.
This manuscript is constructed around the concepts
identified during the development and piloting of the
Ethics in Implementation Research Toolkit and aims to
highlight the differences in application of ethical princi-
ples between clinical and implementation research, and
to highlight the current gaps in ethical guidelines for the
conduct of IR.
Background
IR involves increasing the understanding of how to im-
prove access to health products and strategies that are
already available and have been shown to work, but re-
main beyond the reach of many of the people who could
benefit from them. IR therefore provides the link be-
tween what should happen in theory and what actually
happens in practice. It is rooted in the identification of
practical problems facing disease control programmes
and in finding solutions which improve access to health
interventions and lead to better health outcomes. IR ad-
dresses different aspects of implementation including so-
cial and contextual factors (poverty, environment,
culture), the process of implementation (which approach
best answers the implementation issue?) or the out-
comes of implementation (clinical/process end points).
For example, in case of a new vaccine for prevention of
dengue, basic science and traditional clinical research
address vaccine development and safety and efficacy
testing. IR then addresses the questions of accessibility,
acceptability, appropriateness, and feasibility in the com-
munities where the vaccine is needed. IR questions,
however, are not always related to a clinical disease en-
tity or implementation of a treatment or prevention pro-
gram. IR also addresses process issues in health care
delivery, as well as cost-effectiveness, policy uptake and
implementation, health education etc. IR therefore draws
on a wide variety of research approaches to address the
diverse research questions. The research designs there-
fore are not restricted to traditional trial designs, but
include methods such as participatory action research
(PAR),1 qualitative design, and effectiveness implementa-
tion hybrid designs 2. Flexibility is a great advantage in
IR as the research question largely drives the design, the
research process is iterative, and the findings at each
stage feed back into the design. IR is usually carried out
in close collaboration between researchers and disease
control programme staff or policy-makers. The costs are
generally modest, yet IR has the potential for a large
magnifier effect, as effective implementation expands the
impact of health interventions delivered by programmes.
As a pre-requisite therefore to the design of a successful
implementation strategy, the clinical/public health prob-
lem must be identified, the epidemiology of the disease/
health status must be understood, and a situation ana-
lysis must be performed to identify why access is sub-
optimal, and what the actual bottlenecks/gaps in care
delivery are (not merely presumed), such that interven-
tions can be targeted to reduce these bottlenecks/gaps.
In the case of adoption of a successful intervention from
one country by another country or scaling-up of inter-
ventions from a pilot phase to a wide area, a local situ-
ational analysis should be carried out to determine
differences and similarities between the communities
where an intervention has been successfully imple-
mented and the communities in which the intervention
will be tested. IR is relevant when this analysis shows
important differences but points to the proposed inter-
vention as the most appropriate strategy, or justifies full
scale implementation of the intervention [5]. Awareness
of the appropriate application of ethical principles in IR
is important in study design and data generation to
ensure ethical conduct of IR and to effectively contribute
to health system strengthening. In the planning stages,
researchers must also be able to effectively communicate
their consideration of the ethical principles to research
ethics committees, who must also have insight into the
adaptations of ethical principles required in IR (as
opposed to traditional clinical research) such that
protocols are appropriately and fairly reviewed.
Are there ethical considerations which apply particularly
to implementation research?
IR is aimed at identifying the best process to implement
and scale-up research evidence, whereas biomedical and
clinical research focuses on establishing the evidence.
This fundamental difference between clinical and imple-
mentation research necessitates a modification in the
application of ethical principles in their conduct as
highlighted in Table 1.
Most researchers and research ethics committees are
familiar with the ethical challenges posed by traditional
clinical research, which emphasizes respect for individ-
ual autonomy and the importance of individual informed
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Table 1 Differences between clinical and implementation research which impact application of ethical principlesa
Domain Clinical research Implementation research
Research participants Individuals Countries, institutions, communities, and individuals
Informed consent Informed consent by competent individuals, assent
by minors and consent by legally authorized
representatives
Consent may be difficult to obtain in cluster randomized trial
design. There may be a need for a two level
consent—consent for randomization from gatekeepers and
consent for participation at the individual level. Sometimes
individual consent may not be feasible. However, gatekeeper
consent does not replace the need for individual consent.
Ethical committee should oversee the informed consent
requirement and process
Equipoise Clinical equipoise Clinical as well as contextual equipoise (genuine
uncertainty that the implementation will work in a new
context as well as whether the implementation package
will work at all)
Pre-requisites Understanding of disease pathophysiology
Intervention aimed at disease-specific management
Identification of population health needs
Understanding relative priority of need for intervention
within local context
Community engagement to understand community needs,
ensure scalability, and sustainability
Research conditions Generally controlled research environment Real-life or pragmatic research environment
Research designs Cross-sectional, case-control studies,
Cohort studies, randomized clinical trials
Cluster randomized trials
Pragmatic, mixed methods, effectiveness implementation
hybrid designs, participatory action research, quasi-
experimental design, realist review
Integration within health system Often, there is no a priori plan for health system
integration. Findings of clinical research go through
IR before integration into health system
IR has a strong health system strengthening focus. It creates
horizontal integration into the health system. There is an ethical
imperative for health system integration
Predominant research disciplines Physiology, genetics, biochemistry, and other basic







Control groups In most epidemiological designs, control groups are
required. But some phase 1 clinical trials and
observational studies may not require control groups
Having a no intervention control group may not be
acceptable. Alternative designs of quasi-experimental
studies do not require a control group
Boundary between research and
clinical care
This boundary is usually clear, but may be unclear in
case of therapeutic misconception especially in
cancer trials
Is often unclear, because the intervention is of proven
efficacy
Types of research question Efficacy and safety of a therapeutic strategy in the
individual
Operationalization of an intervention in local context
Implementation of an intervention in local context prior
to scale-up
Policy analysis
Health system functioning at multiple levels
Anticipated outcomes Well-defined hypothesis at the beginning of the
clinical research. Expected outcomes clearly stated.
Multifaceted holistic impact on health systems
functioning with regard to intervention tested.
Sometimes outcomes may be unexpected
Risks assumed by: Mostly, the risks are for the study participants.
However, families and communities may also be
affected in specific contexts
Usually population level risks. Moreover, the people
getting the benefits and people suffering the risks may
be different.
Benefits accrued by: Benefits accrue to the participants, the community.
The research finding may be a common good
Individuals, communities, health system, institutions may
benefit. The research findings may be common good.
The people accruing benefits may be different from
those who suffer risks
Generalizability Generalizability is sometimes possible in multicentric
and well sampled studies, however most studies are
specific to the target populations.
Generalizability may be limited by contextual factors.
However, findings may be generalizable to similar
contexts
Social justice implications Social justice is usually not a primary consideration.
However, justice considerations are required in
selection of research participants. Research on
vulnerable participants is often contentious because
of compromised autonomy and other logistics
Social justice considerations are primary. Working with
vulnerable groups essential to understand
implementation issues in these groups so that the
intervention can reach them
aDeveloped from References [2, 6–13, 20, 43]
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consent, beneficence, justice, and the necessity for clin-
ical equipoise. Clinical research is usually carried out to
answer a focused clinical question, under controlled cir-
cumstances, in a well-defined subject cohort with rigid
inclusion and exclusion criteria. In IR, in contrast, be-
cause the goal is to generate knowledge that leads to
wide-scale implementation of interventions in new con-
texts, the priority focus is different from that of clinical
research [2, 6–13]. IR tends to occur in real-world cir-
cumstances to test the feasibility and effectiveness of an
intervention in real-life situations and not under the
controlled environs of clinical research, therefore the
boundary between research and clinical care/public
health practice can be quite blurred. The implementa-
tion ethics issues that arise in the context of IR may also
be distinguished from those that arise in the context of
programmatic implementation [14]. A priority in IR is
broad inclusion of research subjects, specifically includ-
ing vulnerable populations to optimize equity and justice
in access to the intervention. An ultimate goal of IR is to
generate knowledge that will be translated into health
policy and health action, and therefore studies must be
conducted with the vision of sustainable scale-up and
roll-out of effective interventions. Although many ethical
principles are common to biomedical research and IR,
there may be some differences in the way these princi-
ples are applied. The key ethical issues relating to IR
may be broadly divided into those that arise during the
planning phase, the implementation phase, and the post-
research phase. Although some ethical issues cut across
multiple phases, for the purposes of this review we will
discuss the issues as illustrated in Fig. 1. A case study is
presented in Table 2 to illustrate the relevance of such
ethical issues in the conduct of IR (case adapted from
published experiences for the didactic purposes of this
manuscript) [15].
Ethical concerns in the planning phase of IR
Responsiveness of IR
Problems addressed by IR must be of high local priority
in order to justify the research [16]. One could argue
that the requirement for responsiveness is greater from
IR compared with clinical research as IR should address
priority health needs whereas clinical research is con-
cerned more with proof of principle, and wider applica-
tion should be tested with subsequent IR. Conversely,
when there is an available intervention for an important
unmet health need in a community, there is an ethical
imperative to conduct IR to try to address the imple-
mentation barriers. As such, IR studies are often
commissioned by local health authorities. The know-
ledge of which problems are indeed local priorities relies
on epidemiology and health data reporting, which may
not always be optimal in resource-challenged environ-
ments. Engagement with local health experts and com-
munities is therefore essential in the planning stages of
IR to determine whether a health problem is indeed per-
ceived to be a local priority. If a particular problem is
not perceived to be a local health priority, the ethics of
conducting IR becomes questionable [17].
Fig. 1 Ethical considerations in various phases of Implementation Research
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Equipoise
Equipoise is an important ethical imperative in the con-
duct of research, it is required to justify any potential
risk to research subjects. Clinical equipoise refers to the
fact that investigators conducting a randomized
controlled trial do not know in advance if an interven-
tion is better than what it is being compared with. In IR,
however, such clinical equipoise is generally not present
(e.g., a medication is known to cure malaria), but in-
stead, situational or contextual equipoise justifies the
conduct of IR, i.e., there remains genuine doubt whether
a new and untested package of interventions will work
in a specific context [18]. To ethically justify IR, there-
fore, equipoise regarding the effectiveness of the imple-
mentation processes must be preserved.
Study design
A balanced discussion about study design is important
before embarking on an IR study to weigh the ethical
obligation to ensure scientific standards are maintained
against the ethical demands of equity and justice [2, 19].
Though the randomized controlled trial is considered
the gold standard in clinical research, health system
strengthening interventions often do not lend them-
selves to such a design. Many different study designs,
often with multidisciplinary involvement, have been used
in IR, each raising particular ethical concerns [17]. Both
qualitative and quantitative methods are used in IR and
often within the same study. Examples of specific and
different ethical considerations may arise with each
method as outlined in Table 3. CRTs are often used in
health systems research, but when a public health inter-
vention is known to be effective, withholding the
intervention from those randomized to the control arm
is ethically problematic [4, 20, 21]. As a compromise, a
stepped-wedge approach is sometimes justified to ad-
dress this dilemma in CRTs, as this may mirror the real-
world scale-up process [22]. In a stepped-wedge design,
an intervention is delivered sequentially to groups of
participants with the goal of ultimately including all
participants, however in the early stages some groups do
not receive the intervention and therefore are analogous
to controls, which may pose an ethical challenge even if
short-term because for that short period of time the par-
ticipants are deprived of the proven intervention [23].
Alternatively, quasi-experimental designs where a con-
trol group may not be included may be ethically more
acceptable in IR, but the scientific rigor and validity may
be questioned [24]. The use of random allocation, with-
out consideration of the specific needs and vulnerabil-
ities of the participants, raises concerns of justice and
equity. Other appropriate study designs for IR include
pragmatic designs, hybrid and mixed methods designs,
and open-label demonstration projects which may each
have specific ethical issues that will require careful con-
sideration at the planning stage [25–27]. Engagement
with all stakeholders is crucial to develop the most
effective and fair study design.
Table 2 A case study illustrating the multiple ethical challenges
arising in implementation research
Implementation research of strategies to improve vaccine coverage in
children in nomadic populations
Study description. Country X had a low rate of vaccine coverage largely
because a significant group of nomadic populations were not reached
by the routine vaccination strategies. A basic needs assessment was
performed among the nomadic populations and found their vaccine
coverage rate to be very low. In addition, the assessment found that
insufficient knowledge of the location of the nomadic populations, lack
of logistical support and lack of community engagement in the
vaccination drives were important reasons for poor coverage. In order
to overcome these problems, an implementation research study was
planned. Special Outreach Teams (SOTs) were trained and deployed to a
selected sample of known nomadic groups. These SOTs were provided
with all logistical requirements such as vehicles, ice boxes, vaccine
stocks, and temperature logs. They were also trained to engage with
the communities, to deliver the vaccinations to the children under five
according to schedule and also to collect data on the existing level of
vaccine coverage, numbers vaccinated, documentation of feasibility
challenges, and costs. The SOTs coordinated their work with the routine
health care workers in the communities where these nomadic groups
were stationed at the time of contact. In addition, a small subsample of
the nomadic groups were invited to participate in a mobile phone-
based GPS tracking study to assess the feasibility and utility of locating
the nomadic groups in real-time. Solar powered battery packs were
provided to the key members of the community who held the GPS
tracking mobile phone. Their GPS coordinates were relayed to the SOTs
so that they can deliver their services effectively.
Ethical issues. This implementation research study brings out several
important ethical considerations. There is an ethical imperative to
engage and work with this special marginalized group in order to
increase coverage of vaccination as it is the duty of the health system
to protect and promote their health and also in order to more
effectively protect the rest of the community with whom the nomadic
groups will come in contact. Equipoise to justify the conduct of the
study lies primarily in the uncertainty of how the intervention will be
taken up and effective within this context as it is known that the
vaccinations are effective from other populations. Despite this fact,
however, effectiveness of the vaccine should be tracked in this new
population as there may be modifiers of the effect, e.g., nutritional
status etc. that may also require ancillary care. The findings of the study
will help understand the feasibility and acceptability of the intervention
among nomadic communities thus facilitating the implementation of
the vaccination coverage campaign. Community engagement is a key
ethical consideration in this context. Marginalized communities like
these have inherent mistrust in health systems and community
engagement helps build trust. Identification of appropriate gatekeepers
of the community by appropriate selection process will facilitate both
the informed consent process as well as representation of long-term
voices of the communities. The tracking of the position of the nomadic
groups for the sake of facilitating the vaccination process using the GPS
tracking system is a significant intrusion into the privacy of the communities.
This needs to be carefully weighed and balanced against the benefits of
enhanced vaccine coverage and reduced child mortality because of that.
Moreover, confidentiality of the GPS tracking data should be clearly
maintained. Issues of sharing the GPS tracking position with local health
system, other parties who may be interested to track them for other
purposes etc. needs to be carefully deliberated. In addition, it is likely that
many other health needs would be identified in these communities, raising
the ethical issues associated with ancillary care responsibilities.
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Stakeholder and community engagement
The term stakeholder has numerous definitions, many of
which are contextual [28]. Two general definitions are
relevant in the context of IR: the first defines a stake-
holder as a “person or group with an interest, involve-
ment or investment in something” [29]; the second
describes stakeholders as “people who will be affected by
a project, or who can influence it, but who are not dir-
ectly involved in doing the work” [30]. Key stakeholders
in IR may include the government, policy-makers, public
health functionaries, health care providers, health care
managers, financing mechanisms, health care industry,
and the community. Communities may include individ-
uals on who interventions are planned, the broader com-
munity or social structures to which these individuals
belong and the broader society to whom an intervention
may eventually be rolled out. Communities and individuals
with specific roles are important stakeholders in the re-
search process. Meaningful engagement with stakeholders
at all levels is crucial in IR, as a means to identify health pri-
orities, to identify key participants, to communicate trans-
parently and effectively about the goals, design, risks,
benefits, and process of a proposed intervention, to gain
trust and develop partnerships to enhance success of the
study, and to gain feedback and identify unforeseen barriers
that could be mitigated at the planning stage [31, 32]. Com-
munity engagement is a related but different concept where
the members of the community who will benefit from or
face the risk of the IR are actively consulted and engaged
with, with the goal that they play an active partnership role
throughout the IR process.
Stakeholder and community engagement are cross-
cutting processes which must be carried out during the
planning, implementation, and post-research phases of
Table 3 Ethical issues relating to examples of implementation research designsa
IR design Features Example Ethical concerns
Cluster randomized trials (group
randomized, place-based, community
wide intervention trials)
-Random allocation of groups or
“clusters” to study arms and
outcomes are measured in
individual subjects and at
community level
-Randomization of clusters of
obstetrics unit staff to education
on hand washing or usual
practice, measurement of rates of
puerperal sepsis in women
delivering at study clinics
-Different units of intervention and
outcomes measurement
-Consent before and after
randomization, whom to consent?
-Choice of gatekeepers
-No opt-out option within cluster
-Risk: benefit balance
-Ethics of randomization to known
intervention, equipoise,
-Identification of vulnerable groups
Effectiveness-implementation
hybrid trials






-Evaluate impact of ITN on
reduction of malaria and assess
robustness of availability and
uptake of ITNs in the community
-The trade-off between the
scientific rigor required for
effectiveness assessment and the
realistic contextual considerations
required for implementation is an
important ethical consideration












-The trade-off between the scientific
rigor required for quantitative
methods and the realistic contextual
considerations required for the
qualitative component
Participatory action research -Research question, design, and
data collection in a participative
manner by the research
participants
-“Bottom-up” approach
-Peer support groups to improve
adherence to ARV in HIV +
subjects




Pragmatic trials -Effects of intervention in routine
practice
-Maximize variability of settings,
practitioners, patients
-Introduction of community
health workers for home
management of malaria
-There may be concerns of standards
of care and ancillary care, which in
pragmatic conditions may be
ethically debatable.
Quasi-experimental study -Real-life conditions
-With or without control group
No randomization
-Open label demonstration
project of effectiveness of self-
reported use of pre-exposure
prophylaxis for HIV
-There is a concern regarding
scientific rigor of the research
Realist view -Analysis of how and why an
intervention works in a context
combining theory and empirical
evidence.
-Integration of traditional healers
into home management of
malaria strategies
-Community engagement is of
utmost importance to retain cultural
and contextual sensitivity
aAdapted from References [5, 17, 20, 21, 24, 26, 60]
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IR. Particular ethical underpinnings of engagement with
policy-makers and health financers at the planning stage
include determination that the intervention will address a
local priority health need and to gain buy-in and commit-
ment for the scale-up and sustainability of an effective
intervention. Scale-up is considered by some to be an eth-
ical corollary of IR. Important ethical goals for engage-
ment with communities as partners in planning and
design of IR include to determine acceptability of a pro-
posed intervention, maximize uptake, ensure inclusion of
vulnerable populations, establish accountability processes,
and particularly when individual informed consent is not
feasible due to the research design, to ensure individuals
are aware of the rationale and opt-out possibilities. The
process of decision-making in IR should consider the
power differential between the researchers and the com-
munity and allow adequate representation of the research
participants and the community at large [33–35].
Often community representatives are selected to facili-
tate communication between researchers and the commu-
nity. The selection of community representatives must be
an inclusive and fair process of democratic election or
nomination, guided by the community itself, to ensure ap-
propriate, acceptable, and comprehensive representation
of all sectors of the community irrespective of class, race,
gender, sexual orientation, or ethnicity and to avoid any
potential conflicts of interest-specific individuals may have
[33–36]. Engagement with disadvantaged and marginal-
ized groups is imperative up-front and throughout the IR
process to ensure acceptability and equitable participation
in IR, and importantly, to identify any specific unantici-
pated barriers they may face and to develop strategies to
mitigate further marginalization or stigmatization through
the research [8, 37].
The balance between the risks and benefits
The clinical efficacy and safety of an intervention is gen-
erally known before IR is conducted. In clinical research,
an individual participant can personally weigh the rela-
tive risks and benefits before giving their informed
consent, and the risks and benefits are usually borne by
the same individual. For example, in clinical research
testing, the efficacy of a new vaccine, the benefit of per-
sonal protection, and the risk of side-effects are borne
by the individuals who participate in the study. In IR, for
example in mass drug administration interventions, the
community may benefit from large-scale treatment of
individuals, but an individual may experience side-
effects from a medication they may not personally have
required. In addition, the potential risks of an IR inter-
vention may also result from the modality of implemen-
tation [2]. For example, a community wide public health
screening campaign for sexually transmitted infections
which had been successful in one low-income country
may carry different risks of stigmatization, religious os-
tracism, and social discrimination if implemented in an
underdeveloped and religiously orthodox country, lead-
ing to a different risk-benefit balance. The risks associ-
ated with IR may not always be obvious up-front as
health systems are complex adaptive systems, and inter-
actions between the components in the health system
are not often clearly understood [38]. Diligent situational
analysis must therefore be conducted during the plan-
ning phase of IR to identify potential risks before harm
is done [19]. In addition, a particular feature of IR is that
at times an intervention is implemented in one group,
but the benefit may accrue to another group [2]. For ex-
ample, IR studying the implementation and uptake prior
to scale-up of a malaria transmission-blocking vaccine
exposes vaccinated individuals to the risks of vaccin-
ation, but unless a large proportion of the community is
vaccinated, the individuals vaccinated will protect others
from malaria transmission, but will not be protected
themselves. How to balance the risks experienced by one
group against the benefits gained by another requires
ethical deliberation and effective communication with
the research participants. The ethical deliberation should
be based on the solidarity principle and should be trans-
parent, involving communities and all stakeholders [39].
To what extent individuals within a group should be ex-
posed to risks for the benefit of others cannot be clearly
defined, but it should be decided based on community
and stakeholder consultations [2]. A line which cannot
be crossed is knowingly exposing one group to harm or
significant risk for the benefit of another.
Ethical concerns in the implementation phase of IR
Autonomy and informed consent
A key principle driving the ethics of clinical research in
humans is individual autonomy. In public health research
autonomy has two dimensions, one concerns individual
autonomy and the other concerns relational autonomy in
the context of the community to which the individual and
the health system belong [40]. Informed consent is the
process through which a research participant can exercise
their autonomy. In clinical research, a fully informed indi-
vidual can determine whether or not they wish to freely
participate in a study and can usually opt-out of the re-
search at any stage. In IR, there may be difficulties in oper-
ationalizing informed consent [2, 20, 41, 42]. For example,
an individual in a cluster in a CRT may not have the
chance to decide and give consent to randomization as
randomization happens at the cluster level. In the case of
non-excludable cluster level, interventions such as envir-
onmental modifications, an individual may not be able to
exercise a meaningful refusal to participate. In such situa-
tions in IR therefore there is a need to articulate informed
consent differently from traditional individual consent in a
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clinical trial. At one end of the spectrum is a complete
waiver of individual informed consent where the ethical
risks are minimal, and the interventions are largely at a
cluster level (i.e., no individual can opt-out), rendering
refusal meaningless. For example, in an IR study of an
ultraviolet wave system to provide safe drinking water to a
population, the harms are considered minimal, and it is
not possible for any individual participant in a cluster ran-
domized to the intervention arm to easily opt-out of the
study [43]. Such a waiver of consent does not however
preclude the need for meaningful community engagement
and provision of information. At the other end of the
spectrum is the example where individuals have the op-
portunity to refuse participation in the research project,
even though the intervention will occur at the cluster
level. This could occur for example when public health
professionals wish to test whether community health
workers can be trained to provide injections in the com-
munity, and individuals have the option to refuse partici-
pation and visit the health facility to receive the injection
from a nurse. Individual informed consent would be the
norm in this case, even though consent for randomization
cannot be provided by the individual and it is operational-
ized at the cluster level prior to individual contact [20, 43].
In the middle of the spectrum is dual consent from gate-
keepers and individuals. Community agreement relies on
the identification of an appropriate gatekeeper, who
should have a keen interest in the welfare of the commu-
nity and represents the community in a fair manner [36].
There are several challenges in selection of the gatekeeper.
In traditional communities where collective decision-
making is practiced, selection of a gatekeeper may not be
problematic. But in more complex societies, or more com-
plex studies, selection of one voice to represent the com-
munity is often challenging. The community leader may
not be the most appropriate person to make decisions on
whether a community or its members should participate
in a study or not. For example, an elderly male village
leader may not be an appropriate gatekeeper to consent to
an IR intervention on pregnant women in his community.
Selecting community representatives fairly requires inclu-
sion of a variety of representative stakeholders, especially
those from the target groups, and ensuring transparency
of the process [20, 36]. The agreement of the gatekeeper,
however, cannot replace individual consent or assent
where relevant as discussed above [4]. Ultimately, it is im-
portant that proper ethical oversight is in place through
Institutional Ethics Committees to ensure that the appro-
priate informed consent process is followed, maximally re-
specting autonomy of individuals in the study [44].
Challenges in operationalizing informed consent in the
context of IR also include whether the beneficiaries are
individuals or populations, and appropriate identification
of who the actual research participants are [18]. For
example, when implementing a taxi voucher system to
increase the rates of institutional deliveries and reduce
maternal mortality, should consent be obtained from the
pregnant women, the taxi drivers, or the health care
workers whose performance will also be evaluated? The
Ottawa statement on ethical conduct of cluster random-
ized controlled trials define a research participant as: the
intended recipients of the experimental or control inter-
vention; the direct targets of experimental or control en-
vironmental alterations; persons with whom researchers
interact to collect their data; persons whose identifiable
private information is accessible to the researcher for
collection of their data [21]. As such, in the example
above, patients and health care workers should provide
consent, but whether this should extend to the taxi
drivers is questionable and may be difficult to
operationalize. A further important ethical issue in the
informed consent process is the extent of information to
be revealed to the participants in the intervention and
control arms, where applicable. In IR, especially when
behaviour change interventions are being studied, know-
ledge of the intervention itself may change the outcomes
and implementation process. There is, therefore, often
the need to conceal some information about the inter-
vention. The ethical justification for this is debatable,
and it must be balanced against the risks/benefits and
the potential impact on study validity as discussed in the
CIOMS guidelines [45]. The informed consent process
in IR therefore may be quite different from that in clin-
ical research and requires thorough consideration to en-
sure optimal ethical conduct of IR.
Privacy and confidentiality
Particular issues relating to privacy and confidentiality in
IR relate to the fact that IR often requires that facility
level data on patient outcomes be available or that indi-
vidual level data from facility health records be obtained.
For example, if a public health intervention is imple-
mented to regulate institutional deliveries and improve
the quality of skilled institutional deliveries, there may
be interventions at the health facility level, but confiden-
tiality restrictions on access to data from women who
deliver in the facilities may hamper effectiveness analyses
of the health system impact [19]. In such cases, the data
that is obtained from facilities should either be anon-
ymized, or the individuals about whom data is being
sought should provide consent for their data to be
reviewed by the researchers. Where such consent is not
possible, it is the responsibility of the researcher to ob-
tain a waiver of consent from the respective ethics
board, and put in place mechanisms to ensure that the
confidentiality of the patient information is respected. A
proactive strategy of informing patients about potential
data collection for research and quality improvement
Gopichandran et al. Implementation Science  (2016) 11:161 Page 8 of 13
purposes up-front, but reassuring them about privacy
and confidentiality could also serve strengthen the
patient-researcher partnership and build trust [46].
Standard of care or prevention
There are two approaches to decide on standard of care
or prevention to be given to a control group [47–49]. One
approach is to allocate the local de facto existing standard,
which in some situations may be grossly insufficient,
making it ethically unacceptable based on justice and
fairness principles. For example, in an IR trying to study
prevention of mother to child transmission of HIV in a
country where routine anti retroviral therapy is not avail-
able, the local de facto standard of care is no treatment.
Having a placebo control arm in the study is not accept-
able in spite of the local de facto care being no treatment,
because an effective treatment which reduces transmission
is available and should be accessible to the mothers. The
second approach is to provide the local de jure standard
of care or prevention, which is agreed upon by public
health experts of that region and is acceptable to the com-
munity. This approach may still be unfair in that this
standard may be unsustainable for the local health system
after the IR is completed. For example, in a public health
behaviour change implementation study focused on hand
washing among schoolchildren, the intervention group re-
ceives a school-based lunchtime hand washing program,
and the control group receives soap and water in all
schools, but without any emphasis on hand washing be-
fore eating. In this case, the standard of care is provision
of hygiene tools, and the intervention is emphasizing the
use of these tools. In this context, allowing the control
group to have no intervention can be considered ethical.
The consideration of standards of care or prevention may
therefore identify new gaps as targets for future IR.
Ancillary care
Ancillary care refers to the identification of problems
that may contribute to ill-health that are beyond the
scope of the study in question, for example, researchers
studying home management of malaria may come across
household members with other diseases needing atten-
tion [11, 50, 51]. Sometimes ancillary care responsibil-
ities can be foreseen at the design stage and at others
they are encountered only during the conduct of the IR.
Ancillary care obligations are present when the need is
serious in terms of severity or urgency or both and when
there is a possibility of provision of care within the scope
of the research [11]. For example, in the school-based
hand washing behaviour change IR study, uninterrupted
tap water supply may be lacking and this is an ancillary
care requirement. However, this example illustrates that
it may not be realistic to expect implementation re-
searchers to assume all ancillary care responsibilities.
Researchers may not have the expertise to provide the
ancillary care; the provision of the care may be costly or
may require system-level interventions. The researchers
must, however, establish process of accountability for an-
cillary care need identified through the research, deter-
mine which needs may realistically fall within the scope
of responsibility of the researchers, and proactively en-
gage with the local government or non-governmental or-
ganizations during the planning and conduct phases of
IR to identify who will be able to meet other needs [52].
Research capacity and health system strengthening
Well conducted IR should lead to strengthening of re-
search capacity of the local institutions as well as individ-
uals’ capacity to conduct research in settings where such
capacity is weak [53]. Research capacity strengthening can
range from creating a trained workforce of researchers
and research volunteers up to training and capacity build-
ing of research experts and infrastructure to permit inde-
pendent conduct of locally responsive IR in the future.
Based on the need in the area where the IR is being con-
ducted, appropriate research capacity strengthening
should be facilitated. This can be facilitated by appropriate
stakeholder engagement ensuring commitment by donors
and governments to build sustainable research capacity.
Not only is it important for the IR to strengthen local re-
search capacity, it should also strengthen the health sys-
tem within which it is conducted. For example, true
partnership in an implementation research study of rapid
diagnosis of tuberculosis resistance should build sustain-
able infrastructure in technology required, expertise to
run and maintain the technology, strengthen the local
health information system to track data acquired, train
local researchers in design, conduct, analysis and reporting
of study findings as well as participation in post-
intervention scale-up, thereby strengthening the local re-
search and health system capacity. IR projects focusing on
specific health gaps may, however, create vertical program
structures within the health system which may be disem-
powering to the system through inefficient resource
utilization [13]. It is ethically important that the conduct
of IR should focus on horizontal integration of public
health interventions into the health system such that a
project empowering any component of the health system
may have positive repercussions for the entire system.
Strengthening the capacity to translate research findings
into health policy is a specific imperative in IR and must
be a component of all phases of the IR process [53].
Ethical concerns in the post-research phase of implemen-
tation research
Dissemination of research findings
Given the important public health impact of IR, there is
an ethical obligation to disseminate the research findings
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widely, including feeding back to the communities and
stakeholders who participated in the research [54, 55]. If
an implementation strategy had a negative or positive
impact in a certain context, either finding may be im-
portant for researchers planning similar interventions
elsewhere. Therefore, irrespective of the results, the find-
ings of the IR should be disseminated. Furthermore, re-
source utilization globally could be enhanced by an
imperative for dissemination of IR findings, as once an
intervention has been tested in many different local con-
texts, its findings may be presumed to be generalizable
and obviate the need for new IR studies and delays in
scaling-up of the intervention in new contexts.
Data ownership and sharing
In case of donor or sponsor-driven IR, data is often
owned donor, who may regulate and restrict further
handling of the data. Data ownership should be fairly ne-
gotiated through transparent stakeholder engagement in
the planning phase of IR, and ethical oversight of the
data ownership process is required to ensure appropriate
access to the research findings by the relevant stake-
holders post-study, including the local researchers and
communities when appropriate, to maximize the utility
of the knowledge generated. It may be acceptable for re-
searchers or donors to own data without further respon-
sibility. However, given the policy and public health
implications of IR and the necessity of trust especially
with the communities, there may be a responsibility for
data sharing which should also be negotiated up-front,
considering the important implications of protecting
privacy and confidentiality as well as to allow strength-
ening of local research capacity.
Translating findings into public health action
Due to the inherent nature of IR, there is an ethical obli-
gation for IR findings to be used to inform effective and
equitable public health action. This necessitates timely
consideration and uptake as relevant of the IR findings
into public health policy and practice. Potential barriers
to translating knowledge into action include lack of prior
consultation with policy-makers, lack of funding, weak
health systems, poor communication of findings by re-
searchers to policy-makers, and absence of a culture of
evidence-based decision-making among others [53].
Therefore, in order to translate the research into public
health action, implementation researchers should engage
with policy-makers and health system officials, import-
ant stakeholders in IR, upfront to ensure commitment
to sustainability should the intervention prove success-
ful, and must communicate their research findings
rapidly, clearly, and concisely to engage and inform
policy-makers in a timely fashion. Researchers should
also propose actionable suggestions based on the
research findings to facilitate uptake and scale-up of suc-
cessful interventions. Barriers identified during IR may
require further study to develop strategies to overcome
them. Effective communication between researchers and
policy-makers, as well as education of the public are im-
portant social justice obligations in IR, ensuring that ex-
pectations raised during the research are met, and those
who participated as control subjects gain access to inter-
ventions withheld from them during the study.
Scalability and sustainability
Scalability and sustainability are important ethical con-
siderations at both planning and post-study phases, as
ultimately these are the goals of IR [13, 56]. The duty to
ensure sustainability post-study cannot only lie with the
researchers. Multiple stakeholders must come together
to promote this goal which requires ongoing stakeholder
engagement throughout the IR process. The researchers
should ensure through effective engagement during the
planning and conduct stages of IR that the non-research
stakeholders such as policy-makers, local providers, and
health system officials remain committed to sustaining
implementation of an intervention if found to be effect-
ive. If access to a proposed public health intervention
cannot be ensured for a community after the IR, it may
not be ethical to carry out such a research activity. If
specific interventions are provided during IR without a
plan for sustainability, this could lead to exacerbation of
inequity and harmful effects to the community as well as
loss of trust in the health system.
Benefit sharing
Irrespective of the context in which IR is conducted,
LMIC or developed countries, there is an ethical obli-
gation to share benefits of the IR with the community
[57]. There are various classifications of the benefits
that can be achieved as a result of conduct of the IR.
The benefits may be direct as a result of the interven-
tion being studied, or indirect and not related to the
intervention per se. The benefits may accrue to indi-
vidual participants or to the community at large. For
example, IR may be conducted in communities where
the local health system is weak, therefore success of an
intervention may result in introduction of a new inter-
vention that was effective in the local context, provid-
ing individual benefit. In addition, the IR likely
identified and overcame barriers which would have
contributed to some strengthening of the local health
system that would have a broader impact. IR re-
searchers can facilitate sharing of direct benefits by ad-
vocating for sustainable translation of research
findings into action, and sharing of indirect benefits
through building research capacity and health system
strengthening. The unique nature of IR where the
Gopichandran et al. Implementation Science  (2016) 11:161 Page 10 of 13
individuals who bear the risks of the IR are not always
the ones who enjoy the benefits is a challenge as dis-
cussed above. Optimal benefit sharing can be pro-
moted through proper pre-IR planning and ethical
conduct. Community and stakeholder engagement
plays an important role in achieving benefit sharing as
when adequately informed they can advocate for ac-
cess to proven benefits. Benefit sharing has important
social justice implications, and it is the obligation of
the researcher to achieve a balance of risks and bene-
fits to both individuals and communities [58, 59].
Conclusion
Putting public health evidence into practice in specific
populations requires the generation of knowledge about
the feasibility of public health interventions within a spe-
cific context, the relative harms and benefits, how an
intervention is taken up, whether it reaches the most
vulnerable populations, and the logistics of the imple-
mentation process. IR aims to generate this knowledge
with the goal of enhancing health system performance
while upholding fairness and justice in the reach of the
intervention to all parts of the community. The ethical
principles pertaining to IR are not unique to IR, but may
require adaptation in application given the particularities
of IR. The stakes of IR are high because of the research
contexts within fragile health systems, the large numbers
of subjects involved and the reduced ability to predict
outcomes and consequences as compared to clinical re-
search [8]. Awareness of the ethical challenges relating
to IR is important throughout the planning, implemen-
tation, and post-study phases of the research not only to
ensure studies are conducted appropriately and that re-
sults are maximally useful, but is also important for eth-
ics review committees and institutional review boards to
provide appropriate and insightful review of IR projects.
This paper emerged out of the development of the
Ethics in Implementation Research Toolkit. Through the
consultation process, an important need was identified
to clarify the differences in the application of research
ethical principles between clinical research and IR, both
to guide researchers in planning and conduct of IR and
to facilitate review of IR proposals by research ethics
committees. As such, this paper complements the Im-
plementation Research Toolkit (http://www.who.int/tdr/
publications/topics/ir-toolkit/en/) and the Framework
for Operations and Implementation Research in health
and Disease Control Programs (http://www.who.int/hiv/
pub/operational/or_framework.pdf ). It is hoped that this
paper will generate discussion in further refining roles
and obligations of implementation researchers in low re-
sources settings and in further defining the obligations
of policy-makers and funders in committing to long-
term sustainability of successful interventions.
Endnotes
1PAR is a community-based approach to research that
emphasizes community participation in research design,
data collection, analysis, and interpretation. PAR tries to
understand situations and phenomena by changing them
and making observations. The experimentation is
grounded in community wisdom and experience.
2Effectiveness implementation hybrid designs include
simultaneous testing of clinical effectiveness and effect-
iveness of the method of implementation. It may be of
three types: (1) primarily doing an effectiveness study
while at the same time gathering data on implementa-
tion, (2) primarily doing an implementation study while
simultaneously gather data on effectiveness, or (3) dual
testing of both effectiveness and implementation
strategies.
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Interpretation:	
In	 paper	 5	 the	 ethical	 challenges	 faced	 by	 patients,	 families	 and	 health	 care	 workers	 are	




or	 living	 in	 remote	 areas	 the	possibility	 to	 exercise	 their	 autonomy	 is	 limited.	 	 Some	ethicists	
would	 contend	 that	 simply	being	 informed	 that	dialysis	 exists	 as	 a	 therapeutic	option	 in	 their	
situation	fulfills	respect	for	a	patient’s	autonomy.		Others	would	argue	that	when	no	real	choice	
exists,	it	is	not	possible	to	truly	exercise	or	respect	autonomy.	Some	go	as	far	as	to	state	that	it	is	
important	 not	 to	 “mislead	 people	 with	 unrealistic	 promises	 of	 autonomy”.
78
	 As	 shown	 in	
Chapter	1	(Table	3),	a	significant	proportion	of	patients	disappear	from	hospital	after	receiving	a	
diagnosis	of	kidney	failure.	This	is	an	autonomous	act,	but	the	likely	associated	distress	cannot	
make	 this	 morally	 acceptable.	 From	 the	 clinician’s	 point	 of	 view	 the	 tension	 in	 addition	 lies	
between	 balancing	 beneficence	 and	 maleficence.	 It	 would	 be	 easiest	 for	 clinicians	 to	 offer	
dialysis	if	available,	regardless	of	the	cost,	hiding	behind	the	principle	of	“doing	good”	at	all	costs	




















































































































































































































































































































































































































































“Accountability	 for	 Reasonableness”	 (A4R)	 framework.
88
	 The	 A4R	 framework	 comprises	 4	






Western	 Cape,	 South	 Africa.	 This	 process	 was	 driven	 by	 clinicians	 struggling	 to	 decide	 fairly	
which	 patients	 should	 gain	 access	 to	 limited	 dialysis	 slots.	 Such	 processes	 must	 include	 all	
stakeholders	in	the	quest	to	maximize	equitable	access	to	care	within	resource	restraints	and	to	
optimize	use	of	the	available	resources.	As	shown	in	the	Western	Cape,	ongoing	monitoring	of	
the	 outcomes	 of	 policy	 implementation	 is	 required:	 some	 components	 of	 equity	 have	 been	
improved	 under	 the	 new	 guidelines	 (more	 women	 have	 access	 to	 dialysis),	 but	 few	 patients	





Responsible	 policy	 making	 and	 priority	 setting	 should	 involve	 iterative	 cycles	 of	 informed	
planning,	 implementation	and	evaluation	to	ensure	goals	are	being	met	and	undue	harm	does	
not	 accrue.	 Such	 a	 process	 requires	 establishment	 of	 partnerships	 across	 multiple	 sectors,	
including	 civil	 society,	 analogous	 to	 the	optimal	 conduct	of	 IR.
91-93
	 Indeed,	 the	 goal	 of	 IR	 is	 to	
address	 the	 needs	 of	 the	 disadvantaged	 in	 sustainable	 and	 scalable	 ways.	 Priority	 setting	 is	
inherently	a	“value-laden”	process,	and	cannot	be	whittled	down	to	technical	considerations	of	




of	 the	 evidence	 requires	 a	 broad	 perspective	 and	 consideration	 of	 multiple	 values,	 with	 a	
willingness	 to	 learn	 and	 adapt	 such	 that	 decision	 making	 can	 be	 optimized	 in	 an	 iterative	
fashion.
96
	 As	 such,	 the	 ethical	 considerations	 relevant	 to	 the	 various	 phases	 of	 IR	 (Figure	 1,	
Paper	6)	could	provide	a	useful	complement	to	the	A4R	process	for	public	health	policy-making	
regarding	high	cost	 interventions	such	as	RRT.	Some	authors	have	suggested	the	addition	of	a	
5th	 criterion	 to	 the	 A4R	 framework:	 empowerment.
97
	 Indeed,	 advancing	 empowerment	 and	
capacity	 building	 for	 patients,	 communities	 and	 those	 functioning	 within	 the	 health	 system	
would	conceivably	significantly	strengthen	the	policy-making	and	implementation	processes.		A	
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Rigorous	 evaluation	 of	 the	 process	 is	 key,	 as	 suggested	 by	 the	 comprehensive	 framework	 for	
evaluation	of	 successful	priority	 setting	 in	LMIC	put	 forward	by	Kapiriri	and	Martin.
98
	 It	 is	also	
key	 that	 more	 outcomes	 of	 actual	 priority	 setting	 processes	 on	 policy	 development	 and	







The	data	 generated	 throughout	 this	 PhD	 serves	 to	 fill	 gaps	 in	prior	 knowledge	 relating	 to	 the	
diverse	facets	of	the	burden	of	kidney	disease	in	SSA	and	the	associated	ethical	implications,	and	
progressively	builds	the	case	for	the	need	for	pragmatic	and	transparent	policy	development	in	










hospital	 remain	 high.	 These	 circumstances	 raise	 important	 ethical	 challenges	 across	 the	
spectrum	of	 the	health	system.	Reliance	on	out-of-pocket	payments	and	availability	of	dialysis	




(and	 other	 health	 care	 workers)	 struggle	 between	 trying	 to	 respect	 patient	 autonomy	 and	
balancing	the	spectrum	of	benefits	and	harms	related	to	dialysis	care	for	patients,	families	and	
institutions.	 Decision	 makers	 face	 multiple	 ethical	 dilemmas	 in	 terms	 of	 resource	 allocation,	
priority	setting	and	transparency.	As	highlighted	in	Papers	3	and	4,	many	social	determinants	of	




	 Such	 strategies	 however	 require	 robust	 health	 systems,	
reliable	 health	 information,	 well	 trained	 and	 well	 equipped	 health	 care	 workers,	 and	











the	 ethical	 challenges	 faced	 by	 patients,	 families	 and	 health	 care	 workers	 are	 highlighted	 to	
demonstrate	the	need	for	policy	development	and	transparency	regarding	dialysis	care	in	lower	
income	 settings,	 specifically	 in	 SSA.
100
	 It	 is	 clear	 that	 in	 most	 countries	 dialysis	 cannot	 be	
universally	 provided	 by	 the	 state,	 and	 that	 the	 current	 reality	 reflects	 very	 limited	 and	
inequitable	access	to	care.	As	such,	the	implications	of	several	potential	broad	policy	options	are	
discussed	 within	 the	 public	 health	 ethics	 frameworks	 of	 Marckmann	 et	 al.	 and	 A4R.
79
	 The	








bedside	 when	 faced	with	 a	 choice	 which	 would	 impose	 CHE.	 Opportunity	 costs	 are	 however	
highly	 relevant	 especially	 in	 low-resource	 settings.	 Pragmatic	 solutions	 to	 meet	 the	 need	 for	
high-cost	 care	 in	 low	 resource	 settings	 are	 not	 obvious	 and	 therefore	 should	 be	 arrived	 at	
systematically,	 transparently	and	progressively.	Building	on	 the	arguments	presented	 thus	 far,	
important	components	of	this	process	include	acknowledging	the	impact	of	the	status	quo	and	







not	 hard	 to	 imagine	 that	 dialysis,	 costing	 many	 fold	 more,	 would	 always	 induce	 CHE	 if	 not	




explicitly,	 or	 de	 facto,	 adopted	 a	 form	 of	 dialysis	 distribution	 and	 financing	 as	 illustrated	 in	
Chapter	4,	Table	4.	Unsubsidized	costs	for	one	session	of	HD	across	SSA	range	from	USD	100	to	
350	per	 treatment	and	are	only	 sustainably	 feasible	 for	a	 few	privileged	 individuals	with	 their	





the	 state,	 requiring	 an	 out-of-pocket	 payment	 of	 USD	 10	 per	 treatment.	With	 the	 minimum	
wage	 of	 USD	 50	 per	 month,	 even	 this	 reduced	 cost	 is	 unsustainable	 for	 many	 patients.
83
	





this	 does	 not	 address	 the	 needs	 of	 those	 whose	 kidney	 function	 may	 not	 recover.	 Some	






place,	 and	 without	 parallel	 development	 of	 prevention	 programs.
48,82
	 A	 few	 countries	 only	
support	 temporary	 dialysis	 for	 those	 who	 have	 available	 living	 donors	 and	 can	 be	 sent	 for	
transplantation	elsewhere	(given	longer	term	cost-effectiveness),	meaning	that	patients	without	
a	 donor	 do	 not	 receive	 dialysis.
100
	 “Availability”	 of	 an	 intervention	 therefore	 does	 not	 mean	
equity	of	access,	and	many	patients	in	SSA	die	untreated	daily	because	of	high	costs,	geographic	
inaccessibility	 of	 appropriate	 care,	 young	 age	 or	 female	 gender.
1,65,66,105-107
	 The	 inherent	







most	 high	 and	 some	 middle-income	 countries.
33
	 Indeed,	 for	 ESKD	 especially,	 in	 Paper	 2	 we	






be	 a	 negative	 predictor	 of	 outcomes	 in	 ESKD	 even	when	 RRT	 is	 paid	 for	 by	 the	 state,	 and	 is	
therefore	 included,	 although	 controversially,	 as	 a	 potential	 exclusion	 factor	 for	 chronic	
dialysis.
87,110,111
	 Similarly,	 in	 Andhra	 Pradesh	 (India)	 and	 at	 the	 Sindh	 Institute	 of	 Urology	 and	
Transplantation	(Pakistan),	where	dialysis	itself	is	provided	free	of	charge	to	the	patients,	63.5%	
and	18%	 respectively	of	 those	who	 initiate	dialysis	 stop	 treatment	within	months,	most	 likely	
	 131	
because	 of	 uncovered	 expenses	 of	 medication,	 transport,	 lodging	 and	 lack	 of	 family	
support.
112,113
	 Payment	 for	 dialysis	 alone	 therefore	 is	 not	 enough.	 In	 addition,	 if	 patients	 die	
early,	the	opportunity	costs	of	such	expense	to	the	health	system	does	not	seem	justifiable.	In	
depth	 objective	 analysis	 of	what	 is	 required	 in	 each	 setting	 for	 a	 patient	 on	 dialysis	 to	 thrive	
(including	 health	 system	 components	 and	 patient	 factors)	 must	 be	 conducted	 in	 order	 to	




Priority	 setting	 is	 a	 cornerstone	 of	 health	 system	 stewardship.	 Priority	 setting	 dilemmas	 arise	
when	tradeoffs	must	be	made	about	what	kind	of	services	should	be	provided	and	to	whom,	i.e.	
a	“trade-off”	decision	to	withhold	some	services	from	people	that	could	benefit,	and	to	allocate	
the	 resources	 to	 other	 services	 that	 benefit	 other	 people	 instead.
114,115
	 For	 example,	 in	 SSA,	
where	resources	are	particularly	scarce	and	the	burden	of	kidney	disease	is	arguably	high,	there	
is	an	urgent	need	for	relevant	evidence	to	inform	legitimate	and	transparent	priority	setting	and	
decision	 making	 regarding	 provision	 of,	 and	 access	 to,	 dialysis	 within	 the	 contexts	 of	 kidney	
disease	 as	 a	whole,	 as	well	 as	 other	 health	 priorities.	 Some	 authors	 suggest	 that	 “upstream”	
public	health	interventions	(i.e.	prevention	of	disease),	as	maximizers	of	health	and	capabilities	
for	 the	greatest	numbers,	may	be	ethically	 superior	 and	 should	be	prioritized	over	 individual-
level	 interventions.
116
	Although	 likely	 true,	 regardless	of	prevention	activities	 some	 individuals	
will	develop	illness	through	no	fault	of	their	own,	and/or	possibly	because	of	adverse	structural	
factors	 tolerated	 by	 the	 state,	 therefore	 this	 illness	 cannot	 be	 ignored.	 A	 balance	 therefore	
between	 prevention	 (i.e.	 horizontal	 equity,	 treating	 like	 cases	 with	 like	 interventions)	 and	
treatment	(i.e.	vertical	equity,	treating	unlike	cases	with	unlike	interventions)	must	be	struck.	
	
UHC	 is	 increasingly	 being	 recognized	 as	 the	 fulcrum	 of	 an	 effective	 health	 system	 and	 it	 is	
intricately	 linked	 to	 priority	 setting.	 The	 goal	 of	 UHC	 is	 to	 ensure	 access	 to	 priority	 health	






	 The	 initial	 challenge	 in	 determining	 what	 should	 be	 included	




be	 static,	 and	 over	 time	 additional	 services	 should	 be	 progressively	 included.	 	 Priority-setting	






The	 priority	 setting	 process	 therefore	 requires	 reliable	 local	 evidence	 on	 disease	 burdens.	
Evidence	on	cost-effectiveness	is	important	and	can	be	used	to	rank	interventions	according	to	
which	 one	 would	 maximize	 population	 health	 gains	 for	 a	 given	 cost.
119
	 Despite	 the	 seeming	
objectivity	 of	 cost-effectiveness	 analysis,	 this	 is	 a	 highly	 value-laden	 process	 in	 itself,	 and	
mounting	criticism	points	out	that	crucial	factors	such	as	financial	risk	protection	for	individuals,	





reviewed	 in	 detail	 elsewhere.
121-123
	 Data	 from	 such	 analyses	 should	 be	 utilized	 to	 develop	















































dialysis	 until	 all	 cases	 of	 diarrhea	 and	 pneumonia	 have	 access	 to	 appropriate	 care	 could	 be	
defended.	 	Would	this	however	mean	that	the	 life	of	someone	with	diarrhea	 is	more	valuable	
than	that	of	someone	with	ESKD?	Or	that	someone	with	diarrhea	has	a	greater	right	to	health	






An	additional	 layer	of	complexity	often	present	 in	 low	income	settings	 is	that	high	cost	care	 is	
(only)	 available	 through	 private	 providers,	 religious	 organizations	 and	 non-governmental	





if	 private	 care	 is	 the	only	 care	 available,	 patients	may	 essentially	 have	no	 choice.	 The	private	










or	not	acceptable,	e.g.	between	health	maximization	and	 financial	 risk	protection,	 for	 fair	and	
equitable	 health	 resource	 allocation.	 Relative	 cost-effectiveness	 is	 expressed	 as	 a	 percent	 of	
gross	 domestic	 product	 (GDP)	 per	 capita.	 Kenya	 is	 presented	 as	 an	 example	 (Figure	 6)	where	
	 134	
UHC	 for	 diagnosis	 and	 management	 of	 tuberculosis	 (A)	 and	 traffic	 safety	 regulation	 (B)	 are	
considered	cost-effective	“best	buys”,	i.e.	saving	the	most	lives	at	lowest	cost,	and	are	therefore	
considered	high	priority	 services,	whereas	 treatment	of	mild	asthma	 (C),	 given	higher	cost	 for	
fewer	 lives	 saved,	 would	 be	 of	 medium	 priority.	 According	 to	 this	 reasoning,	 coverage	 for	
dialysis	(D),	despite	the	significant	financial	protection	it	would	afford	to	affected	individuals,	is	





lower	 priority	 services	 be	 covered.	 As	 such,	 dialysis	 for	 AKI	 and	 palliative	 care,	 both	 highly	


































	 There	 are	 therefore	 often	 competing	 values	 (technical,	 socio-political	 and	


















































Broader	 frameworks	 for	 decision	making	 have	 also	 been	 proposed	 by	 leading	 thinkers	 in	 the	




Whichever	 framework	 a	 government	 decides	 to	 use,	 the	 policy	 making	 process	 should	 be	
transparent,	 participatory	 and	 relevant	 in	 terms	 of	 clinical	 effectiveness,	 cost	 and	 equitable	
distribution	 of	 interventions.
140
	 Governments	 should	 be	 held	 accountable	 for	 such	 policies.	
Importantly,	however,	communities	and	health	care	workers	must	be	effectively	engaged	with	





In	 all	 countries	 it	 is	 difficult	 to	 justify	 provision	 of	 dialysis	 because	 the	 cost-effectiveness	
argument	against	 it	 is	 strong.	Arguments	about	protecting	patients	and	 families	 from	financial	
risk	protection	and	favoring	the	worst	off	become	the	deciding	factors.	As	discussed	above,	 in	
high-income	settings	the	high	costs	of	RRT	have	been	accepted	by	society	as	a	trade-off	for	the	
















(most	 likely	 to	 benefit),	 dilution	 (fewer	 staff	 per	 patient),	 delay	 (wait	 times),	 deterrence	 (red	
tape)	 and	 deflection	 (referrals	 elsewhere).
53,144,145
	 Some	 of	 these	 forms	 of	 rationing	 may	 be	
justifiable,	 especially	 when	 faced	 with	 scare	 resources,	 such	 as	 allocation	 of	 organs	 for	
transplantation	to	those	most	 likely	to	benefit,	but	others	often	exacerbate	existing	inequities,	
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such	 as	 disadvantaged	 populations	 having	 to	 navigate	 complex	 bureaucracy	 to	 gain	 access	 to	
care.		
	
At	 present	 in	 low-income	 settings	 it	 would	 be	 naive	 to	 insist	 that	 dialysis	 be	 provided	 for	 all	
under	UHC,	however	dialysis	is	available	and	the	associated	ethical	dilemmas	cannot	be	ignored.	
When	policy	decisions	were	made	to	provide	dialysis	in	lower	income	settings,	for	AKI,	ESKD	or	



















continue	 to	 advocate	 as	 best	 they	 can	 within	 the	 set	 limits.
146
	 This	 view	 does	 “insulate”	 the	
physician	 from	 making	 rationing	 decisions	 per	 se,	 but	 implementation	 would	 require	 the	
development	of	evidence-based	guidelines	to	 justify	where	rationing	would	be	acceptable	and	
would	 require	 close	 oversight.
146
	 This	 view	 would	 be	 inconsistent	 with	 the	 Western	 Cape	
guidelines	 developed	 by	 nephrologists	 attempting	 to	 advocate	 for	 equity	 among	 individual	
patients	 while	 functioning	 within	 strict	 limits,	 but	 as	 discussed	 above	 nephrologists	 are	 not	
unanimous	 in	 their	 support	 for	 these	 guidelines	 and	 therefore	 practice	 is	 still	 somewhat	
inconsistent.	 In	 the	 combined	 view,	 the	 physician	 must	 balance	 patient	 advocacy	 with	
stewardship	 of	 resources.
146
	 This	 view	would	 support	 the	 development	 of	 transparent	 ethical	
guidance,	 developed	 and	 accepted	 through	 a	 multi-stakeholder	 process,	 where	 physicians	 in	
individual	cases	would	have	to	weigh	relative	benefits	and	harms	to	the	patient	and	to	society	in	




of	 rationing	 on	 doctor-patient	 relationships,	 education	 of	 the	 public	 and	 health	 care	workers	






potentially	 acceptable	 ethical	 justification	 (indicated	 in	 parentheses).
148
	 Many	 of	 these	
approaches	are	however	mutually	exclusive	which	 illustrates	 the	 tensions	between	 them.	 It	 is	
likely	when	decisions	 are	made	ad	hoc,	 in	 the	 absence	of	 formal	 guidance,	 different	 forms	of	
rationing	may	be	employed	at	different	 times	 leading	 to	unacceptable	 inconsistency	based	on	
implicit	 or	 explicit	 biases	 of	 individuals.	 It	 is	 important	 to	 bear	 in	 mind	 that	 “in	 a	 resource-
constrained	system,	giving	additional	weight	to	something	or	someone	 implies	that	something	
or	 someone	will	 lose	 out”
142
.	Given	 these	 consequences,	 fairness	 and	 equity	must	 be	 actively	



















































































































rationed	 in	 the	public	 system,	which	caters	 to	84%	of	 the	population.
110
	 In	 the	Western	Cape,	






options	 outlined	 in	 Table	 7,	 in	 that	 a	 relatively	 clear	 objective	 (“transplantability”,	 i.e.	 a	
utilitarian	 approach	 was	 taken	 to	 allocate	 resources	 to	 those	 most	 likely	 to	 benefit	 most)	 is	
articulated.	 The	 guidelines	 outline	 3	 patient	 groups	 based	 on	 inclusion	 and	 exclusion	 criteria:	
Category	1	(<	50	years,	otherwise	healthy)	-	unequivocal	acceptance;	Category	2	(50	-60	years,	
or	 generally	 clinically	 acceptable	but	poor	 social	 circumstances,	prior	 conviction	of	 an	offence	











children	with	ESKD	 fit	 into	 this	 algorithm	 is	 not	 stated.	Often	 children	are	denied	dialysis	 and	
transplantation	 in	 SSA	 because	 of	 lack	 of	 social	 support.
109







insurance)	 in	 South	 Africa	 is	 thriving,	 with	 no	 eligibility	 criteria	 for	 dialysis	 besides	 ability	 to	
pay.
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	 Ironically,	had	the	patient	belonged	to	a	health	 insurance,	the	 insurance	













compromise	 autonomy	 in	 terms	 of	 choice	 of	 treatment,	 although	 they	 still	 technically	 retain	
autonomy	 deciding	 whether	 to	 accept	 treatment	 and	 stay	 alive.	 Given	 that	 outcomes	 with	
transplantation	are	almost	always	superior	to	those	on	dialysis,	this	paternalistic	policy	could	be	
argued	 to	 be	 in	 the	 patient’s	 best	 interest	 and	 therefore	 adheres	 to	 the	 principle	 of	
beneficence.
158
	 The	 question	 of	 avoiding	 harm	 in	 this	 situation	 is	more	 complex,	 however.	 A	
patient	being	pressured	 into	 transplantation	may	experience	multiple	harms,	and	the	decision	
to	remove	a	patient	from	dialysis	as	a	consequence	of	refusal	of	transplantation	directly	hastens	
death.	 Harm	 to	 other	 patients,	 however,	 through	 a	 transplant-eligible	 patient	 remaining	 on	




Official	 rationing	guidelines	 for	access	 to	dialysis	do	not	exist	 in	 the	rest	of	SSA	beyond	Sudan	








basis	seems	problematic.	“Transplantabilty”	 in	these	cases	 is	presumed	to	be	an	 indicator	of	a	





Transparency	 of	 rationing	 criteria	 is	 therefore	 not	 enough	 to	 absolve	 stakeholders	 of	 moral	




	 In	 addition,	 if	 life-saving	 treatment	 such	 as	 dialysis	 is	 to	 be	 rationed,	 the	
responsibility	 of	 this	 decision	 implies	 provision	 of	 an	 alternative	 –	 compassionate	 supportive	
care	for	the	patient	and	family	until	death	ensues.	This	level	of	care	is	also	often	lacking	in	SSA.	
CONCLUSIONS	AND	PERSONAL	REFLECTIONS	




resource	 allocation,	 in	 terms	of	 progressive	 realization	of	UHC	and	 the	 right	 to	health,	 and	 in	
terms	of	transparent	policy	development	regarding	access	to	high	cost	care	when	resources	are	
limited.	Communities	must	be	well	informed	and	health	care	workers	must	be	well	trained	and	
supported.	 All	 stakeholders	 must	 be	 willing	 to	 engage	 in	 the	 policy	 process	 and	 in	 holding	
governments	 and	 each	 other	 accountable	 for	 practice	 and	 progress.	 The	 continuum	 of	 this	
process	from	the	health	systems	perspective	is	illustrated	in	Figure	6.	Each	stage	originates	from	
population	 health	 needs	 and	 is	 associated	with	 ethical	 values	 or	 principles	which	 necessitate	
effective	 engagement	 with	 all	 relevant	 stakeholders.	 Once	 policies	 are	 developed	 and	












At	present,	 in	 addition	 to	 illness	 itself,	 there	 is	much	harm	associated	with	developing	 kidney	
failure	 in	 SSA:	 access	 to	 life-saving	 dialysis	 is	 highly	 inequitable	 and	not	 accessible	 to	 the	 less	
privileged	 in	 society;	 dialysis	 quality	 when	 obtained	 may	 be	 suboptimal	 because	 of	
infrastructural	barriers,	 insufficiently	trained	staff,	patient	and/or	 institutional	cost	constraints;	
CHE	 is	 frequent;	 mortality	 is	 high;	 moral	 distress	 of	 health	 care	 workers	 is	 frequent.	 Patient	
autonomy	 appears	 a	 relative	 luxury	 under	 current	 circumstances.	 The	 benefits	 of	 dialysis	 are	
primarily	limited	to	those	who	can	continue	to	pay	and	survive,	to	those	who	make	a	profit	from	
dialysis	 (industry	 and	 fee-for-service	 practitioners/institutions),	 and	 to	 enhancement	 of	





































































































































and	 some	 are	 pulled	 out	 by	 the	 physician	 downstream,	 at	 times	 they	 can	 be	 resuscitated,	 at	
times	not.	The	physician	cannot	stop,	but	feels	demoralized.		
	
If	one	 looks	at	 this	 story	 through	an	ethical	 lens,	on	 the	 face	of	 it,	 it	 seems	 less	a	problem	of	
ethics	 than	 a	problem	of	 coping	with	 reality.	However,	 governments	 are	obligated	 to	make	 it	
possible	for	people	to	be	educated	about	the	dangers	of	the	river,	to	be	able	and	strong	enough	
to	 swim	 and	 ideally	 to	 have	 their	 own	 life	 jacket.	 This	 is	 not	 happening	 as	 fast	 as	 it	 should	
therefore	there	is	an	ethical	imperative	for	this	process	to	speed	up	and	be	comprehensive.	An	
urgent	ethical	challenge	arises	when	there	are	not	enough	life	jackets,	to	whom	should	they	be	




I	 have	 argued	 here	 that	 having	 transparent	 guidelines	 in	 place	 for	 both	 priority	 setting	 and	
rationing,	 to	 guide	 consistent	 and	 equitable	 policy	 development	 and	 implementation	 should	
make	 it	easier	 for	all	 stakeholders	and	 in	effect	“insulate”	 individuals	 from	having	 to	make	ad	
hoc	 decisions	 on	 access	 to	 dialysis.	 From	 a	 nephrologist’s	 perspective,	 this	 is	 true	 to	 a	 large	
extent,	and	may	be	the	most	pragmatic	solution	available	at	present,	but	this	does	not	change	
the	 fact	 that	 care	 will	 still	 be	 denied	 to	 some	 patients	 in	 need.	 As	 illustrated	 by	 the	 tension	
within	 South	Africa	 about	 the	 category	 2	 patients,	many	 patients	will	 fall	 into	 grey	 areas	 and	
strict	 application	of	 any	 rationing	 criteria	will	 not	be	 simple.	Nephrologists	 also	 cannot	 simply	
ignore	 that	 kidney	 disease	 is	 often	 a	 result	 of,	 or	 at	 least	 is	 exacerbated	 by,	many	 social	 and	
	 146	
structural	 factors,	 that	 if	 left	 unremedied	 will	 continue	 to	 increase	 the	 burden	 of	 disease.	










patients’	 lives,	 and	 as	 such	 have	 an	 ethical	 obligation	 to	 raise	 awareness	 and	 advocate	 for	 a	
holistic	 and	 more	 primordial	 approach	 to	 optimizing	 health	 and	 maximizing	 individual	
capabilities	 to	 thrive.
165-167




to	 shy	 away	 from	 the	 reality	 that	 rationing	 is	 happening.	 Physicians	 and	 other	 health	 care	




had	a	niggling	 feeling	 in	 the	back	of	my	mind	 that	 if	 I	was	 successful	 some	other	programme	
would	not	 get	what	 they	 asked	 for.	On	 some	 level	 I	 felt	 it	was	 the	 responsibility	 of	 others	 to	
advocate	for	their	own	patients,	but	increasingly	I	realized	that	it	was	also	the	responsibility	of	
the	 hospital	 chief	 executive	 officer	 to	 determine	 where	 the	 limited	 resources	 might	 be	 best	
allocated.	Having	been	more	exposed	 to	 the	arena	of	public	health	 in	 the	past	 few	years,	my	
view	 point	 has	 been	 broadened	 to	 understand	 that	 striving	 for	 distributive	 justice	 is	 key	 in	
health	care	decision	making,	however	the	tension	between	the	bedside	and	the	boardroom	will	
always	 exist.	 Three	 common	 values,	 described	 in	 a	 study	 of	 20	 Australian	 public	 health	















also	 that	 it	 is	 at	 best	 an	 uncomfortable	 compromise.	 Complacency	 with	 the	 status	 quo	 is	







kidney	disease	and	dialysis	 in	SSA.	The	added	complexities	of	access	 to	 transplantation	 in	SSA	
must	be	further	explored.	The	nephrology	community	is	calling	for	access	to	dialysis	for	AKI	as	a	
human	 right.	 The	 concept	 of	 health	 as	 a	 human	 right	 and	 how	 far	 state	 obligations	 should	
extend	 regarding	 access	 to	 unaffordable	 high-cost	 interventions	 requires	 further	 deliberation.	










health	 care	 in	 resource-limited	 settings	 is	 necessary	 but	 ethically	 complex.	 Public-private	
partnerships	are	being	promoted	as	a	sustainable	way	 forward	 in	 low	resource	settings.	Work	
towards	 the	 development	 of	 some	 broad	 ethical	 guidelines	 is	 required.	 Professional	 societies	
are	 pushing	 for	 expansion	 of	 dialysis	 practice	 in	 low-income	 settings	 and	 are	 embarking	 on	
interventions	 without	 being	 embedded	 in	 the	 local	 health	 system.	 As	 such,	 despite	 good	
intentions,	 in	 the	 bigger	 picture,	 more	 harm	 may	 be	 being	 done	 than	 good.	 The	 ethical	
principles	 applying	 to	 implementation	 research	 must	 be	 applied	 in	 planning	 such	
“humanitarian”	interventions	even	when	not	labeled	research.	These	concepts	must	be	brought	
into	 the	 mainstream	 to	 ensure	 responsiveness,	 consistency,	 transparency	 and	 sustainability.	
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